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Summary 
 
Human T-lymphotropic virus type 1 (HTLV-1) is a retrovirus that persists lifelong within the infected 
host by driving expansion of infected CD4+T-cells.  It is the cause of adult T-cell 
leukaemia/lymphoma (ATL), an aggressive CD4+ T-cell malignancy, which arises in approximately 5% 
of individuals typically following decades of asymptomatic infection.  The reasons why some 
individuals develop ATL remain unknown. 
In this laboratory a novel customised high throughput sequencing and bioinformatic method has 
been developed in order to map and accurately quantify the proviral integration sites within each 
host genome in order to identify clonal populations within each host.   In this study I aimed first to 
test the hypothesis that there is a single provirus integrated into each host genome, and secondly to 
test the hypothesis that the site of retroviral integration determines the risk of leukaemia. 
In order to quantify the average number of proviral integration sites in each host cell, we isolated 
infected T-cells from the peripheral blood of infected individuals by limiting dilution cloning.  
Integration site analysis of these clones revealed that in natural infection each T-cell clone carries a 
single integrated provirus. This work formed the basis of a publication in the journal Blood (Cook et 
al 2012). 
I describe the systematic analysis of the clonality, structure and the integrity of the proviral tax gene 
in a large cohort of ATL patients (n=197).  I correlate these findings with the clinical subtype of ATL 
and the landscape of the host genome flanking the proviral integration site.  Based upon our findings 
we conclude that the integration site in cis does not directly cause leukaemogenesis and hypothesise 
that the absolute number of infected clones within an individual, and not oligoclonal proliferation, 
predisposes to malignant transformation.  
4 
 
Acknowledgements 
 
Firstly I would like to thank my supervisor Charles Bangham for his guidance, encouragement and 
patience over the last few years.  I would like to extend this thanks to Graham Taylor and his clinical 
team who have welcomed me into the HTLV-1 service at St Mary’s and supported my transition back 
to clinical medicine to develop a clinical ATL interest. 
I would like to thank all former and current members of the Bangham and Taylor labs for their day-
to-day good humour and for teaching me how to hold a pipette, not laughing too loudly at my 
mistakes and encouraging my transition from the Excel spreadsheet to R.  In particular I would like to 
thank Anat Melamed, Aileen Rowan, Heather Niederer and Yorifumi Satou. 
This work would not have been possible without collaboration from Professor Masao Matsuoka, 
Kyoto University who supported this project, provided patient material and clinical information to 
undertake the work and for helpful discussion with regards to the results.  I would also like to thank 
Leukaemia and Lymphoma Research for funding my fellowship and for providing additional support 
to travel to Kyoto University.  
Finally, love and thanks to my husband Stewart and the rest of the Cooks for their unswerving 
support and patience, and for not being too disappointed that I haven’t found the cure for cancer. 
  
5 
 
Table of Contents 
Declaration .............................................................................................................................................. 2 
Summary ................................................................................................................................................. 3 
Acknowledgements ................................................................................................................................. 4 
List of figures ......................................................................................................................................... 11 
List of tables .......................................................................................................................................... 12 
List of abbreviations .............................................................................................................................. 13 
Glossary ................................................................................................................................................. 16 
Statement of collaboration ................................................................................................................... 17 
Chapter 1. Introduction .................................................................................................................... 18 
1.1. Human T-lymphotropic virus .................................................................................................. 19 
1.2. Epidemiology and Transmission ............................................................................................. 20 
1.3. HTLV-1 associated diseases .................................................................................................... 21 
1.3.1. Adult T-cell leukemia/lymphoma .................................................................................... 21 
1.3.2. HAM/TSP clinical manifestation ...................................................................................... 24 
1.3.3. HAM/TSP disease pathogenesis ...................................................................................... 24 
1.3.4. Associated diseases ......................................................................................................... 26 
1.4. Cellular and Molecular biology ............................................................................................... 26 
1.4.1. HTLV-1 receptor............................................................................................................... 26 
1.4.2. Mechanism of cell-to-cell spread .................................................................................... 27 
1.4.3. Mechanism of HTLV-1 proviral integration ..................................................................... 28 
1.4.4. Mapping and quantification of proviral integration sites ............................................... 30 
1.4.5. HTLV-1 viral gene expression .......................................................................................... 31 
Structural genes ............................................................................................................................ 32 
6 
 
The pX region ................................................................................................................................ 32 
1.4.6. Mechanism of viral proliferation (mitotic versus infectious spread) .............................. 36 
1.5. Immune determinants and response to HTLV-1 .................................................................... 37 
1.5.1. Immune response in ATL ................................................................................................. 39 
1.6. Animal models of ATL ............................................................................................................. 41 
1.7. Aims and Hypothesis .............................................................................................................. 42 
Chapter 2. Materials and Methods ................................................................................................... 43 
2.1. Primary cells and cell lines ...................................................................................................... 44 
2.1.1. Patients samples .............................................................................................................. 44 
2.1.2. Cell lines ........................................................................................................................... 44 
2.2. Isolation of CD4+ T-cell clones by limiting dilution ................................................................ 45 
2.3. Molecular biology methods .................................................................................................... 46 
2.3.1. Proviral load measurements ........................................................................................... 46 
2.3.2. 5’ long terminal repeat sequencing ................................................................................. 46 
2.3.3. Long range PCR to identify defective proviruses ............................................................. 47 
2.3.4. Identification of exon 2 and exon 3 tax gene mutations ................................................. 49 
2.3.5. Identification of hypermethylated 5’LTR ......................................................................... 50 
2.3.6. T-cell receptor gene rearrangement studies ................................................................... 52 
2.4. Analysis and quantification of proviral integration sites ........................................................ 52 
2.4.1. Preparation of integration site libraries for high-throughput sequencing ...................... 52 
2.4.2. Library quantification prior to sequencing ...................................................................... 56 
2.4.3. High throughput sequencing and mapping using Illumina pipeline ................................ 56 
2.4.4. Data extraction pipeline .................................................................................................. 58 
7 
 
2.4.5. Calculation of abundance of each integration site .......................................................... 60 
2.5. Bioinformatic and statistical methods .................................................................................... 61 
2.5.1. Annotation of integration sites with genomic environment ........................................... 61 
2.5.2. Random sites (in silico datasets) ..................................................................................... 61 
2.5.3. Calculation of Oligoclonality index .................................................................................. 62 
2.5.4. Statistical analysis ............................................................................................................ 62 
Chapter 3. Integration site analysis of naturally infected HTLV-1    CD4+CD25+ T cell clones .......... 65 
3.1. Introduction ............................................................................................................................ 66 
3.1.1. High throughput sequencing in retroviral mapping ........................................................ 66 
3.1.2. Clonal distribution of HTLV-1 integration sites in PBMC ex vivo ..................................... 69 
3.1.3. Aim ................................................................................................................................... 71 
3.2. Results .................................................................................................................................... 72 
3.2.1. Non-malignant infected CD4+ T cell clones contain a single integrated provirus. ......... 72 
3.2.2. Confirmation of PCR bias to selectively amplify short PCR products .............................. 74 
3.2.3. Clones with defective proviruses can be isolated ex-vivo ............................................... 75 
3.2.4. T-cell clones from patients with acute ATL are difficult to expand in vitro .................... 76 
3.3. Discussion ............................................................................................................................... 77 
3.3.1. Non-malignant clones of HTLV-1 contain a single provirus............................................. 77 
3.3.2. Clones carrying defective proviruses can be isolated from ACs and patients with 
HAM/TSP. ...................................................................................................................................... 79 
3.3.3. The malignant clone from ATL cells is difficult to isolate and expand in vitro ................ 80 
3.3.4. Chapter summary ............................................................................................................ 81 
3.3.5. Publication associated with this chapter ......................................................................... 81 
Chapter 4. Characterisation of ATL cohort ....................................................................................... 82 
4.1. Chapter abstract and summary .............................................................................................. 83 
8 
 
4.2. Introduction ............................................................................................................................ 84 
4.2.1. Tax expression is not a requirement for ATL cells ........................................................... 85 
4.2.2. Subtypes of defective provirus in ATL ............................................................................. 86 
4.2.3. Tax mutations in ATL ....................................................................................................... 87 
4.2.4. Hypermethylation of the 5’LTR in the ATL ...................................................................... 88 
4.3. Results .................................................................................................................................... 89 
4.3.1. Samples removed from analysis following unblinding of clinical diagnosis .................... 89 
4.3.2. Number of cases within each clinical subtype and proviral load. ................................... 90 
4.3.3. Defective proviruses are detected in 39% of the ATL cohort .......................................... 91 
4.3.4. Tax gene mutations are detected in 7% of the ATL cohort ............................................. 92 
4.3.5. Hypermethylated 5’LTR TRE causes tax silencing in approximately 8% of ATL cohort ... 96 
4.3.6. No difference in the median proviral load by clinical or proviral subtype ...................... 97 
4.3.7. No difference in the median oligoclonality index by clinical or proviral subtype ......... 100 
4.3.8. Definition and character of abundance bins ................................................................. 102 
4.3.9. Identification of multiple proviruses within a dominant clone ..................................... 104 
4.4. Discussion ............................................................................................................................. 108 
4.4.1. Identification of a novel category of defective provirus ............................................... 108 
4.4.2. Identification of novel nonsense mutations in the tax gene ......................................... 109 
4.4.3. Wide variation in the PVL in ATL samples ..................................................................... 110 
4.4.4. Evidence of multiple proviruses in ATL cases. ............................................................... 112 
4.4.5. The significance of intermediate sized clonal populations is uncertain........................ 113 
Chapter 5. Genomic landscape of HTLV-1 proviral integration sites .............................................. 115 
5.1. Chapter Abstract and summary ............................................................................................ 116 
5.2. Introduction .......................................................................................................................... 117 
9 
 
5.2.1. Proviral integration site bias .......................................................................................... 117 
5.2.2. HTLV-1 integration site selection .................................................................................. 118 
5.2.3. Determinants of clonal abundance in vivo .................................................................... 120 
5.3. Results .................................................................................................................................. 123 
5.3.1. Definitions of the genomic environment flanking the host genome ............................ 123 
5.3.2. Control datasets ............................................................................................................ 124 
5.3.3. The absolute abundance of all ATL clones is larger than seen in ACs ........................... 124 
5.3.4. Preferential integration of small clones into chromosomes 13, 14, 15 and 21 ............ 127 
5.3.5. Integration within 10Kb of a TSS or CpG island is associated with acute subtypes of ATL 
and those carrying defective or tax mutated proviruses. ........................................................... 131 
5.3.6. Same sense transcriptional orientation and proximity to genes favours clonal 
expansion. ................................................................................................................................... 133 
5.3.7. Integration is favoured in proximity to activatory epigenetic marks ............................ 135 
5.3.8. Integration in proximity to TFBS .................................................................................... 137 
5.3.9. In vivo integration sites are associated with proximity to oncogenes, but are not 
associated with malignant transformation. ................................................................................ 140 
5.3.10. No hotspots of integration are associated with ATL ................................................... 141 
5.3.11. Ingenuity Pathway Analysis (IPA®) suggests ontogeny of the nearest downstream gene 
may play a role in ATL proliferation. ........................................................................................... 143 
5.4. Discussion ............................................................................................................................. 146 
5.4.1. Preferential integration into acrocentric chromosomes in small clones ...................... 147 
5.4.2. Effects of the genomic environment on clonal expansion in vivo ................................ 149 
5.4.3. Intermediate sized clones contain proviruses with unique host genomic characteristics
 150 
5.4.4. ATL is not caused by integration in proximity to cancer-associated genes .................. 153 
Chapter 6. General discussion and summary of thesis work .......................................................... 155 
6.1. Chapter Aim .......................................................................................................................... 156 
6.2. Summary of major findings .................................................................................................. 157 
10 
 
6.3. Absolute number of clones, rather than oligoclonal expansion, contributes to 
leukaemogenesis ............................................................................................................................ 161 
6.4. Directions for future ATL research and direction of clinical management .......................... 163 
References .......................................................................................................................................... 167 
Appendix 1: Datasets used in this work .............................................................................................. 189 
Appendix 2:  Summary results for each patient sample ..................................................................... 193 
Appendix 3:  Shimoyama classification of ATL .................................................................................... 198 
Appendix 4:  Samples not suitable for bioinformatic analysis ............................................................ 199 
Appendix 5: Abstract of publication associated with this thesis ........................................................ 200 
Appendix 6:  Summary of permission for third party copyright works .............................................. 201 
 
 
  
11 
 
List of figures 
Figure 1.1:  Retroviral integration (DNA breaking and joining reactions) ............................................ 29 
Figure 1.2: The HTLV-1 proviral genome .............................................................................................. 35 
Figure 2.1: Schematic representation of wild type (WT) and defective proviruses ............................. 48 
Figure 2.2: Pipeline for library preparation of HTLV-1 integration sites. .............................................. 54 
Figure 2.3: Basic linker structure .......................................................................................................... 55 
Figure 2.4: Basic structure of amplicon for high-throughput sequencing ............................................ 57 
Figure 3.1: ATL is not necessarily caused by a monoclonal expansion of T-cell clones ........................ 70 
Figure 3.2: PCR most efficiently amplifies short amplicons .................................................................. 74 
Figure 4.1: Frequency of predicted amino acid sequence changes in exon 2 and exon 3 of the tax 
gene ...................................................................................................................................................... 95 
Figure 4.2: Proviral load (PVL) by clinical subtype (Panel A) and proviral tax gene status (Panel B) ... 99 
Figure 4.3:  Oligoclonality index by clinical and proviral subtype ....................................................... 101 
Figure 4.4: Relative abundance of the largest clone in each ATL patient is >35% ............................. 103 
Figure 4.5: Clonal structure of the ATL cases ...................................................................................... 107 
Figure 5.1: Clonal evolution in ATL ..................................................................................................... 122 
Figure 5.2: Definition of the host environment flanking the host genome ........................................ 123 
Figure 5.3: Absolute abundance of small, intermediate and large clones in AC and ATL cases ......... 126 
12 
 
Figure 5.4: Preferential integration into chromosomes 13, 14, 15 and 21 ........................................ 129 
Figure 5.5: Preferential integration within 10Kb TSS and CpG islands ............................................... 132 
Figure 5.6: Integration in proximity to genes in the same sense transcriptional orientation ............ 134 
Figure 5.7: Small and large clones favour activatory epigenetic marks, whilst intermediate ATL clones 
favour inhibitory marks ....................................................................................................................... 136 
Figure 5.8: Intermediate sized ATL clones only are associated with integration in proximity to specific 
TFBS ..................................................................................................................................................... 139 
Figure 5.9: Functional classification of genes over-represented amongst the large ATL clones ........ 145 
List of tables 
Table 2-1: Primer sequences ................................................................................................................. 63 
Table 3-1: Summary of identified integration sites derived from 10 individuals with HTLV-1 infection
 .............................................................................................................................................................. 73 
Table 4-1: Proportion of each clinical subtype within cohort ............................................................... 90 
Table 4-2: Subtypes of provirus identified by long-range PCR ............................................................. 91 
Table 4-3: Summary table of amino acid alterations following tax sequencing ................................... 94 
Table 4-4:  Summary table of methylation status of the 5’LTR (n=113) ............................................... 96 
Table 4-5:Summary of Tax silencing mechanisms for cohort ............................................................... 97 
Table 4-6: Summary table of PVL and Tax status .................................................................................. 98 
Table 4-7:  The number of integration sites within each abundance bin ........................................... 103 
Table 5-1: Preferential integration into chromosomes ...................................................................... 130 
  
13 
 
List of abbreviations 
AC   Asymptomatic carrier 
AP1   Activator protein 1 
APOBEC3G Apolipoprotein B mRNA-editing, enzyme-catalytic, polypeptide-like 3G 
ATL   Adult T-cell leukaemia/lymphoma 
BCP   Bayesian change point 
BLV   Bovine leukaemia virus 
BSP   Bisulfite sequencing PCR 
CCL22   C-C motif chemokine 22 
CCR4   C-C chemokine receptor type 4 
CGH   Comparative genomic hybridisation 
ChIP-seq  Chromatin immunoprecipitation-sequencing 
CNS   Central nervous system 
CRE   c-AMP responsive element 
CREB/ATF  CRE binding/activating transcription factors 
CSF   Cerebrospinal fluid 
CTL   Cytotoxic T-lymphocyte 
ELAND   Efficient Large-Scale Alignment of Nucleotide Databases 
FBS   Fetal bovine serum 
FOXP3   Forkhead box P3 
GITR   Glucocorticoid-induced TNF receptor 
GLUT-1   Glucose transporter 1 
HAM/TSP  HTLV-1 associated myelopathy/tropical spastic paraparesis 
HBZ   HTLV-1 bZIP factor 
HDAC   Histone deacetylase 
HIV   Human immunodeficiency virus 
14 
 
HLA   Human leucocyte antigen 
HSPG   Heparan sulphate proteoglycan 
HTLV   Human T-lymphotropic virus 
HTS   High throughput sequencing 
ICAM   Intercellular adhesion molecule 
IFN   Interferon 
IPA®   Ingenuity® pathway analysis 
IPCR   Inverse PCR 
IS   Integration/insertion site 
KIR   Killer cell immunoglobulin-like receptor 
LEDGF   Lens epithelium-derived growth factor 
LMPCR   Linker-mediated PCR 
LTR   Long terminal repeat 
MAD1   Mitotic spindle assembly checkpoint protein 
MSP   Methylation specific PCR 
MLV   Murine leukemia virus 
NFkB   Nuclear factor kappa-light-chain-enhancer of activated B cells 
NRES   National research ethics service 
NRP   Neuropilin 
OCI   Oligoclonality index 
ORF   Open reading frame 
PBMC   Peripheral blood mononuclear cell 
PCAF   P300/CBP-associated factor 
PCR   Polymerase chain reaction 
PCR ISH   PCR in situ hybridisation 
PHA   Phytohaemagglutinin 
PVL   Proviral load 
15 
 
RTPCR   Reverse transcription PCR 
QPCR   Quantitative PCR 
STAT   Signal transducer and activator of transcription 
STLV   Simian T-lymphotropic virus 
TCR   T-cell receptor 
TFBS   Transcription factor binding site 
TNFα   Tumour necrosis factor α 
TRE   Tax-responsive element 
Treg   Regulatory T-cell 
TSS   Transcriptional start site 
UCSC   University of California, Santa Cruz 
UIS   Unique integration site 
ZDV   Zidovudine (azidothymidine) 
  
16 
 
Glossary 
 Sisters   HTLV-1 infected cells which share a common integration site  
                                           and are assumed to have arisen from a single infection event                                                                              
 Clone   The entire population of sisters for a given integration site 
 Clone abundance The number of sisters within a clone 
 Relative abundance The proportion of the proviral load occupied by each clone 
 Absolute abundance The abundance of each clone per 10,000 PBMC 
 Small  clones*  Relative abundance <1% PVL 
 Intermediate clones* Relative abundance ≥1% PVL and <35% PVL 
 Large clones*  Relative abundance ≥ 35% PVL 
 
*Details for abundance bins defined in section 4.3.8  
17 
 
Statement of collaboration 
 Chapter 3:  High throughput sequencing of naturally infected T-cell clones 
Patient recruitment, consent for research and clinical diagnosis by Professor Graham Taylor, 
National Centre for Human Retrovirology, St Mary’s Hospital, Imperial College Healthcare NHS Trust. 
The protocol for isolating and expanding infected T-cell clones was established by Dr Aileen Rowan 
in this laboratory, who isolated many of the T-cell clones analysed here, and supervised me to isolate 
and expand further clones.  The manuscript published in Blood based upon this work was co-
authored by Cook and Rowan. 
 Chapter 4:  Characterisation of ATL cohort 
Patient recruitment, consent for research and clinical diagnosis by Professor Masao Matsuoka, Kyoto 
University. 
T-cell receptor gene rearrangement studies on 40 samples were undertaken by Mikel Valgannon, in 
the diagnostic Molecular Pathology Unit, Hammersmith Hospital, Imperial College Healthcare NHS 
Trust. 
 Chapter 5: Genomic landscape of HTLV-1 proviral integration sites 
Datasets:   The asymptomatic carrier cohort dataset was provided to me by Dr Heather Niederer and 
the in vitro dataset by Dr Anat Melamed.  Downstream bioinformatic and statistical analysis of these 
AC and in vitro datasets was undertaken by me. Dr Nirav Malani (FD Bushman group, University of 
Pennsylvania USA) developed the hiAnnotator R-package and generated in silico datasets. 
Dr Anat Melamed developed the bioinformatic integration site data extraction pipeline (DEISA) and 
in conjunction with Daniel Laydon designed the multivariate analysis test.  
18 
 
Chapter 1. Introduction 
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Human T-Lymphotropic Virus Type-1 (HTLV-1) was first isolated in 1980 from cultured cells taken 
from a patient diagnosed with a cutaneous malignancy (Poiesz et al., 1980) and is the cause of adult 
T cell leukaemia/lymphoma (ATL).  In 1985, HTLV-1 seropositive patients in French Martinique were 
diagnosed with a neurodegenerative disease known as tropical spastic paraparesis (TSP) and a 
similar disorder, HTLV-1 associated myelopathy (HAM) was later reported in Japan (Osame et al., 
1986). Since no viral particles have been identified in the plasma HTLV-1 was thought for many years 
to be a latent virus.  Now, it is understood that there is a complex and dynamic interaction between 
the virus and host immune system.  Alterations in the balance of these interactions allow clonal 
expansion and subsequent transformation to malignant disease.  The two broad major questions 
that remain in HTLV-1 research are how does the virus persist despite a strong, constitutive immune 
response, and, what factors determine the risk of clinical disease? 
 
1.1. Human T-lymphotropic virus  
 
HTLV-1 is a member of the deltaretrovirus family and so far, there have been four genotypes of 
human HTLVs identified (Wolfe et al., 2005) and four genotypes described which infect non-human 
primates (Slattery et al., 1999).  There is high sequence identity between HTLV-1 and simian T-
lymphotropic virus type 1 (STLV-1) suggesting a relatively recent common ancestor. HTLV-1 is of 
major clinical interest since it is the only HTLV to be definitely associated with clinical disease. Whilst 
HTLV-2 may be frequently observed within specific populations, especially amongst indigenous 
populations and intravenous drug users (Chang et al., 2013) it is not associated with specific clinical 
disease and is carried at an extremely low proviral burden (Murphy et al., 2004).  The more recently 
described HTLV-3 and -4 have no known disease associations (Mahieux and Gessain, 2007). 
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There are 3 genotypes of HTLV-1:  Melanesian, Central African and Cosmopolitan types, with four 
subsets of the Cosmopolitan group (Transcontinental, Japanese, Western African and North African).  
However, there does not appear to be any clear association between the viral genotype and disease 
which suggests that host specific factors must account for the remarkable variation observed in the 
clinical manifestations of HTLV-1 infection. 
 
1.2. Epidemiology and Transmission 
HTLV-1 has been recently estimated to infect over 10 -15 million people worldwide (Gessain and 
Cassar, 2012) and is endemic in regions of southern Japan, the Caribbean, sub-Saharan Africa, Brazil 
and northern Iran (de The and Bomford, 1993).  Whilst over 90% of infected individuals remain 
asymptomatic, 1-2% will develop a debilitating progressive neurological condition known as HTLV-1 
associated myelopathy/tropical spastic paraparesis (HAM/TSP) and approximately 5% will develop 
adult T cell leukaemia/lymphoma (ATL) (Yamaguchi and Watanabe, 2002).  Prevalence of HTLV-1 in 
the Kyushu district of Japan has been reported at over 10% of the general population and the 
cumulative incidence of developing ATL among adult virus carriers is estimated at 6.6% males and 
2.1% females (Arisawa et al., 2000). Epidemiological data in many other endemic regions, such as 
Sub-Saharan Africa, remain unknown. In Europe and North America HTLV-1 is mainly present among 
immigrant communities from endemic regions and within the UK it is estimated that there are 
approximately 22500 infected individuals (Tosswill et al., 2000).  
Transmission of HTLV-1 requires cell to cell contact (Yamamoto et al., 1982) and cell-free blood 
products are non-infectious (Jason et al., 1985).  HTLV-1 can be contracted through infected cellular 
blood product transfusions  with a recent look-back by the UK Blood and Transplant Service 
reporting 29.4% transmission rate prior to leucodepletion of blood products and 3.7% following 
leucodepletion which was introduced in the UK in 1998 (Hewitt et al., 2013).  HTLV-1 can also be 
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transmitted  by sexual contact (Murphy et al., 1989) or by solid organ transplantation (Glowacka et 
al., 2013).  In endemic countries, the major route of transmission is through breast feeding 
(Uchiyama, 1997; Verdonck et al., 2007), with an increased risk of transmission directly correlated 
with duration (Ureta-Vidal et al., 1999). 
In the UK universal screening of blood donors for HTLV-1 antibody has been in practice since 2002 
and diagnosis is based upon repeated reactive enzyme immunoassay confirmed with specific 
immunoblot (Dow et al., 2001).   Seroprevalence among blood donors in England and Wales is 
estimated at 8 cases/million donations (Hewitt et al., 2013) and 470 cases per million pregnant 
women (Taylor et al., 2005).  However the screening of blood, organ donors and pregnant women is 
still not undertaken in many regions of the world, including ‘wealthy’ nations. 
 
1.3. HTLV-1 associated diseases 
1.3.1. Adult T-cell leukemia/lymphoma  
 
Adult T cell leukaemia is a neoplasm of mature, post thymic T-lymphocytes with a tumour that 
typically consists of an oligoclonal or monoclonal outgrowth of CD4+ CD25+ T lymphocytes carrying a 
complete or defective provirus of HTLV-1.  Approximately 4% of cases are CD4-CD8+ and a similar 
proportion CD4+CD8+ or CD4- CD8- (Kamihira et al., 1992).  The cells usually express the markers 
CD2 and CD5 whilst CD3 and TCRβ are frequently downregulated at the cell surface.  The ATL cells 
frequently express molecules characteristic of activated and regulatory T-cells including CD25, CCR4 
and the transcription factor FoxP3, making flow-cytometric cell identification of malignant, from 
non-malignant HTLV-1 infected cells difficult (Chen et al., 2006; Toulza et al., 2009).  The molecular 
pathogenesis of ATL is discussed in more detail in chapters 4 and 5. 
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The median age of presentation is 40 years in Afro-Caribbean patients and 50 years in Japan, and the 
disease typically occurs decades after asymptomatic infection usually in individuals who are believed 
to have become infected during infancy.  In contrast to HAM/TSP, ATL is not associated with 
recipients of HTLV-1 contaminated blood transfusions, the recipients of such transfusions typically 
being adults in the 6th and 7th decade.     
Clinical manifestation of ATL is heterogeneous and may be characterised by lymphadenopathy, 
abnormal lymphocytosis, hepatosplenomegaly, skin lesions, pulmonary infiltrates and 
hypercalcaemia.  Diagnosis is based upon the presence of morphologically abnormal lymphocytes 
(‘flower cells’ are typical but not necessarily present), presence of antibodies to HTLV-1 in the serum 
and the demonstration of monoclonal integration of HTLV-1 provirus in the tumour cells.  
 The disease is classified into 4 subgroups under the Shimoyama classification (Shimoyama, 1991) 
(classification detailed in Appendix 3); broadly they are considered as either ‘aggressive’ (acute and 
lymphoma subtypes) or ‘indolent’ (chronic and smouldering).   The most common presentation is 
the acute form (60% of cases) and typically presents as an emergency with complications from a 
rapid leucocytosis and associated cytopenias, hypercalcaemia, bulky lymphadenopathy and 
infectious complications.  In the chronic form, the lymphocytosis may be marked, but the patient 
may be asymptomatic for a number of years with the major clinical complications being skin lesions, 
opportunistic infection and the risk of transformation to acute disease.  Approximately 20% of 
individuals present with a pure lymphoma with a normal circulating white cell count and normal 
peripheral blood film.  There remain difficulties using the Shimoyama criteria in the classification of 
certain subtypes of disease e.g.  (1) The acute subtype with bulky lymphadenopathy who behave 
clinically like the lymphoma subtype (2) The significance of the smouldering subtype, since a high 
percentage of abnormal lymphocytes may be present in the peripheral blood films of patients with 
non-malignant infection (Hodson et al., 2013) and (3) The Shimoyama classification excludes the 
recently recognised purely cutaneous subtype (Amano et al., 2008).  However, with these caveats in 
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mind, it still remains useful for purposes of standardising clinical trials, comparing disease outcomes 
internationally, selecting therapies and for prognostic information.   
 Patients with aggressive ATL generally have extremely poor prognosis, mainly due to resistance to 
steroids and cytotoxic agents combined with significant immune suppression and susceptibility to 
opportunistic infection.  In the aggressive subtypes, the best clinical trial results to date report 
complete response rates in only 25-40% patients, median progression free survival time of 5 to 7 
months and median overall survival time of approximately 13 months (Tsukasaki et al., 2007; 
Yamada et al., 2001).  Whilst the chronic and smouldering forms of ATL have a relatively indolent 
course they may transform into aggressive ATL and under a ‘watchful waiting’ strategy the median 
survival is approximately 5 years (Takasaki et al., 2010).  By contrast, in Europe, Martinique and the 
USA where combination zidovudine and interferon (IFN) -α is the standard of care for chronic ATL, 
100% overall survival has been reported and the median survival not reached (Bazarbachi et al., 
2010).   The risk of relapse with all subtypes remains extremely high and there are many unanswered 
clinical questions. For example, the role of zidovudine and IFN-α in long term consolidation 
treatment, the place of immunomodulatory therapies such as proteasome inhibitors, arsenic trioxide 
or the precise role of new monoclonal antibodies such as mogamulizumab which targets CCR4 
expression on the tumour cells. The only truly curative approach remains allogeneic bone marrow 
transplantation, but this is only a therapeutic option for those individuals who are young-enough 
and fit-enough, have achieved a response to induction treatment , have a suitable HLA matched 
donor and in itself  is a procedure associated with substantial morbidity and mortality. 
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1.3.2. HAM/TSP clinical manifestation 
 
The lifetime risk for developing HAM/TSP is 0.25-4% (Kaplan et al., 1990) and is characterised by a 
gradual symmetric paraparesis of lower limbs with signs of pyramidal tract involvement, which 
progresses slowly and without remissions.  Early in the disease the first symptoms are of weakness 
of the lower limbs and lumbar pain, although there may be sensory symptoms too.  In many 
patients, urinary and sexual problems can be the first symptoms (De Castro-Costa et al., 2006).  
Dizziness is common (with normal clinical examination) and suggests disease in the vestibulospinal 
and motor tracts (Felipe et al., 2008). 
The weakness in the lower limbs is associated with moderate to severe spasticity, up-going plantar 
reflex and hyperreflexia.  Vibratory sense is frequently impaired with relatively preserved 
proprioception.  In the upper limbs there is usually hyperreflexia without weakness. As the disease 
progresses, the weakness and the spasticity increase, and the gait deteriorates (Nagai and Osame, 
2003).  Neuropathic pain becomes common as the disease advances.  Autonomic dysfunction of 
bladder and bowel are a common cause of morbidity resulting in recurrent urinary tract infections 
and resultant chronic renal failure.   
 
1.3.3. HAM/TSP disease pathogenesis 
The major histopathological changes found at post mortem in patients with HAM/TSP are long tract 
degeneration and demyelination affecting pyramidal, spino-cerebellar and spinothalamic tracts and 
hyalinoid thickening of media and adventitia of blood vessels in the brain, spinal cord and 
subarachnoid space  (Akizuki et al., 1987; Cartier et al., 1997).  
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Immunostaining  of post mortem biopsies shows that early in the disease process the 
leptomeninges, blood vessels and parenchyma are infiltrated with both CD4+ lymphocytes and CD8+ 
lymphocytes, B- lymphocytes and foamy macrophages whereas  later in the disease CD8+ 
lymphocytes predominate with subsequent progression to a relatively acellular, atrophic pattern 
with axonal and myelin degeneration.   The entire spinal cord can be affected, although the lower 
thoracic level is predominantly affected (Iwasaki et al., 1992).  
Cerebrospinal fluid samples (CSF) may show mild pleomorphic lymphocytosis with mild to moderate 
increase in protein.  Antibodies against HTLV-1 are present in the CSF and, in general, the HTLV-1 
proviral load measured in the CSF of individuals with HAM/TSP are typically greater than twice their 
load in the peripheral blood (Takenouchi et al., 2003), whereas the ratio of CSF to peripheral blood 
HTLV-1 proviral loads in asymptomatic carriers are typically lower, reflecting either recruitment or 
expansion of HTLV-1 infected cells in the CNS (Oh and Jacobson, 2008).  There is no evidence that 
HTLV-1 directly infects neuronal cells, astrocytes or microglia.  However, HTLV-1 specific CD8+ 
lymphocytes that secrete the neurotoxic cytokines, IFN-γ and TNF-α are present (Greten et al., 1998) 
supporting a bystander damage effect (Ijichi et al., 1993). The proposed sequence of events for 
“bystander damage” may be:  Activation of T cells following HTLV-1 infection allows the activation 
and migration of CD4+ and CD8+ T cells across the blood-brain barrier (from the peripheral blood 
into the central nervous system).  The HTLV-1 specific CD8+ T cells are preferentially recruited or 
expanded within the CNS, and respond to HTLV-1 antigen expressing cells, most likely HTLV-1 
infected CD4+ T cells.  The HTLV-1 specific immune response that occurs in the CNS results in the 
release of neurotoxic cytokines and subsequent CNS damage (Nagai and Jacobson, 2001). 
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1.3.4. Associated diseases 
 
HTLV-1 has been associated with a wide variety of other inflammatory diseases, such as uveitis 
(Mochizuki et al., 1992), polymyositis (Morgan et al., 1989), Sjogren’s syndrome (Vernant et al., 
1987) and bronchiectasis (Einsiedel et al., 2012).  Typically these are diagnosed in known HTLV-1 
carriers rather than following investigation for an underlying cause of these diseases.  HTLV-1 
carriers are susceptible to serious outcomes following secondary infection with pathogens such as 
varicella zoster, Mycobacterium tuberculosis (Pedral-Sampaio et al., 1997) and Strongyloides 
stercoralis (Marcos et al., 2008). 
 
1.4. Cellular and Molecular biology 
1.4.1. HTLV-1 receptor 
Whilst HTLV-1 has been shown to infect a wide variety of cell types in vitro (Jones et al., 2008; 
Koyanagi et al., 1993), the major reservoir of infection in vivo appears to be the CD4+ T-cells and a 
smaller component in the CD8+ T-cells (Nagai et al., 2001; Richardson et al., 1990).  The observation 
that HTLV-1 can infect several different cell types in vitro is consistent with the relatively recent 
identification that the widely expressed glucose transporter-1 (GLUT-1)  (Manel et al., 2003), 
neuropilin-1(NRP)  (Ghez et al., 2006), and heparan sulphate proteoglycans (HSPG) (Jones et al., 
2005) receptors play an important role in HTLV-1 viral entry.  The interplay between these molecules 
and the virus is not fully understood,  although it is postulated that sequential binding of HSPGs, 
NRP1 and GLUT-1 allow a conformational change of viral Env and thus cell entry (Ghez et al., 2010). 
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1.4.2. Mechanism of cell-to-cell spread 
 
HTLV-1 is highly cell associated (Yamamoto et al., 1982) requiring cell-to-cell contact for 
transmission.  Several mechanisms of cell-to-cell spread of HTLV-1 have been proposed.  Igakura  
(Igakura et al., 2003) first described the virological synapse through which HTLV-1 is transmitted 
from target cells to donor cells by polarisation of the cytoskeleton towards the uninfected cell, 
triggered by the viral tax gene in concert with stimulation of the intercellular adhesion molecule-1 
(ICAM-1) (Nejmeddine et al., 2009).   Electron tomography of the  virological synapse demonstrates 
viral particles present in multiple clefts within the synapse, surrounded by tightly bound plasma 
membranes forming confined intercellular sites (Majorovits et al., 2008), consistent with the 
observation that cell free virus particles are not found in plasma thus allowing escape from immune 
surveillance by HTLV-1 specific neutralising antibody (Nejmeddine and Bangham, 2010).  
More recently a biofilm-like extracellular structure has been described in which HTLV-1 infected cells 
covered with recently budded viral particles on the surface are rapidly transferred to the surface of 
target cells, resulting in new infection (Pais-Correia et al., 2010).  In addition, HTLV-1 p8 protein, 
derived from processing of the p12I protein of the pX region, may induce the formation of cellular 
conduits among T-cells allowing HTLV-1 transmission (Van Prooyen et al., 2010).  It is possible that 
HTLV-1 may combine multiple strategies to establish efficient viral transmission between cells and it 
is difficult to quantify the role played by each mechanism in vivo. 
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1.4.3. Mechanism of HTLV-1 proviral integration 
 
The HTLV-1 viral replication life-cycle, as with other retroviruses, is characterised by two distinctive 
steps.  Firstly, following viral entry into the cells, the viral genome is reverse transcribed in the 
cytoplasm using reverse transcriptase delivered to the host cell as part of the viral core, which 
generates a double stranded DNA copy.  Secondly, after viral DNA synthesis the HTLV-1 genome is 
stably associated with the viral integrase, also carried in the viral core, and later transported to the 
nucleus for integration (Figure 1.1):  The viral DNA is first processed by viral integrase at each 3’ end 
whereby two nucleotides are removed resulting in new CA-3’ ends (‘3’-end processing’).    These 
new ends attack a pair of phosphodiester bonds in the target DNA – in the case of HTLV-1 these lie 6 
base pairs apart.  The 3’ end of the viral DNA joins to the 5’-end of the host genome, and to 
complete integration, the two unpaired bases left at the 5’ ends of the viral genome are removed 
and the 5’-ends of the provirus can be ligated to host target DNA.  Whilst the viral integrase is 
responsible for 3’-end processing, the remaining steps are thought to be catalysed by host genomic 
cellular enzymes (Craigie and Bushman, 2012).  HTLV-1 viral targeting is not random and there is a 
preference for proviral integration in proximity to transcriptional units (Gillet et al., 2011; Meekings 
et al., 2008) and in proximity to specific transcription factor binding sites (TFBS)  (Melamed et al., 
2013).   
The provirus is then replicated along with cellular DNA during cycles of cell division, using the highly-
faithful host DNA polymerase.  The provirus also serves as a template for transcription of viral RNAs 
– some of which are translated to yield viral proteins, whilst a proportion of full-length viral RNA 
serves as genomic RNA in progeny virions. 
 
29 
 
 
 
Figure 1.1:  Retroviral integration (DNA breaking and joining reactions) 
Figure adapted from Craigie and Bushman, © 2012, Cold Spring Harbour Lab Press (Cold Spring Harb 
Perspect Med 2012;2:a006890).  DNA molecules shown by coloured balls.  (A) Linear blunt-ended 
viral DNA (green and yellow) and the target host DNA (blue and red). (B) 3’end processing:  Two 
nucleotides are removed from each of the 3’ ends of the viral DNA. (C) The 3’ends of the viral DNA 
attack a pair of phosphodiester bonds in the target DNA at the integration site (6 base pairs apart in 
the case of HTLV-1).  The 5’ends of the viral DNA are not joined.(D) Completion of integration 
requires removal of the two unpaired bases at the 5’end of the viral DNA and ligation of the 5’end of 
the viral DNA to the host genome.(E) Integrated provirus. 
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1.4.4. Mapping and quantification of proviral integration sites 
There has been a longstanding interest in accurate mapping and quantification of integration sites in 
HTLV-1 and other retroviral infections e.g. MLV (Wu et al., 2003) and HIV (Schroder et al., 2002).  The 
aim of this type of analysis is to answer questions such as  whether a single locus of integration was 
responsible for adult T-cell leukaemia/lymphoma (Seiki et al., 1984); to understand whether 
integration is truly random or targeted and to determine if there are ‘safe harbours’ of the host 
genome which could be identified as potential targets for therapeutic gene therapy.    
Detection of a single HTLV-1 integration site by Southern blot is characteristic of ATL (Yoshida et al., 
1982) and monoclonal integration of HTLV-1 proviruses into tumour cells remains part of the 
diagnostic criteria for ATL (Tsukasaki et al., 2009).  However, Southern blot lacks the sensitivity to 
detect minor populations of polyclonal HTLV-1 infected cells in both malignant and non-malignant 
infection.  In the 1990s and 2000s, inverse PCR (IPCR, Takemoto et al., 1994) and linker mediated 
PCR (LMPCR, Derse et al., 2007; Meekings et al., 2008; Wattel et al., 1995) followed by cloning, 
transformation and Sanger sequencing  were used to map integration sites in patients with 
malignant and non-malignant HTLV-1 infection.  However, these PCR based techniques have two 
major limitations.  First, the use of restriction enzymes leads to preferential detection of proviruses 
that lie near to the restriction site (30-60 base pairs for the restriction enzyme Msel (Wang et al., 
2008).  Second, PCR amplification preferentially amplifies short DNA fragments.  These classical PCR 
techniques cause a systematic bias in the accurate quantification of infected CD4+ T-cell clones, 
recover relatively few integration sites per experiment, and cannot accurately estimate the 
abundance of each unique integration site within a host.   
The observation of monoclonal integration of HTLV-1 provirus into ATL tumour cells, combined with 
the widespread use of Southern blot or IPCR /LMPCR integration site analysis has led to the widely 
held assumption that there is a single copy of HTLV-1 integrated into each infected CD4+ T-cell.  To 
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overcome these technical  limitations and for further hypothesis testing a customised high 
throughput sequencing method was developed in this laboratory to accurately map and calculate 
clonal abundance of each infected T-cell clone (Gillet et al., 2011) 
 
1.4.5. HTLV-1 viral gene expression 
 
The HTLV-1 proviral genome is nearly 9 Kb long and, similar to other retrovirus, the viral genome is 
flanked by two identical long terminal repeats (LTR).    The virus encodes multiple proteins by using 
both sense and antisense RNA strands and accessing several open reading frames (ORFs).  The 
provirus contains genes for structural proteins Gag and Env and enzymatic proteins (reverse 
transcriptase, integrase and protease).  There is an additional pX region at the 3’ end (Figure 1.2).  
The pX region, located between Env and the 3’LTR, contains genes for non-structural viral accessory 
proteins (p12, p13, p30 and p21) and regulatory genes tax and rex.   In 2002 Gaudray and colleagues 
(Gaudray et al., 2002) identified an ORF on the complementary RNA strand of the pX region whose 
protein product comprises a C-terminal basic leucine zipper (bZIP) and therefore named HTLV-1 bZIP 
(HBZ).  Whilst the viral proteins transcribed from the sense strand of the provirus are under the 
control of a promoter located at the 5’LTR, HBZ is controlled by a promoter within the 3’LTR and is 
therefore transcribed in an antisense direction.  HTLV-1 proviral genes are differentially expressed by 
alternate splicing and may be unspliced, singly spiced or doubly spliced.   
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Structural genes  
Gag, Pro and Pol are translated from a primary full length mRNA transcript, and ribosomal 
frameshifts result in the production of Gag-Pro and Gag-Pro-Pol fusion proteins, which are then 
subject to proteolytic cleavage (Nam et al., 1993).  Gag encodes the structural proteins of the matrix, 
capsid and nucleocapsid forming the structural ‘core’ of the HTLV-1 virion.  Env protein is transcribed 
as a singly spliced transcript and enhances viral entry and infectivity by mediating receptor binding 
and membrane fusion of virus particle with the cellular membrane (Delamarre et al., 1996). 
 The pX region 
The tax gene encodes the viral transactivating protein Tax, the best studied of all the HTLV-1 
proteins. Tax protein enhances viral gene expression through interactions with the Tax responsive 
elements (TRE) of the 5’LTR which consist of three repetitive 21 base pair sequences containing a 
core nucleotide sequence (TGACG)  (Jeang et al., 1988), homologous to the cAMP response element 
binding factor (CREB).  Tax does not bind to DNA directly,  but the formation of Tax-CREB promoter 
complex serves as a high-affinity binding site for the recruitment of the cellular co-activators CBP, 
p300 and PCAF and Tax has been shown in vitro to transactivate many viral and host genes 
(Kashanchi and Brady, 2005) (Grassmann et al., 2005) (Matsuoka and Jeang, 2007).  Host genes 
dysregulated by HTLV-1 Tax include genes involved in cell-cycle, apoptosis, cytokines and DNA 
repair. Several hundred Tax-binding partners have been reported in vitro and it has been 
demonstrated that Tax is subject to post-translational modifications including sumoylation, poly-
ubiquination, phosphorylation and acetylation, each of which alters its binding affinities and 
functions (Shembade and Harhaj, 2010), but it is likely that there are many in vitro artefacts of 
reported Tax-protein-complexes that may never occur in vivo.  The strongest evidence for the 
oncogenic potential of Tax has been demonstrated by its ability to immortalise cell lines in vitro 
(Grassmann et al., 2005) and to promote the growth of tumours in mice in vivo (Pozzatti et al., 
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1990).  Of note, HTLV-2 is not associated with aggressive leukaemia/lymphomas, but the HTLV-2 
associated Tax2 protein is also capable of transforming rat fibroblasts in vitro, albeit less efficiently 
than Tax1 (Endo et al., 2002). 
The regulatory protein Rex regulates proviral gene expression on a post transcriptional level and 
regulates the nuclear export of doubly spliced versus unspliced transcripts of HTLV-1.  The Rex 
responsive element is a short sequence present in the U3-R region of the LTR and recruits Rex to the 
transcript via a stem loop structure (Seiki et al., 1988).  Rex mediated regulation of RNA transport 
has been implicated in determining the kinetics of viral gene expression where initially Tax/Rex are 
expressed followed by other HTLV-1 transcripts (Rende et al., 2011). 
The accessory protein p12 is expressed from ORFI of the pX and localises in the endoplasmic 
reticulum.  It has been described to decrease surface expression of MHC-I (Johnson et al., 2001) and 
activates various pathways such as STAT5, resulting in reduced dependency on IL-2  for cell 
proliferation. 
HTLV-1 p13 and p30 accessory proteins are expressed from ORF II of the pX region and share part of 
their sequence.  Despite this their localisation and function is different:  HTLV-1 p13 can be detected 
in the inner membrane of mitochondria and modulates mitochondrial morphology and metabolism 
(Ciminale et al., 1999) and it has been suggested that p13 has a role in apoptosis (D'Agostino et al., 
2005; Hiraragi et al., 2005). HTLV-1 p30 regulates gene expression by sequestering Tax/Rex mRNA in 
the nucleus and by binding the Rex responsive element and it has been suggested that its function is 
dependent upon its concentration - at high concentrations p30 prevents viral replication by binding 
to Tax-Rex mRNAs and retaining them in the nucleus (Nicot et al., 2004) whilst at lower 
concentrations it functions as a transcription factor by modulating  CREB-responsive promoters 
(Zhang et al., 2000).  
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HBZ is constitutively transcribed in all HTLV-1 infected cell lines and in primary ATL cells (Satou et al., 
2006).  Whilst experiments with HBZ mutants lacking functional domains have demonstrated that 
HBZ is dispensable for in vitro immortalisation of cell lines, cells lacking HBZ have a lower 
proliferation capacity (Arnold et al., 2006).  Furthermore proliferation of infected T-cell lines could 
be inhibited by small interfering RNAs that suppress HBZ expression (Satou et al., 2006) and 
transgenic expression of HBZ in murine CD4+T-cells induces T-cell lymphomas (Satou et al., 2011).  
HBZ protein interacts with several transcription factors via its bZIP domain including JunB, Jun D and 
AP1 and, depending upon its binding partner, variably activates or inhibits host cellular gene 
transcription (Matsuoka and Jeang, 2011).  
HBZ protein is difficult to detect in ex vivo samples with current laboratory techniques, even in the 
presence of high levels of HBZ mRNA (Suemori et al., 2009). Curiously, HBZ protein can be readily 
detected by western blot lysates from cells transfected with HBZ expression vectors which raises the 
question as to whether lack of detection of HBZ protein in patient derived ex vivo samples is 
indicative of a translation block in vivo.  Site directed mutagenesis altering the ATG start codon of 
HBZ, reveals that the effects of HBZ on cellular proliferation is exerted at mRNA level (Satou et al., 
2006).  In addition, cells infected with an HTLV-1 molecular clone retain a large proportion of HBZ in 
the nucleus in a Rex-independent manner (Rende et al., 2011) suggesting that at least some of its 
function is exerted at nuclear RNA level rather than protein. 
The strongest evidence for the expression of HBZ protein in vivo is the recent identification of an 
anti-HBZ immune response:  Approximately 10% of HTLV-1 infected individuals have anti-HBZ 
antibody responses (Enose-Akahata et al., 2013) and HBZ specific cytotoxic T-lymphocytes are found 
in ~ 30% patients (Hilburn et al., 2011; Macnamara et al., 2010).  Thus the difficulty in detecting HBZ 
protein in samples derived ex vivo suggests that either the HBZ protein levels are below the current 
limits of laboratory detection and/or that the translation of HBZ is tightly regulated by the provirus. 
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Figure 1.2: The HTLV-1 proviral genome 
Figure adapted from Rende et al, Leukemia Research and Treatment, 2011.  The 
organisation, alternate splicing and coding potential of HTLV-1 mRNAs is shown.  ORFs are 
indicated by coloured boxes and the numbers correspond to nucleotide positions of HTLV-1 
RNA sequence (Koralnik et al., 1992). 
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1.4.6. Mechanism of viral proliferation (mitotic versus infectious spread) 
 
To persist within the host CD4+ T-cell compartment the virus pursues two strategies.  Firstly via de 
novo infectious spread (as described) and secondly via mitotic proliferation of infected cells.  During 
the chronic phase of infection mitotic proliferation appears to be dominant. 
There is strong evidence to support the conclusion that mitotic proliferation is the dominant force in 
the maintenance of a steady state proviral load (PVL) of infected peripheral blood mononuclear cells 
(PBMC).  Firstly, longitudinal studies of integration site identity demonstrated the existence of long-
lived expanded clones, suggesting that each clone of cells originated from a common progenitor cell 
(Cavrois et al., 1996; Cavrois et al., 1995; Furukawa et al., 1992; Gillet et al., 2011).  Secondly, there is  
remarkably low sequence diversity compared with other retroviruses (Overbaugh and Bangham, 
2001) which is consistent with replication via the highly fidelity, proof reading host DNA polymerase 
rather than the error prone retroviral reverse transcriptase.  In line with this are the results of a 
randomised, double-blind, placebo controlled study of six months’ combination therapy with 
nucleoside analogues (zidovudine and lamivudine) in HAM/TSP:  Inhibition of reverse transcriptase 
did not demonstrate a reduction in proviral load (Taylor et al., 2006).  However, the relative 
contributions of infectious and mitotic spread remain unknown. 
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1.5. Immune determinants and response to HTLV-1 
 
Life-long infection with HTLV-1 is frequently accompanied by a strong and constitutive immune 
response.  It remains uncertain how the virus regulates the balance between proliferation and viral 
gene expression whilst escaping immune control. 
The major predictor of disease is the proviral load:  The proviral load within an individual remains 
relatively constant over years albeit with a slow steady rise over decades.  In a large cohort study in 
Japan, the median PVL of those in the 40-60 year old age group was significantly greater than those 
younger than 40 years (Sasaki et al., 2010).  However, the variation in proviral loads between 
different patients is great.  Individuals may have a PVL that ranges between less than 0.001% PBMC 
to over 100% PBMC, with the risk of clinical disease rising in carriers with a PVL above 4% in Japan 
(Iwanaga et al., 2010) and a PVL > 10% in the UK (Demontis et al., 2013).  The median proviral load in 
Japanese males has been reported as 2.1% and in females 1.4% (Sasaki et al., 2010),  consistent with 
the observation that for unknown reasons more males develop ATL.  Nonetheless, there is overlap in 
the range of proviral load seen between patients with disease and those that remain life-long 
asymptomatic carriers, making per-patient risk analysis extremely difficult. 
The observation that asymptomatic family members of those with HAM/TSP or ATL carry higher 
proviral loads than those without a family history supports the hypothesis that there is a hereditary 
genetic determinant that predisposes to disease (Iwanaga et al., 2010):   Class I HLA genotype plays a 
significant part in determining the risk of HAM/TSP and maintenance of the proviral load in 
individuals from the Kagoshima region of Japan (an HTLV-1 endemic population).  The results 
showed a dominant protective effect of HLA-A*02 and HLA-Cw*08 in reducing the risk of HAM/TSP 
and in control of proviral load in asymptomatic carriers, whilst the presence of HLA-B*5401 or class II 
HLA-DRB1*0101 was associated with an increased risk of disease (Jeffery et al., 2000; Jeffery et al., 
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1999).    In the same cohort of individuals, it has been shown that  the ability to present peptides 
from HBZ to the cytotoxic T-lymphocytes (CTLs), as determined by an individual’s HLA genotype is 
associated with a low proviral load and reduced incidence of HAM/TSP (Macnamara et al., 2010).  
Recent work on same cohort has further shown that the protective effect of HLA- Cw*08 and 
detrimental effect of HLA- B54 was limited to those with a specific inhibitory molecule KIR2DL2 
(Seich Al Basatena et al., 2011).    
Analysis of non-HLA host genetic factors has revealed that specific polymorphisms also affect the risk 
of developing HAM/TSP e.g.  the TNF-α promoter-863 A allele (Vine et al., 2002) promotes the risk of 
disease, whilst IL-10-592A (Sabouri et al., 2004), stromal-derived factor-1 +801A, and IL-15 +191C 
conferred protection against HAM/TSP (Vine et al., 2002), but the contributions of these non-HLA 
genes to the pathogenesis are largely unknown and requires validation in other ethnic populations in 
association with broader genome-wide studies. 
 HTLV-1 can elicit a strong antibody response and often include IgMs in both ACs and HAM/TSP 
suggesting persistent expression of HTLV-1 proteins (Nagasato et al., 1991).  Antibodies to Gag, Env, 
Tax, Rex and HBZ have all been identified and the sera of the majority of patients contains antibodies 
directed against Tax (Souza et al., 2011).  However, since HTLV-1 is highly cell-associated, it is not 
clear what role neutralising antibody may play in controlling infection. 
There are several lines of evidence that  HTLV-1 specific cytotoxic T-lymphocyte (CTL)  responses 
have a significant impact upon infection:  (1) The described observation of an association between 
specific HLA Class I alleles and protection from disease; (2) The existence of escape mutations in 
known CTL epitopes (Niewiesk et al., 1995); (3) The observation that CD8+ T-cells efficiently kill 
autologous Tax expressing lymphocytes in fresh PBMC from infected individuals (Hanon et al., 2000) 
and (4) The more recent identification of HBZ-specific CD4+ and CD8+ cells  in vivo and  a significant 
39 
 
association between the HBZ-specific CD8+ T-cell response and asymptomatic infection (Hilburn et 
al., 2011).   
In recent years, more attention has been focused upon CTL quality rather than CTL frequency 
(Bangham, 2009) and that functional avidity, a metric of the ability of CTL to detect limiting 
quantities of antigen, is a better index (Kattan et al., 2009).  High CTL avidity correlates with a lower 
proviral load and proviral gene expression which suggests that efficient control of HTLV-1 in vivo 
depends on the quality of the CTL response  (Kattan et al., 2009) – although it is difficult to separate 
cause and effect when considering the host-viral dynamics in chronic phase. 
The CTL response may be repressed by regulatory T-cells (Tregs):   Expansion of a CD4+FoxP3+ 
subset is observed in HTLV-1 infection which could be explained by Tax-induced up regulation of 
CCL22 (Toulza et al., 2010), the  natural ligand for C-C chemokine receptor type-4 (CCR4) on FoxP3+ 
cells, and there is an inverse correlation between CTL lysis efficiency and the % CD4+ FoxP3+Tax-  
CTLs (Toulza et al., 2008).  These observations may, in part, contribute to the profound immune 
suppression observed clinically in HTLV-1 infection. 
 
1.5.1. Immune response in ATL 
 
Little is known about the role of HTLV-1 specific CTLs in the prevention of ATL, during transformation 
and following a therapeutic response to treatment.     There have been case reports of ATL following 
solid organ transplantation in the context of immune suppressive therapies (Hoshida et al., 2001; 
Suzuki et al., 2006). 
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Despite the predominance of CD4+ malignant ATL cells, the absolute frequency of CD8+ T-cells 
remains approximately within the normal reference ranges (Arnulf et al., 2004).   There are little data 
describing the functional properties of CTLs in ATL, but it is acknowledged that the ex vivo CTL 
response in ATL is weak (Shimizu et al., 2009).   By comparison with ACs, the Tax-specific CTLs are 
directed at a narrower range of epitopes and are present at low or even absent frequencies with no 
detectable Env-specific CTLs in ATL subjects (Kozako et al., 2006).  A subset of ATL patients have no 
detectable CTL when PBMCs are measured by functional assays, but after culture functional CTL can 
be occasionally observed (Arnulf et al., 2004; Kannagi et al., 1984).   
Although the observed frequency of CTL response to HTLV-1 in ATL is reduced or absent, there is 
evidence for an efficient response in a subset of individuals:  Furukawa observed amino acid change 
within the Tax 11-19 epitope which rendered Tax unrecognizable to CTLs and premature stop codons 
in the tax gene which prevent Tax transactivation (Furukawa et al, 2001).   Loss of Tax expression or 
activity has the downstream effect of reduced expression of other viral genes that require Tax 
transactivation (gag, pol and env).  Therefore, it is implied that the loss of a single viral protein 
allows the infected cell to escape surveillance by CTL specific for other viral proteins.   
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1.6. Animal models of ATL  
 
Since the majority of HTLV-1 infections occur during infancy via breast feeding, it is neither practical 
nor ethically possible to investigate early models of HTLV-1 infection in naturally infected human 
primate hosts.  Therefore, animal models provide an excellent tool for understanding the biology of 
HTLV-1 driven ATL and particularly for the development of future vaccines and novel treatments. 
HTLV-1 animal models vary from those that are naturally infected hosts of similar viruses to 
engineered small animal models. 
Bovine leukaemia virus (BLV) causes an aggressive B-cell lymphoma in <5% infected cattle aged over 
5 years, and is a major economic problem in cattle-trading since infection may be spread through 
milk transmission.  BLV is an appealing model for ATL as large animals tend to provide a more 
relevant model of human cancer development with closer physiology.  The most widely used animal 
model of BLV is in sheep (Djilali and Parodi, 1989; Gillet et al., 2013) and provides some similarities 
with ATL models since the retrovirus contains both Tax and Rex viral genes, although no equivalent 
of the antisense HBZ gene  has been identified (reviewed by (Hajj et al., 2012).  Whilst interesting 
parallels may be drawn between the BLV model of B-cell lymphoma and ATL, these remain distinct 
viruses which infect different cell types and cause disease in hosts with differing immune responses. 
‘Old world’ monkeys are frequently naturally infected with STLV-1, which has a nucleotide sequence 
closely related to HTLV-1 (Watanabe et al., 1985), in which clonal proliferation has also been 
identified by inverse PCR techniques (Gabet et al., 2003) and lymphoproliferative disorders have 
been observed (McCarthy et al., 1990; Tsujimoto et al., 1987; Voevodin et al., 1996).  However, for 
logistic reasons, detailed characterisation of STLV-1 has not been achieved and there has been no 
analysis on the function of accessory or regulatory proteins.  Recently Miura et al, identified that 
STLV-1 contains an STLV-1 bZIP factor (SBZ) on the antisense strand similar to HBZ and have reported 
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a high throughput sequencing technique to map STLV-1 integration sites which has shown 
asymptomatic STLV-1 infected macaques have  proliferative  features in common with those of 
HTLV-1 asymptomatic carriers, suggesting that these animals may serve as suitable models for 
analysis of HTL V-1 carriers (Miura et al., 2013).   
Transgenic mouse models expressing Tax (Hasegawa et al., 2006) or HBZ (Satou et al., 2011) in T-
cells drive tumour formation in vivo, but whether Tax or HBZ expression alone is sufficient for 
human T cell leukaemogenesis remains unclear since it is known that mice primary cells are 
substantially more easily transformed than human primary cells (Hahn et al., 1999).   More recent 
mouse models of HTLV-1 include humanised mice in which human haemopoietic stem cells 
reconstitute a variety of immune deficient mice by infecting the stem cells in vitro prior to 
engraftment (Banerjee et al., 2010) or following intraperitoneal inoculation with irradiated HTLV-1 
producing cells (Villaudy et al., 2011).  Although these mice models allow for the study of early 
infection events and T-cell tumours, a crucial difference is that they lack a functional immune 
response. 
 
1.7. Aims and Hypothesis  
 
The central aim of this work was to test the hypothesis that the site of proviral integration 
determines the risk of developing ATL.  To achieve this aim, I used a customised high-throughput 
sequencing technique previously developed in this laboratory to test the following hypotheses:- 
1. There is a single copy of HTLV-1 integrated into each host genome 
2. The genomic environment flanking the proviral integration site is associated with malignant 
transformation of HTLV-1 infected clones. 
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Chapter 2. Materials and Methods 
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2.1. Primary cells and cell lines 
2.1.1. Patients samples 
 
DNA samples from AC and ATL patient samples were provided by collaborators at the Institute for 
Viral Research, Kyoto University, Japan and were obtained with written consent in accordance with 
regulations defined by the Japanese Government and Kyoto University.   
T-cell clones were derived from blood samples donated by patients attending the HTLV-1 clinic at 
the National Centre for Human Retrovirology, Imperial College Healthcare NHS Trust, with written 
informed consent in accordance with the UK National Research Ethics Service (NRES reference 
09/H0606/106).   
PBMC were immediately isolated from peripheral blood and layered over Histopaque-1077 (Sigma-
Aldrich), centrifuged at 1700 rpm for 25 minutes with a slow brake setting, washed twice with PBS 
and cryopreserved in fetal bovine serum (Gibco-Life Technologies) containing 10% dimethylsulfoxide 
(Sigma-Aldrich) and stored in liquid nitrogen. 
 
2.1.2. Cell lines 
 
Jurkat E6.1 (JKT) was used as an HTLV-1 negative T cell line (Schneider et al., 1977) to identify 
potential contamination during LMPCR and high throughput sequencing (HTS).  Tarl2 is a rat 
lymphoid cell line, containing one integrated copy HTLV-1 provirus per cell (Tateno et al., 1984)  and 
was used for quantification of proviral loads.  All cell lines were cultured in either containment level 
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2 (Jurkat) or containment level 3 (Tarl2) in complete medium: RPMI-1640 medium (Sigma-Aldrich) 
supplemented with 1% L-glutamine, 1% penicillin/streptomycin and 10% heat-inactivated FBS 
(Gibco).  
Methylated and unmethylated DNA from ATL cell lines 43-T (methylated) and 48-T (unmethylated) 
for methylation-specific PCRs were provided by Dr Yorfumi Satou, Kumamoto University, Japan.  
 
2.2. Isolation of CD4+ T-cell clones by limiting dilution 
 
CD4+25+ T-cell clones were isolated from 10 patients (7 female, 3 male) with different clinical 
manifestations of HTLV-1: Two ACs (median PVL 6.2%), 5 HAM/TSP (median PVL 13.6%), 2 ATL 
(median PVL 57.5%) and 1 polymyositis (PVL 18.3%). 
CD4+25+ cells were isolated by magnetic activated cell sorting (CD4+CD25+ isolation kit, Miltenyi 
Biotec). Cells were subsequently cloned by limiting dilution in RPMI containing 10% human AB serum 
(Invitrogen) in the presence of 50 IU/mL IL-2 (Promocell), 1 μg/mL PHA (Sigma-Aldrich), 10μM 
raltegravir (Selleck Chemicals), and 0.5 × 106/mL γ-irradiated feeder cells (mixed PBMCs from 3 
uninfected donors). Clones were expanded with feeder cells and PHA every 14 days and fed with IL-2 
and raltegravir twice weekly.  Clones were cultured for 4-6 weeks before genomic DNA extraction 
(DNeasy Blood and Tissue Kit; QIAGEN, 69504. 
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2.3. Molecular biology methods 
2.3.1. Proviral load measurements 
The proviral load was measured using quantitative polymerase chain reaction (QPCR) using 
ABI7900HTFast (Applied Biosystems). PCR was carried out using ABI Fast SYBR green mastermix 
(Applied Biosystems) according to manufacturer’s instructions.  Proviral copies were quantified using 
tax specific primers (SK43, SK44)(Kwok et al., 1988) normalised to the number of β-actin copies 
(Actin-Fw, Actin-Rev). Primer sequences are shown in table 2.1. 
Cycling conditions for actin and tax PCR consisted of:  95:C for 20 seconds,  40 cycles at 95:C for 1 
second, 60:C for 20 seconds.   
Standard curves were generated using serial dilutions of Tarl2 DNA at six different concentrations 
(5ng/μl to 20 pg/μl).  DNA samples from patients were measured at three different dilutions (5ng/μl 
to 0.56ng/μl).  Proviral load was calculated as a ratio of tax to β-actin copies on the assumption of 
one copy of tax and two copies of actin per cell. 
 
2.3.2. 5’ long terminal repeat sequencing 
Since the HTLV-1 LTR sequence varies between isolates, the LTR was sequenced prior to integration 
site library preparation to identify primer binding site polymorphisms before high throughput 
sequencing. The 3’ and 5’ LTR sequences are assumed to be identical (Seiki et al., 1983). 
5’LTR sequencing was sequenced using a forward primer (5LTR-FW) in the LTR region and the 
reverse primer (5LTR-Rev) located in the viral gag gene sequence downstream of the LTR (primer 
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sequences are shown in table 2.1).  Thermal protocol: 98ᵒC for 3 minutes, 35 cycles 98ᵒC for 10 
seconds, 64ᵒC for 20 seconds and 72ᵒC for 20 seconds followed by 72ᵒC for 10 minutes. 
The amplified PCR product was sequenced using Sanger sequencing (MRC Clinical Sciences Centre, 
Core Genomic Laboratory). 
 
2.3.3. Long range PCR to identify defective proviruses  
Type 1 or type 2 defective proviruses are commonly identified in ATL samples and are unable to 
express Tax due to loss of promoter situated in either the 5LTR and/or pol regions.  First an internal 
control region of the 3’end of the HTLV-1 genome is amplified for each case, followed by a long-
range PCR to identify defective proviruses based upon the length of the long-range PCR product 
between 5’LTR and pX region (Figure 2.1).  A product length of 6.5Kb defines a complete provirus, a 
product less than 6.5Kb as a  type 1 provirus and failure to amplify any product, a type 2 defective 
(Tamiya et al., 1996). 
DNA was amplified using KOD Hot Start DNA polymerase TB341 (Toyobo, Novagen).  The primers for 
the control PCR (Control- Fw, Control- Rev) and long range PCR (LR- Fw, LR- Rev) are listed in table 
2.1.  Cycling conditions for the internal control PCR consisted of:  95ᵒC for 2 minutes, 30 cycles: 95ᵒC 
for 20 seconds, 59ᵒC for 10 seconds and 70 ᵒC for 48 seconds, followed by 70ᵒC for 5 minutes.    
Cycling conditions for the long-range PCR consisted of:  95ᵒC for 2 minutes, 30 cycles: 95ᵒC for 20 
seconds, 66ᵒC for 175 seconds, followed by 72ᵒC for 15 minutes. 
The PCR products were electrophoresed on a 1% agarose gel with expected product size of 2.85Kb 
for the control PCR and 6.5Kb for a complete long-range PCR product. 
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Figure 2.1: Schematic representation of wild type (WT) and defective proviruses 
The complete (WT) structure is depicted in the top panel showing the presence of two LTRs 
and the internal gag, pol, env and pX regions of the provirus.  A type 1 defective provirus is 
characterised by a deletion of the internal gag/pol regions (indicated by dashed box) and a 
type 2 defective provirus is characterised by absence of both the 5’LTR and variable lengths 
of the internal gag/pol regions.  These subtypes of proviruses can be distinguished by PCR 
followed by examination of the length of the PCR product by agarose gel electrophoresis: 
the type 1 product shows a short band and a type 2 product shows absence of long-range 
PCR in the presence of a positive control PCR. 
 
 
 
  
 Control PCR 2.85 Kb Long range PCR 6.5 Kb 
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2.3.4. Identification of exon 2 and exon 3 tax gene mutations 
 
Tax protein is 353 amino acids in length.  Exon 2 provides just the start codon (methionine) whilst 
the remaining amino acids are transcribed and translated from exon 3. The reference sequence 
published by Fan et al was selected (GenBank BAH85788.1) since it was published on amino acid Tax 
sequences in a cohort of patients from a similar region of Japan and in an era of high-fidelity 
polymerases (Fan et al., 2010). 
Exon 2 
PCR products from complete proviruses identified by long-range PCR were purified using DNA PCR 
purification kit as per manufacturers protocol (QIAGEN).  Exon 2 of tax was amplified using Phusion 
high fidelity DNA polymerase (NEB), inspected on 2% agarose gel for product length (318 base pairs) 
and sequenced by Sanger sequencing as before.  Primers (Exon2-Fw, Exon2-Rev) listed in table 2.1.  
Cycling conditions as follows: 98 ᵒC for 30 seconds, 20 cycles: 98ᵒC for 5 seconds, 51.5ᵒC for 20 
seconds, 72ᵒC for 10 seconds, followed by 72ᵒC for 5 minutes. 
Exon 3 
The PCR products of the control long-range PCR (methods 2.3.4) were purified using DNA PCR 
purification kit as per manufacturers protocol (QIAGEN).  Exon 3 of tax was amplified using Phusion 
high fidelity DNA polymerase (NEB), cycling conditions as follows: 98 ᵒC for 30 seconds, 20 cycles: 
98ᵒC for 5 seconds, 51.5ᵒC for 20 seconds, 72ᵒC for 10 seconds, followed by 72ᵒC for 5 minutes.   
 PCR products were inspected on 2% agarose gel for product length (1120 base pairs) and sequenced 
by Sanger sequencing as before using 6 different sequencing primers to capture the entire exon.  
Primers (Exon3-Fw, Exon3-Rev and sequencing primers I-VI) listed in table 2.1.   
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2.3.5. Identification of hypermethylated 5’LTR  
 
Since hypermethylation of the 5’LTR of the provirus has been described in 10-15% ATL cases and has 
been shown to silence tax gene transcript expression,  methylation specific PCR (MS-PCR) was 
undertaken as described by Takeda et al (Takeda et al., 2004).  However, MS-PCR is an imperfect 
method to characterise precise methylation events because it can only determine methylation 
events of the CpGs of the primer binding sites only (and implies methylation of CpGs in the 
amplicon) but since the critical Tax response element-1 (TRE-1) lies proximal to the start of the 
provirus within a large CpG island, it is not possible to design good MSP primers in this region.    By 
contrast,  bisulfite sequencing PCR (BSP) is a method in which custom specific primers are designed 
with no bias towards methylated or unmethylated sequences and can be designed across the 5’ 
proviral integration site (between the host genome and U3 region of 5’LTR, incorporating the critical 
TRE-1).  The PCR products can then be subcloned into plasmid DNA and colonies sequenced.  
However, Takeda et al have demonstrated that MSP between the R-region of the 5’LTR and gag 
correlates extremely well with BSP sequencing results across the integration site and can be used for 
large numbers of samples (Takeda et al., 2004).  
 
Methylation-specific PCR (MS-PCR) 
DNA was treated with sodium bisulfite (Sigma) which converts unmethylated cytosine residues to 
uracil whilst methylated cytosine residues remain unchanged during the treatment.  Bisulfite treated 
DNA was purified using Zymo EZ Bisulfite DNA clean-up as per manufacturer protocol. 
Once converted, the methylation profile of the DNA could be determined by hemi-nested PCR 
amplification using specific primers for either methylated or unmethylated DNA.   ATL control cell 
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lines T-43 (methylated) and T-48 (unmethylated) were used as both positive and negative controls 
for each PCR reaction.   For the first PCR reaction, forward primer in the U3 region of the 5’LTR and 
reverse primer in gag and for the hemi-nested PCR, forward primer in the R region of the 5’LTR and 
the same reverse primer in gag (primer sequences listed in table 2.1).  MS-PCR primers did not 
amplify unconverted HTLV-1 or host genomic DNA. 
DNA was amplified using a non-proof reading enzyme, JumpStart RedTaq polymerase (Sigma). 
Cycling conditions for PCR1 consisted of: 94ᵒC for 2 minutes, 35 cycles: 94 ᵒC for 30 seconds, 53ᵒC for 
30 seconds and 72 ᵒC for 2 minutes. Cycling conditions for PCR 2 consisted of: 94ᵒC for 2 minutes, 30 
cycles: 94 ᵒC for 30 seconds, 57ᵒC for 30 seconds, 72 ᵒC for 2 minutes, followed by 72 ᵒC for 5 
minutes.  The PCR product was inspected on a 2% agarose gel for length (428 base pairs).   
Bisulfite Sequencing PCR (BSP) 
BSP was undertaken with customised primers on 4 specific cases of ATL as proof of concept, to 
demonstrate that MSP correlates with BSP.  DNA was bisulfite converted as before and amplified 
with custom specific primers from the host genome (upstream of the 5’ LTR) to gag followed by a 
hemi-nested PCR in the U3 region, incorporating all three TREs.  Primers are listed in table 2.2 
(custom primers-forward, gag-rev and heminested- U3 rev). Cases were selected for proof of 
concept on the basis of similar melting temperatures.  DNA was amplified using a non-proof reading 
enzyme, JumpStart RedTaq polymerase (Sigma). Thermal conditions for PCR 1 and PCR 2 as follows: 
94ᵒC for 2 minutes, 35 cycles: 94 ᵒC for 30 seconds, 52ᵒC for 30 seconds and 72 ᵒC for 2 minutes. 
PCR products were cloned and transformed into chemically competent E.coli TOPO TA cloning® kit 
for sequencing (Invitrogen).  Twenty colonies were picked per plate and plasmid DNA was purified 
using QIAprep® Spin Miniprep kit (QIAGEN).  PCR products were sequenced by Sanger sequencing as 
before. 
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2.3.6. T-cell receptor gene rearrangement studies 
 
T-cell receptor γ gene rearrangement studies were undertaken by Mikel Valganon in the Molecular 
Pathology Diagnostic Unit, Hammersmith Hospital, Imperial College Healthcare NHS Trust using the 
established BIOMED-2 protocol (Langerak et al., 2012; van Dongen et al., 2003) followed by 
analysis using GeneMapper 4.1 software (Applied Biosystems).  In brief, the BIOMED-2 
protocol consists of a multiplex PCR of the T-cell receptor-γ (TCRG) locus at DNA level, 
selected due to the relative simplicity of the TCRG locus.  The PCR products are then 
analysed for size and fluorescent intensity by heteroduplex analysis or genescanning. 
 
2.4. Analysis and quantification of proviral integration sites  
2.4.1. Preparation of integration site libraries for high-throughput sequencing 
 
This protocol has been designed for amplification of integration sites defined as the junction of 3’ 
end of the viral genome and the host genome (Figure 2.2)   
Up to 10 µg DNA was sheared by focused ultrasonication (Covaris S2) , with the following protocol: 
Water bath at 6 to 8:C, Quick burst step: 5 seconds at 20% duty cycle, intensity level 5 and 200 
cycles per burst followed by 90 seconds at 5% duty cycle, intensity level 3 and 200 cycles per burst 
(Figure 2.2 B).  
DNA ends were then end-repaired using 15U T4 DNA polymerase (New England Biolabs - NEB), 5 
units of DNA polymerase I Klenow fragment (NEB), 50 units of T4 polynucleotide kinase (NEB) and 
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0.8 mM dNTP (Sigma) in T4 DNA ligase buffer (NEB) at 20:C for 30 minutes.  This is followed by the 
addition of adenosine to the 3’ ends of the DNA using 30U Klenow Fragment 3’ to 5’ exo- (NEB) in 
NEB2 buffer (NEB) at 37:C for 30 minutes (Figure 2.2 C/D).   
DNA was ligated to 100pmol/μl of a partially double stranded DNA linker using a quick ligation kit 
(NEB).  Each linker contains a sample-identifying 6 base barcode tag to allow multiplexing during 
sequencing (Figure 2.3). 
Nested (two step) PCR selectively amplifies HTLV-1 at the junction of the 3’LTR.  The first PCR was 
carried out between two primers Bio3 (viral LTR) and Bio 4 (linker) and the second PCR between Bio 
5 in the viral LTR and P7 contained within the linker, (Figure 2.2 E/F).  The second PCR also adds the 
necessary adapter molecules to the amplicons, required for tethering to the Illumina flow cell.  
Thermal conditions for PCR1 and PCR2 were as follows:  96:C for 30 seconds, 7 cycles; 94:C for 5 
seconds, 68:C for 1 minute, followed by 23 cycles; 94:C for 5 seconds and 68 :C for 1 minute 
followed by 68 :C for 9 minutes.  Primer sequences listed in table 2.1. 
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Figure 2.2: Pipeline for library preparation of HTLV-1 integration sites. 
The grey bars represent host genome, green bars HTLV-1 genome and blue bars the linker. (A) The 
region of interest is circled in red and represents the junction of the 3’LTR and host genome.(B) DNA 
is randomly fragmented by sonication. (C)/(D) DNA end-repaired, adenosine molecules added to 3’ 
ends prior to ligation of linker containing customised barcode. (E) First PCR amplifies between Bio3 
(viral LTR) and Bio4 (linker). (F) Nested PCR amplifies between Bio5 (viral LTR) and P7 (linker).  The P5 
and P7 oligonucleotides are required for Illumina sequencing.  P7 is incorporated within the design 
of the linker whilst the P5 oligonucleotide is added by incorporation into the PCR primer (P5-Bio5).  
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Figure 2.3: Basic linker structure 
Schematic structure of the oligonucleotide sequence of the partially double-stranded linker which is 
ligated to DNA during library preparation and allows multiplexing of samples and incorporation of 
the P7 molecule required for Illumina high-throughput sequencing.  The nested PCR primers for 
PCR1 (Bio4) and PCR2 (P7) are incorporated within the linker sequence.  The linker does not contain 
a complementary sequence to the Bio4 primer: This increases PCR specificity since only DNA 
containing proviral sequences will be amplified. The 6 base bar-code tag denoted as ‘NNNNNN’ is 
located between the sequencing primer binding site and the P7 binding site. 
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2.4.2. Library quantification prior to sequencing 
 
Libraries for sequencing were combined based upon DNA concentration.  Libraries were then 
quantified by QPCR using primers specific to the amplicon structure (P5Bio5 and P7) with a standard 
curve based upon a previously quantified and sequenced reference library. 
Each Illumina flow cell contains 8 lanes with a single DNA library per lane.  One lane per flow cell is 
used as a control lane containing bacteriophage PhiX DNA.  
The libraries were constructed such that there was only one DNA sample from an individual patient 
within a given lane and each linker/tag was used only once per lane. 
 
2.4.3. High throughput sequencing and mapping using Illumina pipeline 
 
Libraries were sequenced by Dr Laurence Game’s laboratory, MRC Core Genomics Laboratory, 
Hammersmith Hospital Campus, London on an Illumina GA II or HiSeq2000 sequencer. 
The standard Illumina analysis pipeline was used for image processing, base-calling and alignments, 
with default filter and quality settings.  ELAND Paired algorithm (CASAVA) was used for read 
alignments, against the UCSC human genome build 18 and HTLV-1 sequences. 
Each amplicon was sequenced on both sense and antisense strands (50 base pair reads) with a 6 bp 
barcode tag read (Figure 2.4).   
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Read 1: Uses the sequencing primer (‘HTLVseq’) and generates a sequence from the integration site.  
Read 2: Uses the SBS8 sequencing primer and generates a sequence starting from the linker 
Read 3: Uses the SBS8rev sequencing primer which generates a sequence from the linker to map the 
6 base pair sample tag used for multiplexing. 
 
 
 
 
Figure 2.4: Basic structure of amplicon for high-throughput sequencing 
P5 and p7 are the oligonucleotides added during LMPCR amplification required for illumina 
sequencing.  Each amplicon is sequenced three times.  Read 1 is sequenced from the end of the LTR 
(5’ or 3’ LTR), read 2 from the linker into either the host genome or the viral genome and read 3 
which maps the 6 base pair barcode.  Since the 3’LTR and 5’LTR are sequence identical, we would 
expect half the amplicons to contain HTLV-1 specific sequences and half from the host genome.  
These can be resolved by bioinformatic alignment. 
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2.4.4. Data extraction pipeline 
 
The data extraction pipeline was customised and developed in this laboratory by Anat Melamed 
using Microsoft Access and designed such that other laboratory members can readily adapt it for 
their own usage. 
The pipeline consisted of 3 key steps:- 
1. Data filtering:  
i. Sequences must be specific and begin with the 3’ terminal proviral LTR 
sequence ‘ACACA’.  
ii. Sequences must pass Illumina sequencing quality scores and mapping 
criteria 
2. Calculation of clonal abundance for each sample and each integration site: 
i. Identify distinct read 1 co-ordinates (integration site) and then, for each 
read 1, count the number of distinct read 2 co-ordinates (to distinguish 
distinct shear sites from PCR duplicates). 
ii. Sort different barcode tags (sample specific) to correctly attribute each 
integration to site to a particular sample  
3. Data refinement: 
i. Remove artefacts e.g. frameshifts or other minor PCR or sequencing errors 
that cause mismapping. 
ii. Calibrate the number of shear-sites to overcome the likelihood that two 
samples belonging to the same clone have the same shear site by chance.  
Based upon a calibration experiment by Dr Nicolas Gillet, a spline function 
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was fitted to the data by Professor Charles Berry, UC San Diego and is 
applied to all datasets (Berry et al., 2012). 
iii. To estimate sensitivity of the experiment by calculating an approximate 
input of viral copies (proviral load x input of DNA) and comparing to the 
proportion of proviruses recovered (observed number of copies/ input 
number copies) 
4. Output 
The output of the data-refinement pipeline is a large Microsoft Excel spread sheet containing lists of 
integration sites for each sample with a calculation of clonal abundance for each site.  The lists of 
sites can then be annotated for genomic and epigenetic marks. 
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2.4.5. Calculation of abundance of each integration site 
 
We define an infected clone as all the cells that share an integration site.  Following calibration, the 
number of ‘sister cells’ of a clone can be calculated:  this is defined by the different cells sharing an 
integration site (identical genomic location of read 1 but different read 2). 
The relative abundance of each clone is calculated as the share of the proviral load occupied by each 
clone:- 
 
Equation 2.1   
 
 
The absolute abundance of each clone is calculated as the number of sisters of each clone per 
10,000 PBMC:- 
 
Equation 2.2 
 
Relative abundance of a clone =          (number of sisters in clone)                 x 100     
                                                              (Total number of sisters in sample) 
 
Absolute abundance of a clone =        Relative abundance   X       PVL     
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2.5. Bioinformatic and statistical methods 
2.5.1. Annotation of integration sites with genomic environment 
Each individual integration site, from a random dataset or in vivo, was annotated for specific 
genomic or epigenetic elements.  Detailed information on these annotations and source listed in 
Appendix 1. 
Genomic co-ordinate data on transcriptional units, CpG islands and epigenetic marks was retrieved 
from publicly available NCBI ftp site (ftp.ncbi.nih.gov/gene/) and UCSC genome browser tables 
(http://genome.ucsc.edu/). Data on transcription factor binding site chromatin 
immunoprecipitation-sequencing (ChIP-seq) datasets were retrieved from published datasets 
(Appendix 1). 
Comparison of integration sites and published annotations was carried out using a customised R-
package developed and provided by Dr Nirav Malani from the Bushman group, University 
Pennsylvania, USA (http://malnirav.github.com/hiAnnotator). 
 
2.5.2. Random sites (in silico datasets) 
Much of the genomic integration site data analysis consisted of a comparison with an in silico 
dataset of random integration sites.  An original list of 192000 genomic co-ordinates was randomly 
generated in silico by Dr Nirav Malani (FD Bushman laboratory, University Pennsylvania, USA) based 
upon the human genome hg18 reference build.  Fifty base-pair DNA sequences  at each genomic co-
ordinate was generated using the Galaxy tool (http://galaxyproject.org/) and back-aligned to the 
human genome reference using the standard Illumina pipeline in order to generate integration sites 
consistent with in vivo datasets.  These integration sites were then processed by Anat Melamed 
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(Bangham laboratory) following the same bioinformatic pipeline used to filter in vivo sequencing 
reads to generate 175505 integration sites for comparative analysis.  
 
2.5.3. Calculation of Oligoclonality index 
The oligoclonality index (OCI) is based upon the Gini index (Gini, 1912) and has been adapted by 
Gillet et al in order to quantify the relative dispersion of clonal abundances in a population of HTLV-1 
infected clones (Gillet et al., 2011).   The aim of the OCI was to objectively define clonality and to 
avoid the use of arbitrary terms such a polyclonality/ oligoclonality/ monoclonality.  The Gini index 
for each sample was calculated using the ‘reldist’ R-package (http://cran.r-
project.org/web/packages/reldist/index.html). 
The OCI (Gini) varies between two extremes: A value of 0 denotes equal abundance of all clones, i.e. 
true polyclonality, whereas a value of 1 shows maximal inequality and indicates a monoclonal 
population of cells.  This measure allows rigorous comparison of clonality between individuals, 
within the same individual over time and allows comparison of clonality between differing proviral 
loads and disease states. 
 
2.5.4. Statistical analysis 
Statistics on the large integration site datasets was carried out using R version 2.15.2 (http://www.R-
project.org/).  Where indicated,  analysis in chapter 4 was carried out using GraphPad Prism 5.  Non-
parametric tests were used where appropriate and results were considered statistically significant 
when p<0.05.  The Bonferroni correction for multiple comparison testing was applied where 
appropriate. 
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Table 2-1: Primer sequences 
Primer name PCR amplification Forward or 
reverse 
 (5’ – 3’) 
Sequence 
Actin-Fw PVL Forward TCACCCACACTGTGCCCATCTATGA 
Actin-Rev PVL Reverse CATCGGAACCGCTCATTGCCGATAG 
SK43 PVL Forward CGGATACCCAGTCTACGTGT 
SK44 PVL Reverse GAGCCGATAACGCGTCCATCG 
5LTR-Fw 5’LTR Forward CTCGCATCTCTCCTTCACG 
5LTR-Rev 5’LTR Reverse CTGGTGGAAATCGTAACTGGA 
LTR-seq 5’LTR sequencing Forward GGTTGAGTCGCGTTCT 
Control-Fw Long range PCR control Forward CTCTCACAGTGGGCTCGAGA 
Control-Rev Long range PCR control Reverse CAAAGACGTAGAGTTGAGCAAGC 
LR-Fw Long range PCR Forward CTTAGAGCCTCCCAGTGAAAAACATTTCC 
LR-Rev Long range PCR Reverse GATGCATGGTCCTGCAAGGATAACA 
Exon2-Fw Tax exon 2 Forward CCTCAGCAATAAACAAACCC 
Exon2-Rev Tax exon 2 Reverse CAATTGTGAGAGTACAGCAG 
Exon 3-Fw Tax exon 3 Forward ATACAAAGTTAACCATGCTT 
Exon 3-Rev Tax exon 3 Reverse AGACGTCAGAGCCTTAGTCT 
Exon3seq-I Tax exon 3 sequencing Forward ATACAAAGTTAACCATGCTT 
Exon3seq-II Tax exon 3 sequencing Forward CGTTATCGGCTCAGCTCTACA 
Exon3seq-III Tax exon 3 sequencing Forward TTCCGTTCCACTCAACCCTC 
Exon3seq-IV Tax exon 3 sequencing Reverse AGACGTCAGAGCCTTAGTCT 
Exon3seq-V Tax exon 3 sequencing Reverse GGGTTCCATGTATCCATTTC 
Exon3seq-VI Tax exon 3 sequencing Reverse GTCCAAATAAGGCCTGGAGT 
U3 meth-Fw MS-PCR PCR 1 methylated Forward TTAAGTCGTTTTTAGGCGTTGAC 
U3 unmeth-Fw MS-PCR PCR 1 unmethylated Forward TTAAGTTGTTTTTAGGTGTTGAT 
Gag rev (bisulfite) MS-PCR/ BSP Reverse AAAAAAATTTAACCCATTACC 
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R meth-Fw MS-PCR PCR 2 methylated Forward GAGGTCGTTATTTACGTCGGTTGAGTC 
R-unmeth-Fw MS-PCR PCR 2 unmethylated Forward GAGGTTGTTATTTATGTTGGTTGAGTT 
Heminested-Rev BSP PCR 2 heminested Reverse ACCCCCTCCTAAACTATCCC 
ATL 37  BSP Fw BSP PCR1/2 Forward TTTAGGGTAATTGATTTTTTGG 
 
ATL 35  BSP Fw BSP PCR1/2 Forward TGTTTTTTTTGATTTTTGTTGG  
 
ATL 164 BSP Fw BSP PCR1/2 Forward TTTTTTTGGTATTTGGAAGAAAA 
 
ATL 38  BSP Fw BSP PCR1/2 Forward GTTTTTATGGGGTAGGGATAGA 
 
ATL 52  BSP Fw BSP PCR1/2 Forward TTGTAGTTGAGAGGGTTGAAATT 
 
Bio3 LMPCR PCR1 Forward CCTTTCATTCACGACTGACTGCCG  
 
Bio4 LMPCR PCR1 Reverse TCATGATCAATGGGACGATCA 
(P5)Bio5 LMPCR PCR2 Forward (AATGATACGGCGACCACCGA)GATCTACA 
CTGGCTCGGAGCCAGCGACAGCCCAT 
P7 LMPCR PCR2 Reverse CAAGCAGAAGACGGCATACGA  
HTLVseq LMPCR illumina sequencing Read1 CAGCCCATTCTATAGCACTCTCCAGGAGAGAAACTTAGT 
SBS8 LMPCR illumina sequencing Read2 CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCT 
SBS8rev LMPCR illumina sequencing tag  
read 
GATCGGAAGAGCGGTTCAGCAGGAATGCCGAGACCG 
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Chapter 3. Integration site analysis of naturally infected HTLV-1    
CD4+CD25+ T cell clones 
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3.1.  Introduction 
3.1.1. High throughput sequencing in retroviral mapping 
High throughput sequencing and sequencing of most of the human genome has revolutionised 
science by allowing users to acquire genome-wide data using massively parallel sequencing 
approaches.   This opened the door to deeper analysis of integration site mapping of retroviruses 
(Brady et al., 2009; Bushman et al., 2008), vectors (Li et al., 2011; Ronen et al., 2011), retroelements 
(Williams-Carrier et al., 2010) and detailed evaluation of adverse events in gene therapy trials 
(Cavazzana-Calvo et al., 2010; Hacein-Bey-Abina et al., 2008; Wang et al., 2008). 
All the commercial platforms share 3 critical steps: DNA-sample preparation which requires random 
DNA fragmentation and addition of linkers (‘library preparation’), immobilisation of the library to a 
solid reaction chamber (e.g. a flow cell) and followed by sequencing.   
The Illumina method utilises ‘bridge amplification’ to generate clusters for sequencing: Immobilised 
primers are present on the flow cell surface and contain sequences that correspond to the DNA 
adapters present in the prepared DNA library.  Bridge-PCR initiates by hybridisation of the 
immobilised sequencing library fragment and a primer to form a surface-supported molecular bridge 
structure.  The arched molecule is a template for a DNA polymerase-based extension reaction and 
the resulting bridged double-stranded DNA is freed using a denaturing reagent.  Repeated cycles 
generate groups of thousands of molecules known as “clusters” on each flow cell lane.  DNA clusters 
are finalised for sequencing by unbinding the complementary DNA strand to retain single molecular 
strands in each cluster.  The prepared flow cell is then connected to a high-throughput imaging 
system. Illumina’s ‘sequencing by synthesis’ technology utilises four fluorescently labelled 
nucleotides to sequence tens of millions of clusters on the flow cell in parallel.  During each 
sequencing cycle, a single labelled dNTP is added to the nucleotide chain.  The nucleotide label 
serves as a terminator for polymerisation, and so after each dNTP incorporation, the fluorescent dye 
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is imaged to identify the base and then enzymatically cleaved to allow incorporation of the next base 
(Bentley et al., 2008).  At present, Illumina HiSeq 2000 sequencing can generate 3 billion reads per 
flow cell (Liu et al., 2012). 
Following the rapid take-up of high throughput sequencing techniques in integration site mapping, 
many challenges remain.  Principally to improve the recovery of each DNA sample, quality of 
sequencing and to quantitate the relative abundances of each integration site.     
More recently, within this group, Gillet et al (Gillet et al., 2011) developed a customised novel high 
throughput sequencing approach using an Illumina platform to accurately map and quantify proviral 
integration sites in natural HTLV-1 infection.  The integration site is defined as the junction between 
the 3’LTR of the provirus and the host genome.  This method is based upon classical LMPCR and 
overcomes the described limitations of using restriction enzymes and Sanger sequencing and can 
accurately quantify the abundance of each detected integration site. 
In this method there are 3 main improvements over the classical LMPCR and Sanger sequencing 
technique.   
1. Restriction enzymes are replaced with sonication, which randomly shears the DNA and 
prevents systematic loss of integration sites, such as those that lie distant to a restriction 
enzyme cleavage site.  Furthermore, sonication allows for accurate measurement of clonal 
abundance since PCR duplicates can be distinguished from true sister cells within a clone.  
That is to say, following sequencing, PCR duplicates are identified to have the same 
integration site (read1) and the same shear site (read2), whereas sister-cells within a clone 
have the same integration site (read1) but a different shear site (read 2) and can therefore 
be quantified programmatically (Gillet et al., 2011).  
2. The DNA fragments generated by sonication are then ligated to partially double-stranded 
linkers, which are amplified by nested PCR to increase sensitivity and specificity.  The 
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partially double-stranded linker results in increased specificity as selective amplification 
occurs between the conserved proviral LTR sequence and the linker.  Each linker contains a 6 
base pair ‘tag’ (or ‘barcode’) that allows for multiplexing of approximately 40 samples/lane 
of a HiSeq 2000 platform.   Specificity is further increased by utilising a sequencing primer 
that binds 5 base-pairs short of the terminal LTR sequence.  This means that all sequencing 
reads start with the same proviral sequence ‘ACACA’ and eliminates any mispriming events 
to focus upon true integration sites.  Each amplicon is sequenced three times.  The first 
sequences 50 base pairs complementary to the HTLV-1 sequence (read 1), the second 
sequences 50 base pairs complementary to the linker (read 2) and the third reads the 
barcode tag to allow multiplexing of samples. 
3. High throughput sequencing of integration sites on ex-vivo PBMC generates a large number 
of reads originating from a high number of unique clones within each individual.  Meekings 
et al, who utilised the classical LMPCR technique followed by cloning and Sanger sequencing, 
mapped a mean number of 13 unique HTLV-1 integration sites from 10ug DNA per 
asymptomatic carrier (range 1-24) (Meekings et al., 2008) whilst  Gillet et al, who developed 
this high-throughput approach, identified a mean of 1489 integration sites per 
asymptomatic carrier (Gillet et al., 2011).  Prior to the development of this technique it was 
estimated that each individual carried a total of approximately 100 clones.  Mathematical 
modelling with high throughput data from the Bangham laboratory suggests that each 
asymptomatic carrier possess between 104-105 distinct clones (Laydon et al 2013, in 
submission). 
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3.1.2. Clonal distribution of HTLV-1 integration sites in PBMC ex vivo 
 
Quantification of clonal abundance from the number of integration sites within an individual 
requires knowledge of the (average) number of proviruses integrated within each host genome.  The 
evidence for a single provirus per infected cell is based upon the diagnostic criteria of monoclonal 
integration in ATL tumour biopsy tissue, which is typically demonstrated by Southern blot (Yoshida 
et al., 1982) or classical LMPCR or IPCR techniques (Takemoto et al., 1994; Wattel et al., 1995).  
However, these methods were not sufficiently powered to detect multiple proviruses within a single 
clone of cells since restriction enzymes and preferential PCR amplification of short products are likely 
to recover a single integration site, and to potentially miss any additional integration sites, leading to 
the false conclusion that there is a single proviral integration per cell.  A clinical example is illustrated 
in Figure 3.1 showing the results from high throughput sequencing for two locally treated clinical 
cases of chronic ATL.  Each slice of the pie chart shows the relative abundance of each clone within 
an individual sample.  In one sample, patient LFK (right panel), there is a single dominant proviral 
integration site occupying 98% of the proviral load, whilst the second sample, from patient LGB,  has 
the same clinical disease, but multiple ‘expanded’ integration sites.    When more than 1 dominant 
integration site is identified, many questions arise e.g.  how many of these integration sites might be 
malignant or whether there is one malignant clone containing multiple proviruses and whether 
these different clonal distributions carry any clinical significance e.g. in response to treatment or 
relapse.   
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Figure 3.1: ATL is not necessarily caused by a monoclonal expansion of T-cell clones 
An example of the relative abundance of integration sites detected in two patients with chronic ATL.   
The case on the right (patient LFK) shows that there is a single abundant integration site 
(constituting 98% of the proviral load) with the remaining 2% of the PVL occupied by a further 56 
small abundance integration sites.  However, in the case on the left (patient LGB), also with chronic 
ATL, it can be seen that there are 4 abundant integration sites, constituting between 15 to 38% of 
the proviral load.   
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3.1.3.   Aim 
 
The work within this chapter tests the hypothesis that during natural infection, each infected cell 
contains a single provirus.  In order to test this hypothesis, clones of infected CD4+ CD25+ HTLV-1 
infected T-cells were isolated by a method of limiting dilution and expanded in vitro.   The T-cell 
clones were isolated from PBMC ex-vivo of 10 patients, with different clinical manifestations of 
HTLV-1 infection.  HTLV-1 infection of expanded clones was confirmed by the presence of the tax 
gene by PCR and, if positive, followed by high throughput sequencing to determine the abundance 
of each unique integration site. 
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3.2. Results 
3.2.1. Non-malignant infected CD4+ T cell clones contain a single integrated provirus. 
 
Twenty-seven HTLV-1 infected T cell cultures were successfully expanded in vitro (tax gene present 
by PCR).  To accurately quantify the abundance of unique integration sites within each culture, 
linker-mediated PR and high-throughput sequencing were undertaken.  
We found that in 26 of these cultures, a single unique integration site constituted 99.9% of the 
proviruses detected (range 95.5-100%), with a median of 206197 sequence reads (range 6621-
2599892 reads).  This indicates that 26 clones had been cultured, each with a single dominant 
integration site.  The remainder of integration sites detected within each clone were detected with 
low frequency (median 3 sequence reads) suggesting incomplete inhibition of HTLV-1 infectious 
spread during in vitro culture by raltegravir. 
One HTLV-1 culture contained cells with two equally abundant integration sites. This observation 
suggested either the presence of two proviruses within each genome or that two clones had been 
cultured within the same well.  Analysis of TCRG rearrangement revealed two distinct gene 
rearrangements in the Vγ1-8 region, consistent with the presence of two T cell clones.  Results for 
each culture summarised in table 3.1.  The genomic location for each of the dominant sites is 
reference to hg 18 reference genome (NCBI 36.1). 
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 Table 3-1: Summary of identified integration sites derived from 10 individuals with HTLV-1 infection  
Clone  Clone derived from Genomic location 
of dominant integration 
site  
Proviral load composed of 
 dominant integration site, 
% 
  Proviral structure 
1 Asymptomatic carrier 1 Chr 6: 84613188 98.95 Complete 
2 Asymptomatic carrier 1 Chr 1: 184745603 99.95 Type 2 defective 
3 HAM/TSP patient 1 Chr 16: 52158560 99.9 Type 2 defective 
4 HAM/TSP patient 1 Chr X: 114257179 99.9 Complete 
5 HAM/TSP patient 1 Chr 10: 2277787 100 Complete 
6 HAM/TSP patient 1 Chr 13: 74997821 98.88 Complete 
7 HAM/TSP patient 2 Chr 10: 80828281 99.96 Complete 
8 HAM/TSP patient 2 Chr 5: 1997980 99.9 Complete 
9 HAM/TSP patient 2 Chr 4: 70601874 95.2 Complete 
10 HAM/TSP patient 2 Chr X: 129048967 100 Complete 
11 HAM/TSP patient 2 Chr 14: 45274700 100 Complete 
12 HAM/TSP patient 3 Chr 4: 107219655 99.9 Complete 
13 HAM/TSP patient 3 Chr 12: 40920384 100 Complete 
14 HAM/TSP patient 4 Chr 5: 50609660 98.4 Complete 
15 HAM/TSP patient 4 Chr 3: 76576960 99.9 Complete 
16 HAM/TSP patient 4 Chr 19: 32974427 100 Complete 
17 HAM/TSP patient 4 Chr 19: 38521388 100 Complete 
18 HAM/TSP patient 4 Chr 14: 80728657 95.5 Complete 
19 HAM/TSP patient 4 Chr 4: 169472575 100 Complete 
20 HAM/TSP patient 5 Chr 3:75952018 100 Complete 
21 Polymyositis patient 1 Chr 2: 214080658 99.95 Complete 
22 Polymyositis patient 1 Chr 6: 167451858 99.9 Complete 
23 Polymyositis patient 1 Chr 22: 31885379 100 Complete 
24 Polymyositis patient 1 Chr 3: 32582626 98.6 Complete 
25 ATL patient 1 Chr 22: 42654531 99.89 Complete 
26 ATL patient 2 Chr 4: 9905297 99.8 Complete 
27 Asymptomatic carrier 2 Chr 8: 87708389 52  Complete 
27 Asymptomatic carrier 2 Chr 9: 11420980  42 Complete 
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3.2.2. Confirmation of PCR bias to selectively amplify short PCR products 
 
PCR amplification is biased toward short PCR products (Figure 3.2).  The data within Figure 3.2 is 
taken from a typical sequencing flow cell (Genome Analyser II) and demonstrates that there are 
more PCR duplicates of short DNA fragments, and that the preferred amplicon length for PCR 
amplification and cluster generation is approximately 150-500 base pairs.  There was a direct inverse 
correlation between amplicon size and the number of PCR duplicates (Spearman r -0.87, p<0.0001). 
 
 
 
Figure 3.2: PCR most efficiently amplifies short amplicons 
The number of PCR duplicates (on a log scale) is shown on the y-axis and the size of PCR 
amplicons (x-axis).  Amplicons of approximately 150 base pairs were most efficiently 
amplified by PCR, whilst amplicons over 500 base pairs were infrequently amplified. 
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3.2.3. Clones with defective proviruses can be isolated ex-vivo 
 
Long range PCR (Methods section 2.3.3) on DNA from each culture showed that 2 out of 27 clones 
(7.4%) contained a type 2 defective provirus and 25 clones contained a complete provirus.  No type 1 
defective proviruses were isolated.   
 Type 2 defective proviruses lack the 5’LTR-gag region containing the tax gene promoter/enhancer 
elements and are unable to express Tax protein.  Miyazaki et al measured the frequencies of type 2 
defective proviruses in two asymptomatic carriers by QPCR on DNA from a mixed population of 
PBMCs and reported frequencies of 3.9% and 0.6% respectively (Miyazaki et al., 2007), whilst 
Ramirez et al determined by a similar QPCR technique that no seropositive patients with HAM/TSP 
had type 2 defective proviruses (Ramirez et al., 2003).  These studies were limited by the use of few 
patients, mixed PBMC populations and the relatively low sensitivity of QPCR to accurately quantify 
minor populations.  
Our results suggest that defective proviruses may not be so rare in non-malignant disease,   although 
our study was not powered to robustly quantify the absolute frequency of defective proviruses in 
different disease states – this would require the isolation and expansion of hundreds of unique 
clones. 
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3.2.4. T-cell clones from patients with acute ATL are difficult to expand in vitro 
 
When we compared the integration sites of the clones that were isolated from patients with acute 
ATL with the putatively malignant clone (identified by high throughput sequencing of PBMC), these 
were not the large expanded clone but originated from one of the smaller background clones.     In 
these two individuals, the abundant, putatively malignant clone made up 97% and 52% of the 
proviral load, whilst the isolated clones made up 0.12% and 1.6% of the proviral load respectively. 
In fact, this preferential isolation of low-abundance clones was observed in the clones derived from 
all the non-malignant patients too:  The T-cell clones that were isolated were of low abundance in 
mixed PBMCs (either not detected in the mixed PBMC or up to a maximum relative abundance 
0.17%).  
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3.3. Discussion 
3.3.1. Non-malignant clones of HTLV-1 contain a single provirus 
 
In this study we found that all analysed cultures of HTLV-1 infected CD4+CD25+ T-cells contained a 
single provirus in the host genome, consistent with our hypothesis.  This allows us to infer that each 
unique integration site mapped within the PBMCs of infected non-malignant cases may be called a 
clone, and allows accurate calculation of clonal abundance when analysing sequencing data on 
PBMCs.    Since we did not isolate the abnormally expanded, putatively malignant clone from the ATL 
cases, we make no inference about the malignant clones.  Whilst we undertook this study on 
patients with a broad spectrum of clinical manifestations of HTLV-1 infection, these were individually 
of small number (5 HAM/TSP, 2 AC, 1 polymyositis, 2 acute ATL).  However, this study was not 
designed to investigate the mean proviral copy number between different disease states- this would 
require large numbers from each subtype of disease. 
The approach using high throughput sequencing was justified, since we have observed preferential 
recovery of amplicons measuring between 150-500 base pairs.  If we had used a classical LMPCR 
method that utilised restriction enzyme digestion, cloning and Sanger sequencing of individual T-cell 
cultures, we could not have been confident of the results since the finding of a single integration site 
could have arisen from a preferential restriction position within the host genome. 
One possible mechanism for the observed findings of a single provirus in each T-cell clone is 
superinfection resistance (SIR), which is the capacity of a cell to prevent a second infection by a 
closely related virus.  The mechanism of SIR in HTLV-1 is unknown:  Studies of SIR mechanisms in 
simple retroviruses (e.g. Murine Leukaemia Virus, MLV) or complex retroviruses (e.g. HIV) do not 
reveal a common mechanism and do not appear to be mediated by neutralising antibodies and/or 
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virus specific CD8+T-cells (Allen and Altfeld, 2003).   Viral recombination, an indicator of 
superinfection at a cellular level, is considered to be an important viral evolutionary strategy (Burke, 
1997).  Since recombinants have been identified in HIV patients it can be concluded that SIR is not 
absolute.   
Recently, Josefsson et al quantified the number of HIV-1 proviruses from 9 HIV-infected individuals 
and identified that >85% of infected CD4+ T-cells contain a single copy of HIV DNA which was 
phylogenetically similar to plasma RNA, implying limited potential for recombination (Josefsson et 
al., 2011).  Although it was widely thought that HIV infected CD4+ cells frequently contained multiple 
proviruses, to date they have only been identified in vivo in spleen tissue, which may act as a cellular 
reservoir (Gratton et al., 2000; Jung et al., 2002). 
One of the major characteristics of HIV infected cells is down-modulation of the CD4 receptor (Levin 
et al., 2010) by viral Vpu, Env and Nef.   As receptor down modulation is a simple way of preventing 
second viral infection, and a method that is successfully used by other retroviruses (e.g. Foamy 
virus), CD4 down-modulation was initially assumed to be the main SIR mechanism in HIV infection.  
However, SIR has been demonstrated to occur early (Volsky et al., 1996) (4-24 hours after primary 
HIV infection), whilst CD4 down-regulation occurs later (two days after infection) suggesting an 
alternative mechanisms.  The mechanism responsible for SIR in HIV-1 infected cells is of interest 
particularly for the development of novel approaches to HIV therapy. 
 
In HTLV-1 infection, the virus appears to persist chiefly by mitotic proliferation of infected CD4+ T-
cells, rather than infectious spread.  Since mitotic proliferation utilises the highly faithful host DNA 
polymerase II enzyme, rather than the error prone reverse transcriptase, the sequence of HTLV-1 is 
highly conserved.  Utilisation of this strategy does not provide opportunity for productive viral 
recombination and thus no advantage to the HTLV-1 virus in allowing a multiply infected cell since 
this would not generate productive viral recombination.  Indeed, it can be hypothesised that 
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multiple infection is more likely to result in increased viral gene expression and subsequent CTL 
killing. It is likely that HTLV-1 has evolved an as yet unidentified mechanism of superinfection 
resistance. 
 
3.3.2. Clones carrying defective proviruses can be isolated from ACs and patients with HAM/TSP. 
 
Defective proviruses are common in ATL and the frequency has been reported variably between 25.7 
- 56% cases (Korber et al., 1991; Ohshima et al., 1991; Tamiya et al., 1996; Tsukasaki et al., 1997).  
The discrepancy between frequencies in the literature is in part due to the clinical phenotypes of ATL 
within each cohort, since acute ATL has a higher frequency of defective provirus than lymphoma 
subtype (31.9% versus 8.7%, (Kamihira et al., 2005).  Secondly, there is variation in the method used 
to detect defective proviruses; both southern blot hybridisation and PCR-based techniques have 
been reported. 
While defective proviruses have been frequently observed in ATL, it remains controversial as to 
whether a defective provirus is advantageous to the development of leukaemia, or has arisen as a 
consequence of the leukemic transformation secondary to widespread genomic instability.  During 
the process of HTLV-1 integration, the viral integrase generates a short repetitive sequence of 6 
base-pairs adjacent to both LTRs.  Miyazaki et al sequenced across the 6 base pair repeats that lie 
adjacent to each LTR in 12 cases of ATL, and demonstrated that these repeat sequences were 
present in 8/12 cases and deleted in 4/12 cases.  These findings show that deletion of the 5’LTR can 
occur pre-integration (Miyazaki et al., 2007).  They quantified the frequency of type 2 defective 
proviruses in two asymptomatic carriers at <3.9%. 
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Our findings suggest that type 2 defective proviruses in non-malignant infection may be more 
frequent than these estimates.  There have been no reports on the frequency of these in CD4+ 
clones previously, or on a large scale in mixed PBMC ex vivo.  Whilst the cloning protocol was 
sufficient to clone many uninfected T-cells, it was an unexpected finding that HTLV-1 infected T-cell 
clones containing a type 2 defective provirus were successfully cloned, since expressing Tax might 
provide a proliferative advantage in culture.  The proviral integration sites of both these clones were 
intergenic within the host genome and did not suggest the identity of the selection advantage.  
However, we selected our patients for cloning on the basis of a higher-than-average proviral load (in 
order to increase the likelihood of cloning infected CD4+ T-cells) and so perhaps the PBMC from 
these patients are biased to contain an increased number of defective proviruses.  
 
3.3.3. The malignant clone from ATL cells is difficult to isolate and expand in vitro 
 
The expanded ATL cells are notoriously difficult to isolate and culture ex vivo.  In previous culture 
systems primary ATL cells were able to grow in liquid culture containing IL-2, although they only 
showed transient cytokine-dependent proliferation (Aboud et al., 1987; Lunardi-Iskandar et al., 
1993; Uchiyama et al., 1985).  Furthermore, it was shown that in culture ATL cells began to 
abundantly express the protein Tax, which interacts with a number of transcription factors resulting 
in the trans-activation or repression of many cellular genes involved in cell growth or apoptosis 
(Yoshida, 2001).  However, ATL cells do not produce high levels of Tax protein in vivo, although tax 
gene expression has been reported using PCR ISH and RT-PCR ISH (Ohshima et al., 1996).  Together 
these findings suggest that IL-2 supported growth in vitro does not necessarily reflect the growth 
mechanism of ATL cells in vivo. It has been speculated that there may be important interactions 
between the malignant cell and its micro-environment that may be replicated in vitro using co-
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culture with a bone-marrow-derived stromal cell line (Bajenoff et al., 2006; Imura et al., 1997; Sasaki 
et al., 2005).  Nagai (Nagai et al., 2008) published a novel technique that utilises a stromal cell layer 
co-culture system to provide various factors that support proliferation of ATL cells.  Of note, whilst 
this group reported moderate success (growth in 4/8 acute ATL cases), they assumed monoclonal 
bands identified by southern blot hybridisation represented the malignant clone and did not 
specifically map the integration site to confirm. 
There is currently an on-going project in this laboratory to modify and optimise the protocol 
published by Nagai et al in order to isolate and expand the malignant clones and to confirm the 
presence of the presumed malignant integration site by PCR. 
 
3.3.4. Chapter summary 
 
Modified linker-mediated PCR followed by high-throughput sequencing is an unbiased approach to 
quantify HTLV-1 integration sites.  We have shown that, in natural infection, non-malignant  HTVL-1 
infected CD4+ T-cell clones contain a single provirus and suggest that clones carrying defective 
proviruses may be more frequent in ACs or HAM individuals than previously estimated. 
 
3.3.5. Publication associated with this chapter 
 
HTLV-1-infected T cells contain a single integrated provirus in natural infection,  
Cook LB, Rowan AG, Melamed A, Taylor GP, Bangham CR 
Blood 2012, 120(17):3488-3490 
82 
 
Chapter 4. Characterisation of ATL cohort 
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4.1.  Chapter abstract and summary 
The aim of this chapter is to characterise a large ATL cohort (n=197) of mixed clinical subtype in 
terms of PVL, capacity for Tax expression (defective provirus, tax gene mutation or hypermethylated 
5’LTR) and to quantify the clonal distribution.  This will allow us to determine that the samples are 
representative of published ATL cohorts, for the basis of a robust analysis of the influence of the 
host genomic landscape (presented in chapter 5).   
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4.2.  Introduction 
For several decades the molecular basis of cancer has been thought to be clonal expansion of a 
single common precursor cell that has undergone random genetic or epigenetic damage (mutational 
or epigenetic driver events) that result in a proliferative advantage, followed by subsequent genetic 
or epigenetic damage resulting in a malignant tumour (Aparicio and Caldas, 2013; Parsons, 2008) .  It 
is thought that each mutation may individually only confer a small growth advantage but that 
cumulatively this advantage may result in massive expansion over many years (Vogelstein et al., 
2013).   
There is emerging evidence for a polyclonal origin of tumours where distinct small populations of 
tumour cells are present amongst a seemingly monoclonal tumour.  The notion that cancers are 
ecosystems of evolving clones has implications for clinical practice in order to develop an accurate 
scientific understanding of tumourigenesis, to accurately model the mechanisms of tumour 
development and to improve understanding of different treatment approaches and to predict and 
manage relapsed disease (Aparicio and Caldas, 2013). These subclones might respond quite 
differently to the chemotherapy directed against the major tumour bulk.  Initial response to therapy 
followed by relapse may result in the clonal outgrowth of the untargeted tumour population, 
particularly if therapy is focused upon the presence of a specific lesion, which may not be present in 
the subclones.  This is of emerging interest in the HTLV-1 field since acute, bulky or lymphomatous 
ATL cases are typically associated with a brief clinical response when treated with chemotherapy, 
usually followed by a rapid and treatment-resistant relapse.  Furthermore, a recent study by Seto et 
al demonstrated clonal evolution within individual tumour biopsies in ATL by using an array-
comparative genomic hybridisation (CGH) method (Umino and Seto, 2013).  
As discussed in chapter 3, ATL is regarded as a monoclonal tumour and the demonstration of 
monoclonal proviral integration is cited as part of the diagnostic criteria, although not uniformly 
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performed (Tsukasaki et al., 2009; Yoshida et al., 1984).  One of the aims of this chapter is to 
quantify clonality at the proviral level in order to test the hypothesis that a single provirus is 
integrated within all cells (implying a common cell of origin) using our high-throughput mapping 
strategy.   
 
4.2.1. Tax expression is not a requirement for ATL cells 
Tax is thought to play a central role in ATL leukaemogenesis by its pleiotropic actions such as 
transactivation of NFĸB and CREB (Franchini, 1995; Yoshida, 2001), and functional inactivation of 
p16, p53 and MAD1 (Ariumi et al., 2000; Jin et al., 1998; Suzuki et al., 1999).  However, the enigma of 
Tax-induced leukaemogenesis is that Tax expression is detected in only 40% of human ATL cases 
(Akagi et al., 1995).  There are three commonly observed mechanisms to disrupt Tax: Deletion of the 
5’LTR which contains the promoter and enhancer elements for viral transcription from the sense 
strand (Tamiya et al., 1996); CpG hypermethylation of the promoter elements of the 5’LTR leading to 
transcriptional silencing of the sense strand (Taniguchi et al., 2005); and genetic mutations in the tax 
gene itself leading to silencing in approximately 10% cases (Takeda et al., 2004).  It is noteworthy 
that these changes are predominantly observed in the aggressive forms of ATL (acute and 
lymphomatous subtypes). By contrast HBZ transcripts, encoded on the antisense strand, have been 
detected in 100% of cases of ATL (Satou and Matsuoka, 2007) and the promoter for HBZ is present in 
the U5 sequence of the 3’LTR.  HBZ also possesses proliferative functions (Satou et al., 2006) and 
was originally reported to suppress Tax transcription (Gaudray et al., 2002).  More recently HBZ 
transgenic mice have also been demonstrated to develop tumours (Satou et al., 2011).  These 
findings have given rise to a widely held belief that Tax expression is important during the initiation 
of ATL and HBZ is required to maintain the transformed phenotype (Matsuoka and Jeang, 2011). 
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4.2.2. Subtypes of defective provirus in ATL 
 
The 5’LTR is critical for transcription of viral genes encoded on the sense strand of the provirus and 
its loss results in the inability to express viral proteins including Tax.  Even cells with a type 1 defect 
have been found not to produce Tax in vitro, presumed to be due to the loss of an internal promoter 
in the pol region (Hiramatsu and Yoshikura, 1986) (Figure 2.1).   
A feature of retroviral integration is the presence of a short repeat sequence in the host genome 
flanking the 5’ and 3’LTR of the provirus (Figure 1.1).  HTLV-1 normally generates six base pair 
repeats which Miyazaki et al demonstrated were present at the junction of the host genome and a 
type 2 defective integrated provirus in 8/12 ATL cases (Miyazaki et al., 2007).  This suggests that in 
these malignant cases Tax protein was never expressed during any stage of clonal expansion and is 
therefore contrary to the widely held opinion that Tax is important in early clonal proliferation. 
Both type 1 and type 2 defective  proviruses are reported in 30-50% of ATL cases, and type 2 
proviruses are more frequently observed in aggressive subtypes rather than the chronic or 
smouldering ATL, suggesting a correlation between clinical subtype and defective provirus (Tamiya 
et al., 1996).  The explanation for such a high frequency of defective provirus remains uncertain, 
although it has been suggested that cells infected with a defective provirus cannot express Tax and 
thus escape the immunodominant CTL response, resulting in a greater likelihood of leukemic 
transformation. 
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4.2.3. Tax mutations in ATL 
 
Missense mutations in the tax gene have been widely reported and frequently associate with 
proviral subgroup based upon LTR sequence and are classified as ‘Tax A’ or ‘Tax B’ genotype.  The 
widely used Seiki reference genome is Cosmopolitan B (Tax B) and it has been shown that specific 
nucleotide substitutions are associated with Type A, which are:  C>T at position 7897, C>T at position 
7959, G>A at position 8208 and A>C/G at position 8344.  In addition, nucleotide alterations at 
positions 7720, 8120 and 8297 have been observed as recurrent mutations within the Tax A subtype 
(Furukawa et al., 2000). These Tax A nucleotide alterations are associated with amino acid change 
A>V at Tax position 221, S>N at Tax position 304 and Q>E at Tax position 334 and are not ATL disease 
specific (Furukawa et al., 2000).   Genetic alterations in the tax gene that can escape the CTL 
response have been described (Furukawa et al., 2001).  Furukawa et al firstly identified a stop codon 
in the 5’ half of the tax gene that loses transactivation activity on the viral enhancer; second, a 
specific amino acid change that alters the immunodominant CTL Tax11-19 epitope was observed in the 
presence of HLA-A*02 rendering it undetectable by Tax11-19 -specific CTLs and third, large deletions of 
the tax gene were observed.   Together, these findings suggest that at some stage HTLV-1 infected 
cells can escape the host immune system, gaining a selective advantage which perhaps allows these 
clones of cells to accumulate further genetic and epigenetic alterations, culminating in malignant 
transformation.  Crucially, identical tax gene mutations were found within healthy siblings, 
suggesting that these mutations occurred early, in the mother, and were transmissible (Furukawa et 
al., 2001). 
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4.2.4. Hypermethylation of the 5’LTR in the ATL 
 
Bisulfite-sequencing PCR (BSP), in which sequences from cloned PCR products generated by  primers 
unbiased for either methylated or unmethylated DNA, has shown that  complete methylation of the 
U3 region of the 5’LTR of HTLV-1 provirus results in  loss of tax gene transcription (Takeda et al., 
2004). Hypermethylation of the 5’LTR promoter/enhancer has been reported in 14% ATL samples 
(Takeda et al., 2004) whilst partial methylation of the 5’LTR is predominant and seen in 50% cases 
but does not silence tax gene transcription in cell lines or in fresh ATL cells (Takeda et al., 2004). 
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4.3.  Results 
4.3.1. Samples removed from analysis following unblinding of clinical diagnosis 
 
The original cohort of ATL DNA samples provided by Professor Matsuoka’s group in Japan consisted 
of 242 samples.  The clinical subtype of ATL was unknown to me during both the laboratory work 
and bioinformatic analysis with unblinding at the final step.  This blinding allowed unbiased 
processing and data analysis. However, some samples had to be disregarded either during the 
bioinformatic analysis or following unblinding, for the following reasons:-  
Four cases were removed from the analysis as the provided tumour material did not show any 
evidence of HTLV-1 infection (undetectable long range PCR, undetectable 5’LTR by PCR, 
undetectable exon 2 or 3 tax gene by nested PCR, undetectable integration sites following LMPCR 
and high throughput sequencing).   
Seventeen cases were removed following review of clinical results (undertaken in Japan) which 
suggested they had other haematological malignancies (3 cases with B-cell non Hodgkin lymphoma 
in HTLV-1 carriers), 3 cases were from asymptomatic carriers , 9 cases were from  remission samples 
(not pre-treatment) and 2 were duplicate cases. 
Following high throughput sequencing a further 24 samples were not analysed for a variety of 
reasons:    10 cases were not uniquely mapped to the host genome at both read 1 or read 2 (as 
required by the HTS protocol).  Seven cases failed to amplify by LMPCR for reasons unknown, 
although 1 was found to have a primer binding site polymorphism.  Seven cases amplified in the 
laboratory (as seen by gel smear) but failed to adequately sequence.  Our collaborators confirmed 
that DNA samples were not always freshly extracted and some DNA samples were several (up to 20) 
years old and may have degraded during storage.  There were no common features in terms of 
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clinical subtype or proviral load in the samples that were not suitable for bioinformatic analysis.  This 
resulted in 197 pre-treatment diagnostic ATL samples, suitable for analysis.   
A table detailing each analysed ATL case is listed in Appendix 2 and an attrition table which details 
where cases were removed from the analysis in Appendix 4. 
 
 
4.3.2. Number of cases within each clinical subtype and proviral load. 
 
ATL consists of 4 main clinical subtypes – acute, chronic, lymphoma and smouldering cases.  Acute 
cases constitute approximately 60% of clinical presentations in Japan, lymphoma 20%, chronic 15% 
and smouldering 5%.  The proportions of each subtype in the present cohort are summarised in 
Table 4.1. 
 
Table 4-1: Proportion of each clinical subtype within cohort 
 Acute Chronic Lymphoma Smoldering Unknown 
Number cases 128 30 31 6 2 
% of cases 65 15 16 3 1 
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4.3.3. Defective proviruses are detected in 39% of the ATL cohort 
 
To identify the structure of the provirus, we amplified the provirus by long range PCR (Tamiya et al., 
1996).  We identified complete, type 1, type 2, multiple proviruses and a new entity, named 
‘indeterminate’ defective proviruses in which both of the long range PCRA and PCR B products were 
absent (Table 4.2).  Multiple proviruses were determined if there was both a complete provirus 
present and an additional shorter band, consistent with the presence of an additional type 1 
provirus. 
 
Table 4-2: Subtypes of provirus identified by long-range PCR 
 Complete 
provirus 
only 
Type-1  
defective 
provirus 
Type-2  
defective 
provirus 
Multiple 
provirues 
Indeterminate 
defective 
proviruses 
Number of 
cases 
120  26   36   5  10  
 
Our data identifies 39% cases with a defective provirus which is in keeping with previously reported 
frequencies (Tamiya et al., 1996).    The indeterminate defective proviruses all contained a single 
dominant integration site, consistent with ATL and a median PVL 45% (range 0-154%).  We therefore 
suggest that the proviruses in these samples contain a proviral genomic deletion or mutation in the 
overlapping primer binding sites regions of these two PCR reactions (Figure 2.1) between exon 2 and 
exon 3 of tax (Seiki nucleotides 6483-6570).  Consistent with this hypothesis is that the coding region 
of HBZ, which is known to be expressed in ATL cells, would be unaffected by genomic deletions in 
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this region.  The type 1, type 2, multiple and indeterminate defective subgroups are considered 
collectively as ‘defective proviruses’ for further downstream analysis.  
 
4.3.4. Tax gene mutations are detected in 7% of the ATL cohort 
 
The coding regions of the tax gene were amplified and sequenced (exon 2 and 3) in the 120 cases 
identified to contain complete proviruses.  The methionine start codon is derived from the 
nucleotide sequence in exon 2, whilst the remainder of the protein is coded from the nucleotide 
sequence of exon 3 (amino acid 2-353). Figure 4.1 and table 4.3 summarise the following results:-    
We amplified exon 2 by nested PCR using a high fidelity polymerase in 120 cases with complete 
proviruses and identified the normal start codon in 118 cases.  In two cases, there were non-
synonymous mutations in which the amino acid methionine was changed to isoleucine.  Since these 
mutations removed the methionine start signal, we infer that these two tumour samples were 
unable to express Tax protein. 
We sequenced exon 3 of tax in 120 cases and observed 97 distinct nucleotide alterations from 79 
cases (reference genome NCBI GenBank J02029, (Seiki et al., 1983).  These 97 alterations resulted in 
48 distinct amino acid changes.  Three of these amino acid changes were nonsense mutations at Tax 
amino acid positions 28, 56 and 248 and occurred in 11 cases. Additionally, in one sample there was 
a deletion of 249 base pairs (nucleotide positions 7434-7683).     
In 24 samples, 4 specific nucleotide substitutions  were observed which are known to represent the 
Tax A subtype and are strongly associated with the proviral subgroup Cosmopolitan A based upon 
LTR sequence (Furukawa et al., 2000) : C>T at position 7897, C>T at position 7959, G>A at position 
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8208 and A>C/G at position 8344.  In addition, nucleotide alterations at positions 7720, 8120 and 
8297 which have been observed as recurrent mutations within the Tax A subtype (Furukawa et al., 
2000) were observed in 4/24 Tax A subtype samples and are known not to be ATL disease specific 
(Furukawa et al., 2000).  
Two nucleotide changes have been reported to be specific to ATL and were observed in our cohort:  
A nucleotide change from G to A at position 7464 is a known hotspot of mutation and creates a 
premature stop codon at position 56 of the Tax protein and has been shown to be associated with 
loss of Tax protein function (Furukawa et al., 2001). We observed this mutation in 7 out of 120 
samples (120 samples containing non-defective proviruses).   One of these cases also carried the 
previously described missense mutation in the start codon of exon 2.  The second reported ATL 
specific mutation is a missense mutation A>G at position 7337 resulting in an amino acid change 
from alanine to glycine at Tax position 14. The functional significance of this missense mutation has 
only been identified in the context of HLA-A*02 where it has been demonstrated to escape Tax-
specific CTL killing (Furukawa et al., 2001).  We observed this mutation in 3 cases, but in the absence 
of HLA-typing its precise significance cannot be assessed. 
Two recurrent novel nonsense mutations were observed:  Nucleotide substitutions of G>A at 
position 7380 occurred in 2 samples and results in a premature stop codon at Tax position 28. 
Nucleotide substitutions of G>A at position 8040 occurred in 3 samples and results in a premature 
stop codon at Tax position 248.    Tax forms homodimers that contribute to the transcriptional 
activity from the HTLV-1 promoter (Jin and Jeang, 1997; Tie et al., 1996; Basbous et al., 2003) and 
Basbous et al have shown that the integrity of the Tax sequence is critical for Tax dimerization 
except for the last 16 residues (amino acids 338-353), and so we conclude that these two additional 
nonsense mutations will result in loss of Tax protein function (Figure 4.1).  No splice site mutations 
were observed. 
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Additional missense mutations were found in 42 other amino acid positions, but, in the absence of 
HLA-class I genotype and functional studies we cannot infer that Tax function is diminished by the 
identified missense mutations.  A summary of tax mutations is shown in Table 4.3 and Figure 4.1. 
To summarise:  Whilst missense mutations were frequently observed we have not inferred any 
functional consequence of these since we do not know the HLA type of each case.  Known ATL 
specific nonsense mutations were seen in 7 cases with additional novel nonsense mutations 
observed at both Tax position 28 and Tax position 248 which we suggest would be critical to Tax 
expression.   
 
 
Table 4-3: Summary table of amino acid alterations following tax sequencing 
 Methionine 
start codon 
mutation only 
Nonsense 
mutations 
Large Tax 
deletion 
Number of 
cases 
1* 11 1 
*Two cases with methionine start codon mutations were identified, but one case had an 
additional nonsense mutation in exon3 and has been counted there. 
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Frequency of exon 2 and 3 Tax amino acid changes at each position
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Figure 4.1: Frequency of predicted amino acid sequence changes in exon 2 and exon 3 of 
the tax gene 
All non-synonymous alterations are shown with bars.  Green bars represent amino acid 
changes characteristic of the Tax A proviral genotype (A>V at Tax 221, S>N at Tax 304, Q>R 
at Tax 334); red bars represent premature stop codons caused by nonsense mutations.  The 
location of the functional CREB activation domains (amino acids 1-56), NFĸB activation 
domain (amino acids 112-246) and C-terminal domains (amino acid 289-323) are 
highlighted.   
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4.3.5. Hypermethylated 5’LTR TRE causes tax silencing in approximately 8% of ATL cohort 
Following tax gene amplification and sequencing, MS PCR was undertaken on 107 cases – those 
cases without a defective provirus or a critical tax gene alteration.  The aim was to identify whether 
the tax promoter in the U3 region of the 5’LTR was silenced by methylation. 
The samples were categorised as methylated, unmethylated or partially methylated. 
 
Table 4-4:  Summary table of methylation status of the 5’LTR (n=113) 
 Fully 
methylated 
5’LTR 
Fully 
unmethylated 
5’LTR 
Partially 
Methylated 
5’LTR 
Not 
determined 
 
Number of 
cases 
16 24 64 3  
 
Sixteen of the 107 cases (15%) of the samples contained a hypermethylated 5’LTR.  This represents 
8.1% of the cohort (16/197).  Takeda et al, who first reported and demonstrated the utility of  MS 
PCR and BSP techniques in DNA samples taken from ATL patients, identified hypermethylation  in 
11% ATL cases (14/41 samples).   
As proof of principle, I confirmed hypermethylated 5’LTR MSP findings in 4 cases by integration site 
specific bisulfite PCR (BSP) followed by TOPO® cloning and sequencing of the PCR products.  By 
sequencing between 10 and 20 colonies per sample, I demonstrated that in all cases the critical CpG 
sites covering the first promoter-proximal Tax responsive elements (TRE) were fully methylated.  The 
second TRE was fully methylated in all cases and third TRE was fully methylated in 3/4 cases and 82% 
methylated (45/55 CpG methylated) in the fourth case.  
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Table 4-5:Summary of Tax silencing mechanisms for cohort 
 Complete 
provirus (not 
defective, mutated or 
hypermethylated) 
Defective 
provirus 
Critical tax gene 
mutation 
Hypermethylated 
TRE 
Number of cases 90 78 13 16 
% of cases 46% 39% 7% 8% 
 
4.3.6. No difference in the median proviral load by clinical or proviral subtype 
The proviral load (PVL) was measured by QPCR in all ATL and AC samples by calculating the ratio of 
tax copies to actin.   The aim of measuring the PVL was to ensure that the ATL and control AC 
cohorts were similar to previously published cohorts, and for subsequent calculation of absolute 
abundance of clones following LMPCR and high throughput sequencing. 
In the ATL group the median PVL measured 71.7% (range 0.00% - 700%).  The median PVL for each 
clinical subgroup and each Tax-silenced subgroup is shown in Table 4.6 and Figure 4.2.  The median 
proviral load of the defective proviruses was significantly lower than the complete proviruses 
(Wilcoxon test p=0.004) which could be explained by the defective cases containing deletions of the 
tax gene primer binding sites. The median PVL of ACs measured 1.8% (range 0.14 - 18.4%).   
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Table 4-6: Summary table of PVL and Tax status 
Clinical Subgroup or tax 
subgroup 
Median PVL (%) 
AC 1.8 
Acute ATL 64.7 
Chronic ATL 62.8 
Lymphoma ATL 43.8 
Smoldering ATL 12.9 
Complete provirus 79.4 
Defective provirus 65.6 
Tax mutated provirus 68.3 
Hypermethylated 5’LTR 83.7 
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Figure 4.2: Proviral load (PVL) by clinical subtype (Panel A) and proviral tax gene status 
(Panel B) 
PVL were measured by QPCR and quantified by measuring tax and actin gene copies.  Box-and-
whisker plot show PVL for all cases.  The box displays the 25th, 50th and 75th centile whilst the 
whiskers show results that lie in the top and bottom quartiles.  x-axis;  ATL cohort split by disease 
status (Panel A) or tax gene status (Panel B). y-axis;  PVL % (number of copies of tax per 100 PBMC).   
Proviral load % 
Proviral load % 
100 
 
4.3.7. No difference in the median oligoclonality index by clinical or proviral subtype 
 
The oligoclonality index (OCI) was calculated for each sample (Methods section 2.4.3) to test the 
hypothesis that there was no difference in the clonal distribution between tumour samples that 
were capable of Tax expression and those that silenced Tax (Figure 4.3).   
The median OCI of the ATL clinical subgroups was 0.91 (range 0.47-1.0) and there was no difference 
between ATL clinical subtype or between proviral tax subtypes.  The median OCI of the ACs was 0.33 
(0.14- 0.87). 
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Figure 4.3:  Oligoclonality index by clinical and proviral subtype 
 
The OCI for the ATL and AC cohort split by clinical subtype (Panel A) shows median OCI of the ACs 
was 0.33 (range 0.14-0.87) and the median OCI for the ATL subtypes was 0.91 (range 0.47-1.0).  
There is no difference in OCI between ATL clinical subtypes.  There was no difference in OCI by 
mechanism of proviral silencing (Panel B). 
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4.3.8. Definition and character of abundance bins 
 
The ATL integration sites were subdivided into three abundance bins designated respectively as 
‘small’, ‘intermediate’ and ‘large’.  Since malignant behaviour is defined by growth in vivo and not 
from any specific genomic characteristic, it remains an assumption, widely held, that the large clones 
that are observed in ATL are malignant.    
Since the vast majority of total integration sites are small, with a relative abundance of <1%, we have 
called these ‘small clones’.    We have defined the large clones, presumed malignant in the ATL 
cases, as those integration sites with a relative abundance greater than or equal to 35% of the PVL.  
This threshold was determined after plotting the relative abundance of the largest integration site in 
each sample and observing a distribution in which all of the ATL samples have a dominant 
integration site that occupies >35% PVL (Figure 4.4). The intermediate sized clones are defined as 
those between the small and large clones with a relative abundance of greater than or equal to 1% 
but less than 35% (Table 4.7).  The abundance bins are defined in the glossary for quick reference. 
The relative abundance (rather than the absolute abundance) was determined to be the best 
measure for subgrouping of integration sites for analysis since the proviral load, which is required for 
the mathematical estimation of absolute abundance (Method section 2.4.5), varies significantly in 
the ATL samples due to, for example,  tax gene deletions which would significantly underestimate 
the proviral load whilst the presence of multiple proviruses would overestimate the absolute 
abundance of the malignant clone within a cell population. 
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Figure 4.4: Relative abundance of the largest clone in each ATL patient is >35% 
The relative abundance of the largest clone was plotted for each ATL case (relative 
abundance defined as the proportion of the proviral load occupied by an individual clone).  
The distribution of these integration sites suggested that the large presumed malignant 
clones typically occupied >35% relative abundance.   
 
Table 4-7:  The number of integration sites within each abundance bin 
Clinical 
status 
Number of 
samples 
Small Intermediate Large Total UIS 
AC 75 16001 904 4 16909 
ATL 197 5925 90 217 6232 
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4.3.9. Identification of multiple proviruses within a dominant clone 
ATL is traditionally associated with monoclonal integration of an HTLV-1 provirus within the tumour 
cells, although there have been reports for many years of the presence of multiple proviruses, based 
upon the observation of multiple bands by Southern blot (Kamihira et al., 2005; Tamiya et al., 1996; 
Tsukasaki et al., 1997).  Examples of the 3 ATL clonal distributions identified are shown in Figure 4.5.   
Here, I found that in 157 cases (80% cases) a single dominant clone was present which occupies a 
median relative abundance of 99.4% (range 35-100%) of the proviral load (Figure 4.5, A).  In 40 
cases, monoclonal integration was less certain since more than one abundant integration site was 
observed.  In each case, there was a one integration site with a relative abundance >35% (i.e. falls 
into the ‘large ATL’ abundance bin) but additionally a second site with a minimum relative 
abundance >10%.  In many of these cases the two dominant sites were of near equal relative 
abundance i.e. 45% and 50% relative abundance, but in other cases this was less clear e.g. 65% 
contribution from one site and 30% for the second site (Figure 4.5 B,C).  Therefore the question 
arises as to whether these represent one malignant clone containing 2 proviruses or if there are two 
distinct abnormally expanded clones.  If a single malignant clone contains two proviruses, the cells 
should contain an equal abundance of those integration sites (50% contribution from each 
integration site), assuming a steady kinetic state and no recent re-infection with a second provirus.  
It is unlikely that a superinfected malignant clone would co-exist with its singly infected parent clone, 
since a second infection would confer either a proliferative advantage or a negative survival cost.  
Therefore, we assume that a single clone containing two proviruses would be expected to have near 
equal abundance of both integration sites and express a single TCR gene rearrangement. 
Alternatively, if there are two large independent clones proliferating, we would expect there to be a 
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measurable difference in the abundance of the detected two integration sites and two distinct TCR 
gene rearrangements. 
To test the hypothesis that two observed HTLV-1 integration sites are present in one T-cell clone we 
used the Gaussian approximation to the binomial distribution, outlined below.  The null hypothesis 
was that there is no difference in the number of unique shear sites (read 2) between the two 
integration sites. 
 
Z-score calculated as: 
z = |a-b| - 0.5  with correction for continuity. 
       (2ab/N)0.5 
 
Where,  
a= Number shear sites for integration site 1 
b= Number shear sites for integration site 2 
N=Total number of shear sites (N=a+b) 
The Z-score was converted into a 2 tailed p-value. 
In 18/40 cases (9.1%  of the total cohort)  the null hypothesis was accepted, that is to say there was 
no difference in the number of shear sites between the abundant clones, suggesting multiple 
proviruses present in each T-cell clone. T-cell receptor gene rearrangement studies of DNA were 
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undertaken on these 40 cases and a single TCR gene rearrangement was detected in 7 of the 18 
cases in the cohort containing two equally abundant proviruses (3.6% cohort). 
Of the 18 cases in the cohort containing two proviruses per ‘malignant’ clone, 72% were of acute 
subtype, 11% chronic, 11% smouldering and 6% lymphoma (proportions not statistically different 
from representation within cohort). 
In 22/40 cases, the null hypothesis was rejected.  That is to say there was a significant difference in 
the abundance of the two dominant integration sites.  In these cases there was typically a dominant 
site (occupying 40-80% PVL) with additional intermediate sized expanded clones (in these cases 
occupying 10-35% PVL).   
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Figure 4.5: Clonal structure of the ATL cases 
Examples from the typical clonal structures of ATL cases is shown in pie charts, where each 
sector depicts the relative abundance of the respective detected integration site following 
LMPCR and high throughput sequencing. (A) A typical ATL monoclonal tumour sample, PVL 
107% (relative abundance dominant clone 97%).   (B)  Multiple copies per cell; two equally 
dominant integration sites, PVL 200.7%, (relative abundance 43% and 40% PVL). (C) ATL with 
dominant clone and additional intermediate sized clones, PVL 241% (relative abundance 
67% and 23% PVL).  
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4.4.  Discussion 
 
I characterised the proviral structure in 197 cases of ATL and determined that our cohort was similar 
to previously published ATL cohorts.  That is to say, 46% samples were inferred to be capable of Tax 
protein expression, and I observed the expected frequencies of defective proviruses, tax gene 
nonsense mutations and tax silencing by hypermethylation of the 5’LTR.   Importantly, this similarity 
to previous data gives confidence that any observations or conclusions that are made in subsequent 
host genomic integration site analysis are representative. Furthermore, I made some novel 
observations during the characterisation of this cohort, as summarised below.   
 
4.4.1. Identification of a novel category of defective provirus 
 
The frequency of defective proviruses (42%) is consistent with the published literature (Kamihira et 
al., 2005; Tamiya et al., 1996).  Here, I identified a category of defective provirus which I have 
termed ‘indeterminate’.  These are samples in which the proviruses fail to amplify by conventional 
long range PCR used for characterising defective proviruses, but there is evidence of HTLV-1 
integration e.g. a monoclonal population of cells seen following HTS, suggesting at least the 
presence of the 3’LTR. 
I hypothesise that the cause of the indeterminate provirus is a large deletion or mutations involving 
the primer binding regions of the long-range PCR.  It has been reported that HBZ is detected in all 
HTLV-1 infected clinical states, including ATL (Usui et al., 2008).  Although HBZ expression has not 
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been directly measured in these samples, the primer binding regions overlap with the intronic region 
of spliced HBZ, suggesting that a deletion in this region may not affect HBZ expression.   
On the basis of these results there is a project underway in the local Molecular Diagnostic Unit to 
compare HBZ and tax qPCR results in ATL cases with an unusually low proviral load (<5%-10% PBMC) 
to identify if HBZ may be a more reliable measure of PVL to monitor certain ATL cases. 
 
4.4.2. Identification of novel nonsense mutations in the tax gene 
 
I found nonsense mutations that prohibit the expression of functional Tax protein expression in 13 
cases (7 % cohort) which is consistent with the published literature (Takeda et al., 2004).  There were 
two novel recurrent nonsense mutations that have not been previously reported (G>A at position 
7380 and G>A at position 8040), which, based upon the amino acid position, I hypothesise will 
prevent functional Tax protein expression.  A test of this hypothesis requires formal validation by 
measurement of tax mRNA and protein expression, although there were no cells available from 
these individuals to do so.  Fan et al have described G-to-A base substitutions as the most frequent 
mutations in ATL cells, and responsible for nonsense mutations, which is in accordance with the 
target sequence of human APOBEC3G (Fan et al., 2010), the mammalian host defence against 
retroviruses. The novel nonsense mutations described here occur in the context of a TGG nucleotide 
sequence which is the target of APOBEC3G and results in TAG or TGA sequences and a stop codon. 
Since HTLV-1 proliferates mitotically, the provirus can proliferate with nonsense mutations providing 
it retains a minimum set of viral genes.  Fan et al showed that the only viral gene that does not 
become mutated is HBZ, which is likely indispensable for ATL development (Fan et al., 2010).  From 
these observations, together with the observation that APOBEC3G generates stop codons during 
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reverse transcription and that type 2 defective proviruses may also occur pre integration (Miyazaki 
et al., 2007), I conclude that at least in some ATL cases, Tax expression is not essential for 
immortalisation and expansion of malignant clones. 
 
4.4.3. Wide variation in the PVL in ATL samples  
 
The median proviral load of the ATL cases was 68.3% (range 0.0 -700%) and in the ACs 1.8% (range 0-
18.5%).  These results are comparable to data published on Japanese patients where a recent study 
on 1218 asymptomatic carriers identified a median PVL of 1.39% in females and 2.10% in males 
(Iwanaga et al., 2010).   A recent study of proviral load measurements of ATL patients managed in 
London reported  a median PVL of 50.3% in acute ATL, 7.9% in the peripheral blood of  ATL 
lymphoma and 81.25% in the lymph node biopsy of lymphoma-type ATL (i.e. a 5:1 ratio of load in 
lymph node to peripheral blood)  (Demontis et al., 2013). 
In acute ATL, the PVL is not normally expected to exceed 100% (1 proviral copy in every PBMC), 
although a proviral load > 200% can result from the presence of multiple proviruses, or possibly due 
to genomic instability resulting in loss of an actin copy.   PVL measurements by QPCR are known to 
fluctuate, although reproducibility is better at higher proviral loads (Demontis et al., 2013).  Within 
an asymptomatic individual the proviral load remains constant over many years and a log-fold 
change in proviral load measurements is usually considered to be clinically relevant, although there 
may be little significance between proviral load measurements of 100% and 200%.   
An interesting observation is that the PVL is frequently not 100%, even in cases where examination 
of a peripheral blood film suggests an entirely leukemic picture and heavy burden of disease.  This 
raises the possibility that there is a polyclonal expansion of uninfected PBMCs. These polyclonally 
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expanded PBMCs are unlikely to be CD8+ T-cells since diagnostic flow cytometry of ATL cases 
typically shows predominantly CD4+CD25+ T-cells and  the absolute number of CD8+ T cells is 
between 50% and 100% of the normal range (Arnulf et al., 2004; Rowan and Bangham, 2012; 
Shimizu et al., 2009).    HTLV-1 infected CD4+ T-cells produce CCL22 (Toulza et al., 2010), one of the 
two ligands for the receptor CCR4 which is expressed on both tumour cells and on the non-
malignant CD4+ FoxP3+ cells.  Toulza et al showed that the level of CCL22 produced is sufficient to 
attract CD4+FoxP3+ cells and to enhance their viability, which may contribute to the persistence of 
HTLV-1 by suppressing the HTLV-1 specific CTL response (Toulza et al., 2010).  It is perhaps the 
expansion of uninfected FoxP3+ Tregs that contributes to the expanded CD4+ compartment.  
Furthermore, polyclonal expansions of Treg cells have been reported in other haematological 
malignancies:  For example, in Hodgkin’s lymphoma the characteristic Reed-Sternberg cells 
constitute only a small proportion of the tumour, whilst infiltrating lymphocytes are highly enriched 
for Tregs, attracted by TARC and CCL22 (Marshall et al., 2004) and in B-CLL the presence of activated 
CD4+ T cells is required for tumour proliferation (Devereux, 2011; Patten et al., 2008).  The question 
remains as to whether these reflect anti-tumour responses or are a bystander effect.  
In HTLV-1 infection, separation of the infected and uninfected populations of T-cells by cell-sorting 
followed by high-throughput analysis of TCR gene rearrangements (e.g. ImmunoSeq™) would make 
it possible to quantify the immune repertoire of the infected and non-infected T-cell populations in 
different disease states. 
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4.4.4. Evidence of multiple proviruses in ATL cases. 
 
I obtained evidence by HTS of 2 equally abundant proviruses within a single tumour sample in 18 
cases (9% cohort) and used TCRG gene rearrangement studies on DNA to quantify the number of 
cases with a single TCR gene rearrangement.  I found a single TCR gene rearrangement in 7/18 cases 
(3.6% of the whole cohort). 
TCR gene rearrangement studies are complex to interpret.  One of the major issues in the accurate 
identification of clonality is the occurrence of multiple clonal PCR products.  Thymocytes undergo a 
hierarchical rearrangement in their TCR loci starting with D-D, D-J and V-DJ rearrangements in the 
TCRD locus, followed by V-J rearrangements in the TCRG locus (Langerak, 2012).  Random 
nucleotides are often inserted into the VDJ genes but since an antigen receptor chain can only be 
formed by preserved triplet codons, many rearrangements are non-productive.  For a given TCR 
locus, very frequently two rearrangements have taken place, one from each allele.  The theoretical 
chance for a rearrangement to be in correct reading frame and lacking a premature stop codon is 
estimated between 20% and 30% (Langerak, 2012), implying that diallelic TCR gene rearrangements 
are more the rule than the exception.  This means that monoclonal tumours will mostly contain 
diallelic rearrangements.    This makes distinguishing a diclonal tumour from a monoclonal tumour 
with diallelic rearrangements difficult.  The only definitive means of separating these two 
possibilities is by quantifying TCR gene expression using mRNA.  However, within this cohort there 
were no available cells for RNA extraction. 
On the basis of these data, I would therefore report the incidence of multiple proviruses within a 
single malignant clone at between 3 and 9 %.  The presence of multiple proviruses in ATL patients 
has been widely reported although the incidence has not been previously defined.  The mechanism 
by which the malignant clones have become superinfected is not known and raises the question as 
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to whether the mechanism by which the cells have become superinfected is a cause or a 
consequence of ATL.    
 
4.4.5. The significance of intermediate sized clonal populations is uncertain  
 
We have identified that whilst the majority of ATL tumour cell populations are monoclonal 
(containing either one or two proviruses), other tumours contain a dominant clone but with 
additional intermediate sized clones (figure 4.4, panel C).  This raises several questions as to whether 
we are correct to assume that the most abundant clone is always malignant, whether the smaller 
clones contribute to the pathogenesis of ATL, and whether these intermediate sized clones 
contribute to clonal succession or chemotherapy resistance. 
Malignancy is defined by the abnormal or uncontrolled growth of a cell population in vivo, rather 
than any specific genetic or epigenetic characteristic. Characteristics that must be acquired for a 
lesion to develop into cancer which include self-sufficiency in growth signals, insensitivity to anti-
growth signals, limitless replicative potential, evasion of apoptosis, sustained angiogenesis, tissue 
invasion and metastatic spread (Hanahan and Weinberg, 2000, 2011).  Here we have assumed that 
where there is a single dominant integration site (median relative abundance 99.2%, range 35.5-
100%), this is the malignant clone.  Where there are two proviruses within each clone, we do not 
know at what point during clonal expansion the superinfection arose and whether there was 
originally just a single provirus within the genome during malignant transformation, which later 
became superinfected; perhaps one of those proviruses is more important than the other in tumour 
pathogenesis?   Since we cannot distinguish which of these integration sites might be more 
important, we consider them to share equal importance. 
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The significance of the intermediate sized clones is even less certain:   There are a handful of studies 
describing the functional properties of CTL in ATL, which collectively report that the CTL response in 
ATL is reduced in frequency, or absent, and when present is functionally deficient with Tax-specific 
CTLs directed at a narrow range of epitopes (Arnulf et al., 2004; Kozako et al., 2006; Kozako et al., 
2009; Shimizu et al., 2009).  Perhaps, once transformation has occurred, the reduced or inefficient 
CTL response enables other clones to expand; these proliferative clones might have been formerly 
restricted by CTL killing.  The host genomic landscape of these different clonal populations is further 
characterised in Chapter 5. 
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Chapter 5. Genomic landscape of HTLV-1 proviral integration sites 
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5.1.  Chapter Abstract and summary 
The aim of the work described in this chapter is to test the hypothesis that ATL malignant clones 
arise from the typical low abundance clones seen in asymptomatic carriers (rather than the higher 
abundance clones observed in some AC or HAMTSP patient samples) and to characterise and 
identify host genomic features that are unique to defined clonal populations seen within ATL 
samples and which may suggest an ‘integration site determined predisposition’ to ATL development.  
Furthermore, I aim to correlate host genomic characteristics with capacity for proviral Tax 
expression, in order to postulate mechanisms for aberrant clonal expansion.  Where possible I will 
correlate findings with ATL clinical subtype. 
 
The results described here are derived from a bioinformatic analysis of the high-throughput 
sequencing of ATL and AC samples compared with in silico (random) integration site datasets and, 
where indicated, from in vitro infection data.  In summary the key findings of this chapter are:- 
 AC clones, small ATL clones and large ATL clones show similar genomic characteristics with 
regards to preference for integration in proximity to transcriptional start sites (TSS), CpG 
islands, genes, same-sense relative transcriptional orientation and activatory epigenetic 
marks.   
 Intermediate-sized ATL clones are abnormally abundant and show distinct genomic 
characteristics, not previously found in non-malignant HTLV-1 infection (AC or HAM/TSP). 
 ACs and small ATL clones show a bias of integration into certain chromosomes (acrocentric) 
 The ATL large clones (presumed malignant) do not show any recurrent sites (‘hotspots’) of 
genomic integration 
 Gene ontology analysis of the nearest downstream TSS identifies recurrent cellular 
functions/pathways associated with the large ATL clones (5.6% of all ATL cases). 
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5.2.  Introduction 
 
5.2.1. Proviral integration site bias 
 
The genomic site of retroviral integration into the host genome is important for both virus 
replication and pathogenesis of disease, since it may affect both viral gene expression (Shan et al., 
2011) and host gene expression (Siliciano and Greene, 2011).   
Some retrovirus-induced tumours are caused by insertional mutagenesis (Neel et al., 1981; Payne et 
al., 1982), whereby integration into a specific locus introduces a viral promoter or enhancer that in 
cis may activate an adjacent host cellular oncogene or, inactivate a gene through disruption of 
induction, expression or splicing (Uren et al., 2005).  Seiki et al showed the absence of a common 
region of provirus integration in ATL leukaemia cells, which implied that insertional mutagenesis, 
was unlikely to be a mechanism of ATL leukaemogenesis (Seiki et al., 1984). 
Interest in proviral integration sites has re-emerged in the last 10 years, in part due to improvements 
in the laboratory techniques which identify integration sites, and following publication of the 
annotated human genome.  Additionally,  interest has followed the high incidence of cases of T-
acute lymphoblastic leukaemia (T-ALL) that arose in children treated with gene therapy for severe 
combined immunodeficiency (SCID), which was caused by insertional mutagenesis of the retroviral 
vector near the LM02, BMI1 and CCND2 proto-oncogenes (Hacein-Bey-Abina et al., 2008; Hacein-
Bey-Abina et al., 2003).  The risk of insertional mutagenesis has halted the use of gammaretroviruses 
as suitable vectors for gene therapy and there are active efforts to identify and validate ‘safe 
harbours’ of the genome - regions of the genome that allow predictable expression of the newly 
integrated DNA whilst minimising unwanted interactions between inserted genes and the 
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neighbouring host genome.  Suzuki et al developed a definition for retroviral integration in cancer 
cells to discover potential cancer-related genes and defined a hot-spot as ≥ 4 integration sites within 
a 100 kb region, 3 integrations within 50 kb or 2 within 30 kb (Suzuki et al., 2002), and similar 
definitions have been adopted by others (Schroder et al., 2002,Cattoglio et al., 2007).   
Retroviral integration sites can be found across the host genome, although they are not randomly 
distributed (Wu et al., 2005).  Integration site selection differs between retroviruses but broadly all 
display a preference for integration at 3 distinct levels.  First, integration is biased towards open 
conformation euchromatin which allows the retroviral preintegration complex access to the DNA.  
Second, the nucleotide sequence in the immediate vicinity of integration sites is typically a loose 
palindromic consensus sequence (Chou et al., 1996; Derse et al., 2007; Meekings et al., 2008) which 
is consistent with the two-fold symmetry of the retroviral integrase (Hare et al., 2010; Maertens et 
al., 2010).  Third, there is an additional bias based upon interactions between the preintegration 
complex and specific cellular host factors, e.g. LEDGF/p75 in HIV infection which directs the 
preintegration complex into genes and away from intergenic regions.  Similarly, the transcription 
factor YY1 plays a role in murine leukaemia virus (MLV) guiding integration.  However, in most 
retroviral infections including HTLV-1 similar host co-factors have not been identified. 
 
5.2.2. HTLV-1 integration site selection 
Work undertaken within this laboratory over the last few years has focused on identifying the 
integration sites favoured in initial targeting of infection by using a model of short-term in vitro 
infection of human T-lymphocytes, and comparing the integration sites that are selected to survive 
in chronic infection in samples taken from patients with different clinical manifestations of HTLV-1 
infection. 
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Gillet demonstrated the predominance of integration in transcriptionally active regions and reported 
a positive correlation between clonal abundance and proximity to genes, CpG islands, activatory 
epigenetic marks and same sense relative orientation (Gillet et al., 2011).  
In addition Melamed et al have recently reported a remarkably strong bias toward integration ex 
vivo within 100 base-pairs of certain transcription factor binding sites, for example the tumour 
suppressor p53 and the transcriptional regulator of interferons STAT1, and in each case the 
integrated provirus was between 100 and 350-fold more likely to lie within 100 base-pairs of the 
respective binding site than by chance (Melamed et al., 2013).  Flow cytometric sorting of cells into 
Tax-positive and Tax-negative cells followed by integration site analysis revealed that certain TFBS 
(e.g. STAT1) lying 10 or 100 base pairs upstream of the provirus were associated with spontaneous 
Tax expression, whilst at a similar distance downstream there was no effect.  Conversely, the 
presence of BRG1, an ATPase that powers the chromatin-remodelling complex SWI/SNF, 10 to 100 
base-pairs upstream was associated with the silencing of Tax whilst a BRG1 site at an equal distance 
downstream of the provirus was associated with spontaneous Tax expression.   This asymmetry 
implies a mechanistic interaction occurs between transcription of the provirus and transcription of 
the host genome.  This conclusion is reinforced by further observations that the relative orientation 
of the provirus and nearest host gene associate with frequency of spontaneous proviral expression; 
a same-sense host transcriptional start site upstream appears to suppress Tax expression whilst a 
same-sense host transcriptional start site downstream of the provirus associates with spontaneous 
Tax expression.  These findings strongly suggest that the dominant interaction between the flanking 
host genome and the provirus is transcriptional interference; a nearby host promoter upstream of 
the provirus is able to silence the downstream 5’LTR HTLV-1 provirus (Melamed et al., 2013, 
reviewed  Bangham C.R.M, 2013). 
  
120 
 
5.2.3. Determinants of clonal abundance in vivo 
 
For many years it has been widely believed that oligoclonal expansion of HTLV-1 infected T-cells is 
responsible for both viral persistence of the infection and also maintenance of  the proviral load 
which predisposes to both inflammatory and malignant disease.   
With the development of HTS and the ability to quantify accurately clonal abundance, a strong 
determinant of clonal abundance was identified as proviral orientation:  Proviruses that lie in the 
same sense transcriptional orientation as its nearest host gene or transcriptional start site (Gillet et 
al., 2011).  Additionally, the recently published work by Melamed et al which flow cytometrically 
sorted Tax-positive and Tax-negative cell populations identified that small (low abundance) clones 
are more likely to express Tax in vitro than larger clones.  
The understanding of clonality in ATL lags behind that of non-malignant HTLV-1 infection.  For a 
variety of reasons, including the relative rarity of ATL and due to the labour intensive nature of the 
techniques required, the number of ATL cases that have been systematically analysed is relatively 
small: 23 ATL cases by Hanai (Hanai et al., 2004), 59 cases by Doi (Doi et al., 2005) and 33 cases by 
Ozawa (Ozawa et al., 2004). In addition to the limitations already described, integration site analysis 
in relatively few cases made correlation by clinical phenotype extremely difficult.   
Whilst it is widely assumed that ATL is a monoclonal disease there are indications that clonality is 
more complex.  Firstly, there are many HTLV-1 infected clones in addition to the large, presumed 
malignant clone which are not likely to be detected by classical sequencing methods and the identity 
and role of these clones in supporting the malignant clone is unknown.  Secondly, it has long been 
observed that there may be more than one pathologically expanded provirus present.  It has been 
previously untested as to whether these represent multiple malignant clones or superinfection of 
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one malignant clone with multiple proviruses.   The possibility of more than one independently 
transformed malignant clone would be in keeping with the emerging understanding of the 
polyclonal origin of some solid tumours (reviewed Vogelstein et al., 2013). Third, the malignant clone 
does not necessarily develop from a large pre-existing infected T-cell clone, but may arise rapidly de 
novo from a clone of low abundance- Figure 5.1 demonstrates the emergence of a presumed 
malignant clone from a small clone detected 18 months before disease transformation and not from 
the large clone that was present when the patient was asymptomatic.  Fourth, there have been case 
reports in the literature and anecdotally of ‘clonal succession’, in which the presumed malignant 
clone at a given time point may be replaced by a different clone at a later time point (e.g. at clinical 
relapse) and scenarios in which there are distinct dominant clones, both presumed malignant, 
present at the same time but in different compartments e.g. blood and lymph node (Tsukasaki et al., 
1997). 
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Figure 5.1: Clonal evolution in ATL 
 
The pie charts represent the clonal distribution seen in a single patient at 3 different time 
points prior to and at the development of acute ATL.  Each slice of the chart represents the 
relative abundance of an individual clone.  The patient developed ATL in September 2010 
and the clonal distribution in PBMC (top right) and lymph node (bottom right) on the day of 
diagnosis is illustrated.  The presumed malignant clone is coloured red and when tracked 
back to February 2010 (7 months prior to diagnosis) represents 1.7% of the proviral load and 
in February 2009 (19 months prior to ATL diagnosis) is barely visible representing 0.04% of 
the proviral load.  
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5.3.  Results 
5.3.1. Definitions of the genomic environment flanking the host genome 
 
The definitions of ‘upstream’, ‘downstream’, ‘same-sense’ and ‘opposite sense’ are all made with 
respect to the forward (plus/positive) strand of the proviral open reading frames. Therefore 
‘upstream’ of the integrated provirus denotes genomic annotations closest to the 5’ end of the 
provirus, whilst ‘downstream’ denotes genomic annotations in closer to proximity to the 3’ end of 
the provirus.  For each genomic feature analysed e.g. proximity to a gene, we defined the minimal 
distance to the integration site as the difference between the genomic co-ordinate (position) of the 
nearest respective feature, which may be upstream or downstream (Figure 5.2). 
 
Figure 5.2: Definition of the host environment flanking the host genome 
The red central block indicates the position of the HTLV-1 provirus integrated between two 
genomic elements.  The definitions of ‘upstream’, ‘downstream’, ‘same orientation’ or 
‘opposite orientation’ are defined with reference to the HTLV-1 provirus integrated onto the 
forward strand.  The minimal distances are calculated separately for upstream and 
downstream elements. 
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5.3.2. Control datasets 
 
DNA samples from 75 asymptomatic carriers originating from the Kumamoto region of Japan and 
identified as HTLV-1 seropositive by the Japanese blood service were prepared for high throughput 
sequencing in this laboratory by Dr Heather Niederer over the same time-course and often sharing 
the same sequencing flow cells as the investigated ATL cohort.  Dr Niederer kindly provided the 
integration site dataset for use as a control dataset.  Some experiments were validated 
bioinformatically with a second AC dataset originating from the Kagoshima region of Japan. 
 
5.3.3. The absolute abundance of all ATL clones is larger than seen in ACs 
 
Whilst absolute abundance is not optimal for allocating abundance bins within this cohort owing to 
the heterogeneity  in proviral load and proviral structure, it remains important to compare the 
absolute abundances of small, intermediate and large clones of ACs with ATL in order to understand 
whether any observed differences could be attributed to clonal abundance per se or could be 
directly related to the clinical phenotype i.e. AC or ATL. 
The median absolute abundance of the small ATL and AC clones (Figure 5.3) was numerically similar 
although statistically significantly different (0.588 v 0.478/10000 PBMC, Mann-Whitney test  p=7.13 
x 10-69), and there were also significant differences in the median absolute abundance of the 
intermediate AC and ATL clones (1.52 v 254/10,000 PBMC,  Mann-Whitney test  p=1.53 x10-50) and in 
the median absolute abundance of the large AC clones  and the presumed malignant ATL clones 
(156.9 v 6559/10,000 PBMC, Mann-Whitney test  p=0.0014).  Since the absolute abundance of AC 
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small and intermediate clones was significantly lower than the intermediate ATL clones, the AC 
abundance bins were all grouped together for further analysis. 
 
The observation that in absolute terms the intermediate sized clones in ATL are significantly larger 
than the equivalent clones in ACs is important, since this implies that differences observed between 
the equivalent relative abundance bins in ACs or ATLs may be due to differences in absolute clone 
size, rather than associated with disease itself. 
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Figure 5.3: Absolute abundance of small, intermediate and large clones in AC and ATL 
cases 
Absolute clonal abundance of ATL samples was significantly greater than ACs within each 
abundance category (small, intermediate and large).  Note the breaks in the y-axis which 
highlights that there was a 4-5 log difference in size between the small AC/ATL clones and 
the large, presumed malignant ATL clones. 
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5.3.4. Preferential integration of small clones into chromosomes 13, 14, 15 and 21 
 
In order to test for evidence of an in vivo selection on the distribution of integration sites the 
distribution of integration sites per chromosome was compared with both a random integration 
dataset and an in vitro dataset (in vitro dataset provided by Dr Anat Melamed) and statistically 
analysed by X2 testing with correction for multiple comparison testing. 
Meekings et al had previously analysed a total of 313 integration sites in vivo using the separate 
technique of classical LMPCR followed by cloning and Sanger sequencing and identified a significant 
excess of integration sites into chromosome 13 when compared with random sites (Meekings et al., 
2008) but the biological significance of this observation was uncertain.  Here, by a separate 
technique, I firstly tested whether there is evidence for chromosome targeting in vitro and found 
that there was no bias of integration into any particular chromosome within the in vitro dataset 
compared with random expectation. 
When comparing the in vivo datasets against random, I first tested the control Kumamoto AC 
dataset and the ATL dataset and then validated the findings against a separate AC dataset arising 
from the Kagoshima region of Japan.  Using X2 tests followed by corrections for multiple comparison 
testing, I found a significant excess of integration sites in chromosomes 13 (Kumamoto AC X2-test 
p=8.7 x 10-30, Kagoshima AC p= 7.5 x 10-15, ATL small X2-test p=4.5x10-12) , chromosome 14  
(Kumamoto AC X2-test p=8.35 x 10-10, Kagoshima AC X2-test  p=0.021)   and chromosome 21 
(Kumamoto AC X2-test  p=1.9 x10-17, Kagoshima AC X2-test 2.3x10-19,  ATL small X2-test p=0.027).  
There was a trend towards increased integrations in chromosome 15 (ATL small X2-test p=0.0025 
following correction) although the Kumamoto and Kagoshima cohorts lost significance following 
multiple correction comparison (Figure 5.4 and Table 5-1).  These biases persist when considering 
both chromosome size and the number of genes per chromosome. 
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When comparing the in vivo datasets against in vitro (rather than random), the bias of integration 
into chromosome 13 and 15 remained. 
Analysis of ATL intermediate and ATL large clones did not reveal any increased integrations across 
the chromosomes, but since their combined number of these sites was 307, this may reflect a lack of 
power. 
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Figure 5.4: Preferential integration into chromosomes 13, 14, 15 and 21 
The proportion of unique integration sites (UIS) per chromosome is shown for two 
independent AC datasets (Kumamoto and Kagoshima) and the small ATL clones. The yellow 
overlaid line represents the random dataset.  There are an increased number of integrations 
within chromosomes 13, 14, 15 and 21 in the clones of asymptomatic carriers and small ATL 
clones when compared with random.  The bias remains present in chromosome 13 and 15 
when compared with control in vitro data (not shown). y-axis shows the proportion of 
unique integration sites (UIS) in each chromosome, x-axis chromosomes 1-22, X,Y.  
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        Table 5-1: Preferential integration into chromosomes  
  
Table 5.1 demonstrates the significant associations of the different AC datasets and small ATL clones 
against both random datasets and the in vitro datasets  
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5.3.5. Integration within 10Kb of a TSS or CpG island is associated with acute subtypes of ATL and 
those carrying defective or tax mutated proviruses. 
 
Gillet et al (2011) demonstrated that in vivo integration sites survive in a non-random fashion that 
favours insertion next to genes, CpG islands and epigenetic marks associated with the control of 
gene expression and postulated that this was due to a greater accessibility of these genomic regions 
to proviral integration.  Here, I extend this analysis to consider ATL subgroups (both clonal 
abundance and clinical subtype) and investigate the proximity to transcriptional start sites 
(regardless of whether the integration site is within a gene or not), Figure 5.5.   
When compared with random integration I observed in the Kumamoto ACs that there was a bias of 
integration within 10 Kb of a TSS of a gene (20.5% v 13.9%, X2 test, p<10-117)  and within 10Kb of CpG 
island (20.9% v 14.2%, X2 test, p<10-118).  This was also observed in the small ATL clones (TSS 20.0% v 
13.9%  X2 test p<10-61, CpG 20.9% v 14.2%  X2 test p<10-43) and in the acute subtype of ATL (19.8% 
TSS X2 test p=0.01, 18.9% CpG X2 test p=0.04).   
When the large ATL clones were analysed by clinical subtype and by capacity for proviral tax gene 
expression I found a bias towards integration in proximity to TSS and CpG islands in acute subtype 
(TSS 19.8% v 13.9%X2 test p=0.01, CpG 18.9% v14.2% X2 test p=0.04) and in those clones carrying a 
tax mutation (TSS odds ratio 5.3,  X2 test p=0.0031, CpG odds ratio 5.2, X2 test p=0.00372). 
There was no statistically significant enrichment in integration near TSS or CpG islands in the 
intermediate sized clones compared with random.  
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Figure 5.5: Preferential integration within 10Kb TSS and CpG islands  
The proportion of integration site within 10Kb of a TSS (panel A) or CpG island (panel B) was 
compared between integration sites in AC, ATL cases versus random expectation.  The large 
ATL clones were subdivided into clinical subtype and tax status.  AC and small ATL clones 
show a preference for integration in proximity to TSS and CpG islands compared with 
random expectation.  This is also seen in acute ATL cases and those with a tax mutated 
provirus.  
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5.3.6. Same sense transcriptional orientation and proximity to genes favours clonal expansion. 
The transcriptional activity of the host genome in close proximity to an integrated provirus might 
influence the level of proviral transcription, either directly, through specific interactions between 
host promotor/enhancer elements and the provirus or indirectly, since unfolded chromatin becomes 
accessible to transcription factor complexes.  Melamed et al reported that in non-malignant  
infection activatory transcriptional activity upstream appears to suppress Tax expression by a 
presumed mechanism of transcriptional interference, allowing CTL escape and clonal expansion 
(Melamed et al., 2013). 
We report an increased frequency of integration within 50Kb of genes in ACs (54%, X2 test p<10-24) 
and ATL small clones (55%, X2 test p<10-16) when compared with  random sites (50%). There is an 
increased frequency in the large ATL clones, although not statistically significant after correction for 
multiple testing (54%, X2 test p=0.07).  There was no bias towards integration in proximity to genes 
in the ATL intermediate sized clones (50%). 
By chance, we would expect to see an equal number of integrations in the same or opposite 
transcriptional orientation to the provirus.  When the analysis was extended to investigate 
preference for integration by relative transcriptional orientation, clinical subtype and tax gene 
structure within 50Kb of the nearest gene (Figure 5.6)  we observed that there was a bias towards 
integration within the same transcriptional orientation in AC (X2 test p<10-15) , small ATL clones (X2 
test p<10-4) and  acute subtypes of ATL (X2 test p=0.009) and in those with a defective provirus (X2 
test p=0.02). 
Given the postulated mechanisms of transcriptional interference described by Melamed et al 
(Melamed et al., 2013), we considered whether in acute ATL the same or opposite orientation was 
associated with either upstream or downstream integration of the provirus relative to the nearest 
gene, but there were too few events within each category for meaningful analysis. 
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Figure 5.6: Integration in proximity to genes in the same sense transcriptional orientation 
 
The proportion of integration sites within 50Kb of a gene and in the same transcriptional 
orientation was compared between random expectation and integration sites in AC or ATL 
cases.  The large ATL clones (red dot) were further subdivided into clinical subtype and 
capacity for proviral tax gene expresssion (complete or defective). There were too few 
hypermethylated or tax gene mutated cases to subdivide by both orientation and proximity 
to genes.   AC, small ATL and large ATL clones of acute subtype and defective proviruses 
showed a preference for integration in proximity to genes in the same transcriptional 
orientation.  
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5.3.7. Integration is favoured in proximity to activatory epigenetic marks 
 
By comparison of in vitro and in vivo integration sites, Gillet et al reported that in chronic infection, 
clonal abundance was positively associated with integration in proximity to host activatory 
epigenetic marks and negatively associated with integration near gene-silencing marks.   This 
observation suggested that ACs with low proviral loads and low risk of clinical disease, with efficient 
immune responses, counterselect integration sites in activatory regions of the genome. 
Nine activatory and three inhibitory epigenetic marks were analysed and selected as marks defined 
by Barski (Barski et al., 2007), detailed in Appendix 1.  The proximity to either activatory or inhibitory 
marks was defined by the proportion of integration sites with these marks above the 90th centile 
when compared with a random dataset (within 10 Kb of each integration site).   
Here, I observed an increase in number of activatory epigenetic marks when compared with random 
in both ACs and ATLs (all 9 activatory marks) and there was no significant difference between the 
ACs and large ATL clones.  However, there were fewer activatory marks in proximity to the 
intermediate sized ATL clones (3/9 marks significant) (Figure 5.7, panel A).  
By contrast, there was a striking bias towards integration in proximity to repressive epigenetic marks 
in the intermediate ATL clones compared with the ACs and both small and large ATL clones (Figure 
5.7, panel B).  There were no associations between proximity to activatory or inhibitory marks by 
clinical subtype or by the inferred capacity for proviral tax gene expression. 
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Figure 5.7: Small and large clones favour activatory epigenetic marks, whilst intermediate 
ATL clones favour inhibitory marks 
 
The proportion of integration sites in proximity to 9  activatory (panel A)  and 3 inhibitory 
(panel B) epigenetic marks was calculated, by comparison to a random dataset.  The 
proportion of random sites in proximity to each mark was defined as the number of sites 
above the 90th centile and was the benchmark for comparison with the AC and ATL sites.  
ACs and both small and large ATL clones favour activatory epigenetic marks whilst the 
intermediate ATL clones show a preference for inhibitory marks 
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5.3.8. Integration in proximity to TFBS 
 
We wished to test the hypothesis that proviral integration in proximity to transcription factor 
binding sites (TFBS) is associated with clonal expansion (intermediate sized clones) and malignant 
transformation (large ATL clones) within the ATL cases.  The TFBS data used was downloaded from 
publicly available datasets of TFBS that have been identified by ChIP-seq experiments.  Where 
possible we used datasets from primary CD4+ T-cells; otherwise data sets from only Jurkat or other 
human cell lines were analysed.  Where primary data was available the SISSRs Perl script (Jothi et al., 
2008) was used which is specifically designed to predict the sites of transcription factor binding for a 
given genomic location.  A complete listing of all the datasets used is given in Appendix 1. 
TFBSs have been reported to co-localise in the human genome (Dunham et al 2012), and so we used 
the approach previously described by Melamed (Melamed et al., 2013) to test which of the studied 
TFBS were independently associated with integration:  The statistical approach used was first a 
likelihood ratio test to identify whether a particular integration site was selectively associated with 
either upstream or downstream integration.  Then, each TFBS annotation (upstream and/or 
downstream) was subsequently tested separately in univariate analysis.  Any significant p-value 
(p<0.05) after multiple comparison corrections, were combined into a multivariate model using a 
standard step-down general linear model regression approach, until only independent significant 
factors remained (p<0.05).  Two separate models were run, to identify TFBS within 0- 100 
nucleotides and TFBS within 0- 1000 nucleotides of the integration site. 
There were no independent TFBS predictors for ACs, ATL small or ATL large clones and no predictors 
for clinical subtype or for proviral tax expression. 
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However, when comparing the intermediate sized clones of ATL with either the  ACs or small ATL 
clones, four TFBS were identified to predict intermediate ATL clones:  These factors were PCAF, Rad 
21 and ZNF263 binding sites (upstream or downstream) at 100 base pairs from the integration site.  
With the same analysis at 1 Kb from the integration site, the observed TFBS that were associated 
with intermediate sized ATL clones were E2F4 upstream, Rad 21 downstream and ZNF 263 in either 
direction (Figure 5.8).   
This data was validated against the second AC cohort from the Kagoshima region of Japan and the 
same predictive factors were identified in the ATL intermediate clones when compared with the 
Kagoshima ACs.   
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Figure 5.8: Intermediate sized ATL clones only are associated with integration in proximity 
to specific TFBS 
Intermediate sized ATL clones were associated with close proximity to 4 specific TFBS when 
compared with either Kumamoto ACs, small or large ATL clones; y-axis shows the odds ratio 
when compared with Kumamoto ACs. The x-axis shows the distance in base pairs from the 
integration site upstream (left side of y-axis) or downstream (right side of y-axis). The 
junction of the y-axis with the x-axis represents the integration site.    These results were 
reproducible when compared with an unrelated Kagoshima AC cohort.  The definition of 
‘upstream’ and ‘downstream’ are with respect to the sense strand of HTLV-1. See Appendix 
1 for the full list of TFBS tested. 
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5.3.9. In vivo integration sites are associated with proximity to oncogenes, but are not 
associated with malignant transformation. 
 
HTLV-1 has not been associated with any recurrent genetic lesion, whilst other closely allied 
retroviruses or gene therapy vectors have caused insertional mutagenesis and T cell malignancies. 
Furthermore other  haematological malignancies are associated with over-expression of specific 
oncogenes for a variety of genetic  or epigenetic reasons e.g. Burkitt lymphoma and over-expression 
of c-myc, and  it was therefore important to test the hypothesis that HTLV-1 integration is associated 
with increased proximity to ‘cancer associated genes’. 
The list of ‘cancer associated gene’ databases is shown in Appendix 1.  This is a list of genes known to 
be aberrantly expressed by any mechanism in any published cancer.   
The datasets were annotated to investigate proximity to nearest cancer-associated genes and 
showed a significant association between integration near oncogenes in ACs (at 10Kb from insertion 
site X2 test p<10-12) and, ATL small clones (at 10Kb from insertion site X2 test p<10-6).  The ATL large 
clones showed a bias within 150Kb of the insertion site (X2 test p=0.0085) but was not sufficiently 
powered to investigate at closer proximities, whilst the intermediate clones did not show any bias 
compared with random expectation. 
Since the AC and small ATL clones both showed a bias towards integration in proximity to 
oncogenes, this would suggest that this is a general feature of integration in vivo and unlikely to play 
a significant role in oncogenesis per se. 
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5.3.10. No hotspots of integration are associated with ATL 
 Whilst the analysis of integration into chromosomes did not identify any chromosomes with 
excessive number of integrations within the larger ATL clones (intermediate or large sized), one aim 
of this analysis is to identify whether there could be more subtle clustering or ‘hotspots ‘within any 
given chromosome. 
In order to test the hypothesis that the large ATL clones are associated with hotspots or clusters of 
integration I undertook a bioinformatic analysis initially developed for the analysis of safety of gene 
therapy vectors (Presson et al., 2011) which was specifically designed to compare datasets of 
different sizes.  I combined both the intermediate and large ATL clones on the basis that they are 
both abnormally expanded and this would increase the power of this analysis. Retroviral integration 
clusters in cancer cells have been variably defined as  ≥3- 4 hotspots of integration within a 100 kb 
region, 3 integrations within 50 kb or 2 within 30 kb (Cattoglio et al., 2007; Schroder et al., 2002; 
Suzuki et al., 2002).   
The methodology adopted here applied two methods of hotspot definitions based upon integration 
site densities.  The first method, the ‘z threshold’, applies a threshold to z-transformed densities and 
the second method applies a Bayesian change-point analysis (‘BCP’).  These definitions operate by 
partitioning the genome into 1 Mb bins and sliding these bins across the genome every 0.25Mb in 
order to identify any hotspots at the 1Mb window cut-offs (Presson et al., 2011).  As suggested by 
Wu (Wu et al., 2006) we used in vitro data (acute infection) as a control datatset for defining hot-
spots in the corresponding ATL data.  The acute infection data overcomes any natural virus-specific 
bias, rather than using a random dataset.  Analysis of the in vitro dataset did not identify any 
significant hotspots in the genome.   
We defined ‘hotbins’ as the 1Mb windows in which there appeared to be an excess of integrations 
and only further analysed  hotbins when they were identified by both the z-threshold and BCP 
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methods.  I then undertook both a ChiSq analysis with correction for multiple testing comparisons 
and calculated a Poisson distribution to confirm an excess of integrations in large clones compared 
with all others.  The size of the hotbin could then be refined to a hotspot (the smallest window of 
excess integrations within that hotbin).   
It has been previously reported by Doi (Doi et al., 2005) that alphoid repeats are favoured in both 
non-malignant and malignant infection.  We did observe this effect in the cluster analysis but 
attributed these to mapping errors:  Alphoid repeats (satellite repeats) are typically located in the 
centromeres and telomeres and represent short repetitive regions that are often displayed as gaps 
in the human genome sequencing project.  There are significant efforts to close these gaps, but the 
nature of these repetitions makes it difficult to map a site uniquely and results in apparent clusters 
at the junctions of centromeres and the defined sequenced genome. 
There were no identified hotbins by combined z-threshold/BCP methods in the in vitro, AC or small 
ATL clones.   Within the ATL intermediate and large clones, there was only a single region of the 
genome that fulfilled the described definition in chromosome 14, at position 28230332-28258889 
(human genome build 18).  That is to say following multiple testing comparison there were  
integrations that are closer together than expected by comparison with the random dataset (X2 test 
p = 10-65), versus in vitro (X2 test p = 0.007), versus AC (X2 test p = 0.001), and versus small ATL clones 
(X2 test p =10-9).  However, this 28.6Kb region on chromosome 14, within a large intergenic region of 
the genome, comprises of integration sites from just two presumed malignant clones arising from 
two ATL cases.    
I conclude that within this large cohort, using powerful bioinformatic tools, there is no evidence to 
support the idea that there are any clusters or hotspots of HTLV-1 integration in asymptomatic or 
malignant HTLV-1 infection. 
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5.3.11. Ingenuity Pathway Analysis (IPA®) suggests ontogeny of the nearest downstream gene 
may play a role in ATL proliferation. 
 
Whilst I have previously demonstrated that there is no obvious integration in proximity to ‘cancer 
associated genes’ within the large ATL clones, this may be limited by the relatively few cancer 
associated genes compared with the size of the host genome and does not exclude a functional, 
indirect role for integration in proximity to a category of host genes that may confer a proliferative 
advantage. 
The Ingenuity® platform is a gene ontology software that uses its own ‘Ingenuity Knowledge Base’ 
which contains biological and chemical interactions and functional annotations created from millions 
of individually modelled relationships between proteins, genes, tissues, cells and diseases.  Like 
many gene ontology databases, is widely used by researchers investigating expression microarrays.   
I used IPA  to identify functional clustering of integration sites and the results indicated that there 
was an over-representation of genes involved in the cellular pathways associated with ‘cell 
morphology’, ‘immune cell trafficking’ and ‘haematological system development and function’ 
within the large ATL clones (Figure 5.9). 
The genes associated with these pathways were only observed when looking at the nearest 
downstream gene (TSS) in the large ATL clones and were not observed in the asymptomatic carriers 
nor the small or intermediate sized clones.  Furthermore, these effects were not present when 
looking at the nearest upstream gene in the large ATL clones. 
These functional categories related to 11 specific genes (CD47, ITGA4, DPYSL2, RAP2A, CASP8, 
CDKN2A, GTF2I, TACR1, BCL2, IL6ST and HGF) arising from 11 different ATL cases (5.8% cases).  These 
11 cases were of mixed ATL subtype and of mixed proviral subtype (7 complete proviruses, 3 
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defective proviruses and 1 tax gene mutated provirus) and 10/11 of these genes are known to be 
dysregulated in cancers, particularly leukaemias.  Of note, the median distance to the transcriptional 
start site of these 11 genes from the UIS was 13,733 nucleotides (range 628 – 294,863 nucleotides) 
compared with a median of 122,333 nucleotides when considering the proximity of all integration 
sites to the nearest oncogene (Mann Whitney, p=0.009).  There were too few insertion sites to make 
any estimation of the contribution of relative transcriptional orientation.   
I conclude that the nearest downstream host gene may include a functional category of genes that 
have a contributory role, not specifically causative, in the proliferation of ~6% ATL cases.  
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Figure 5.9: Functional classification of genes over-represented amongst the large ATL 
clones 
 
Functional categories significantly over represented amongst the random, ACs, ATL small, 
intermediate and large ATL clones as analysed by the Ingenuity® software, using the 
Ingenuity Pathways Knowledge Base (IPKB) gene population as background.  Bars are only 
visible where there is a statistical over representation compared with the IPKB.  Since there 
are no over-represented pathways involving the random integration sites, or intermediate 
sized ATL clones the bars are not visible.  The vertical yellow threshold represents the line of 
statistical significance (p<0.05) after correction for multiple testing comparison (B-H 
correction).  The numbers of searchable genes for analysis against the IPKB were: random 
(n=96706), AC (n=5679), ATL small (n=1628), ATL intermediate (n=87), ATL large (acute 
n=141, lymphoma n=31, chronic & smoldering n=38). 
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5.4.  Discussion 
 
Understanding the mechanisms of HTLV-1 cellular transformation is of great importance both in ATL 
and within the wider field of retroviral oncogenesis.  The factors that determine why only  a small 
percentage of carriers develop ATL are unknown, why ATL typically takes decades of asymptomatic 
infection to emerge is unknown and predicting which individuals are at risk of disease remains 
difficult:  Whilst patients with proviral load >10% are at high risk of disease (Demontis et al., 2013), 
there are many high-load ACs who never develop clinical disease. 
The aim of the experimental and bioinformatic analysis within this chapter was to identify whether 
malignant ATL transformation occurs on a ‘normal’ polyclonal HTLV-1 background or whether there 
are specific host genomic differences within the proviral integration sites found in the large 
presumed malignant ATL clones that suggest a selection for certain clones to transform.  
Furthermore, by comparison of the small clones found in ATL samples with ACs, I was able to test 
whether the individuals who develop ATL have a chronic background selection for proviral 
integration sites with specific characteristics that may determine their risk of developing ATL.  This 
has been previously untested, in part because previous techniques are too labour-intensive to 
investigate large numbers of patients and secondly, because only HTS methods are able to recover, 
map and quantify the abundance of smaller clones. 
The AC cohort used as external controls originated from the same region of Japan and were 
experimentally prepared and analysed simultaneously using the same laboratory methods.  Since 
the AC cohort originated anonymously from the Japanese blood service, I was not able to correlate 
my observations with factors such as age or gender.   The age and gender of the ATL cases were not 
known in all samples (Appendix 2).  Additionally, since there is a lifetime risk of developing ATL of 
approximately 5%, we might expect 3 or 4 of these ACs to develop ATL in the future. There is a small 
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bias in the ACs towards those with higher proviral loads, since we are not able to robustly undertake 
high-throughput sequencing on patients with very low proviral loads by QPCR (proviral loads <0.1%).  
This is a frequent problem within the HTLV-1 field when investigating expression of viral genes or 
proteins.   
5.4.1. Preferential integration into acrocentric chromosomes in small clones 
 
Meekings et al identified an excess of integrations into chromosome 13 in DNA samples derived 
from AC and HAM/TSP patients using classical LMPCR and Sanger sequencing, the biological 
significance of which was uncertain (Meekings et al., 2008).  Here, by a separate technique I 
confirmed this observation in chromosome 13 and additionally identified excess integrations into 
chromosome 14, 15 and 21 which are all acrocentric chromosomes.   This was initially observed in 
the two test datasets (Kumamoto ACs and ATL small clones) and independently observed in an 
unrelated dataset from Kagoshima ACs.  There was no bias of integration when the in vitro dataset 
were compared with random suggesting that other factors are important in targeting of integration.  
However, the biases into acrocentric chromosomes within the patient derived integration sites 
remained evident when compared with in vitro (particularly in chromosomes 13 and 15).   In 
addition to chromosomes 13, 14, 15 and 21, chromosome 22 is also acrocentric.  However, whilst 
chromosome 22 was not statistically significantly overrepresented in this analysis, the trend for 
preferential integration was in the same direction.   I did not observe these effects in the expanded 
ATL clones (ATL intermediate or large), possibly due to the smaller number of integration sites (total 
317) across 24 different chromosomes of differing sizes.  The increase in integration sites was evenly 
distributed along the q-arms of these chromosomes and not observed in the p-arms.  However, the 
nucleotide sequences of these p-arms have not been well defined by the various human genome 
sequencing projects, largely due to the repetitive nature of the sequences, and are represented as 
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gap regions in the human sequence (Cole et al., 2008; Kidd et al., 2010).  It has been recently 
estimated that 200 Mbp of the human genome remain unmapped (Genovese et al., 2013) which 
have been largely attributed to sequences within the centromeres and short arms of the acrocentric 
chromosomes.  Next-generation sequence reads from these ‘missing pieces’ are typically 
disregarded or misaligned and it is currently estimated that whole genome sequencing projects 
using the NCBI GRch37 human reference genome build misalign 17Mbp of reads due to the fact that 
they arise from gaps or missing pieces (Genovese et al., 2013).     It is therefore possible that if there 
are integrations that are associated directly with the ribosomal DNA genes, we cannot detect them 
by our method which principally relies upon uniquely mapped paired-end reads.  The significance of 
integration into acrocentric chromosomes is uncertain. 
An important feature of these chromosomes is their association with nucleoli.  The very small p-arms 
contain approximately 400 rDNA genes (across all 5 chromosomes), also known as nucleolar 
organising regions, and after mitosis these regions form the nucleoli which act to concentrate the 
transcriptional and processing machinery required for ribosome formation.   In addition to the main 
function of the nucleolus in ribosomal subunit biogenesis, additional functions have been recently 
described such as a role in cell-cycle progression and in the stress response (Boisvert et al., 2007; 
Pederson and Tsai, 2009). In addition, chromatin associated with nucleoli contains high-density AT-
rich sequence elements, a low gene density, but a significant enrichment in transcriptionally 
repressed genes (van Koningsbruggen et al., 2010). 
The observation of increased number of proviruses on these chromosomes suggests there is a 
selection advantage to integration on these chromosomes.  There is less negative selection by the 
immune system and we hypothesise that the provirus is able to couple its transcription to that of the 
nearby transcriptionally repressed host genes which allows the provirus to persist without 
expressing Tax protein which allows CTL escape. 
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In order to validate these observations and mechanisms, it would be essential to first directly 
visualise these chromosomes and chromosome territories during the cell cycle, for example using 
single-cell FISH.  It would then be useful to test for proviral expression of genes in conjunction with 
nearby host genes, for example using HTLV-1 T-cell clones derived as described in chapter 3. 
 
5.4.2. Effects of the genomic environment on clonal expansion in vivo 
 
The abundance of an HTLV-1 infected clone in vivo will be determined by the net effect of two 
opposing forces:  Mitotic proliferation of an individual clone and its susceptibility to CTL killing.  If 
these forces acted equally upon all clones we would expect clones in vivo to be of equal abundance.  
However, HTS data has shown that there is wide variation in clonal abundance both between 
infected individuals and within each individual and we hypothesise that the proviral integration site 
is a major determinant of this (Gillet et al., 2011; Melamed et al., 2013).  The host genomic 
environment may determine the frequency and intensity of proviral gene expression which 
promotes a proliferative advantage. 
Patient-derived integration sites (AC or small ATL clones) show  identical host genomic 
characteristics in all the investigated host genomic characteristics, i.e. proximity to TSS, CpG islands, 
genes, same-sense transcriptional orientation, preference for activatory epigenetic marks, general 
bias in proximity toward oncogenes, lack of integration ‘hotspots’ and no preferential gene ontogeny 
of nearby host genes.  This similarity suggests that there is no selection bias towards the survival of 
certain clonal populations specific to ATL individuals.    
Interestingly the results here have shown that large ATL clones (putatively malignant) show very 
similar host genomic characteristics to the background polyclonal populations (both small ATL and 
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AC clones).  When analysed by subtype, the bias was greatest in acute ATL and in those with either a 
defective provirus or containing a tax gene mutation that prevents Tax expression.   Since it has been 
previously shown that defective proviruses may arise pre integration and tax gene mutations may 
occur early during asymptomatic infection and may be transmissible from mother-to-child  
(Furukawa et al., 2001; Miyazaki et al., 2007), this supports the hypothesis that by not expressing 
Tax, possibly for many years,  clones have a selection advantage (presumably CTL escape) and that a 
nearby CpG island or host gene TSS that lies in the same transcriptional orientation confers a survival 
advantage.  
Although this was a large ATL cohort, there were still not enough high-abundance ATL clones to 
statistically analyse the relative orientation of the provirus and nearby host genes by clinical ATL 
subtype and tax gene expression in order to test the notion that there is a mechanism of 
transcriptional interaction between the provirus and host.  Nonetheless, the observation that non-
expressing Tax clones integrated in same-sense transcriptional orientation become abundant 
remains consistent with the observation by Melamed et al (2013) in ACs and HAM/TSP. 
 
5.4.3. Intermediate sized clones contain proviruses with unique host genomic characteristics 
 
The most surprising observation was the consistent finding of a population of intermediate sized 
clones with unique genomic characteristics, not seen in the Kumamoto AC cohort and not previously 
observed by Gillet et al or Melamed et al.  As previously described, the usual findings in non-
malignant infection are linear correlations with clonal abundance and no intermediate sized 
population that appear to behave completely differently have been observed.  The intermediate 
sized clones show no preference for proximity to CpG islands, TSS, genes, relative orientation or 
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activatory epigenetic marks.  However, by contrast, there is a striking bias for integration in 
proximity to repressive epigenetic marks. Furthermore, the observation that specific TFBS are 
predicted to bind in proximity to these intermediate sized integration sites, whilst no bias is seen 
ACs, small or large ATL clones further supports the observation that they are a distinct clonal 
population.  This is consistent with observations by Melamed et al who observed a TFBS bias that 
was greatest for targeting of in vitro integration, rather than for in vivo sites and suggested that 
proximity to TFBS did not confer an advantage on the infected clones during chronic infection. 
Since TFBS can cluster or co-localise, I carried out a logistic regression analysis containing all 
analysed TFBS in order to ascertain which TFBS are independently associated with clonal expansion.  
The results (Figure 5.8) identify PCAF, Rad 21, ZNF 263 and E2F4 as independent correlates of 
intermediate sized clones when compared with ACs, small or large ATL clones.   The most striking 
effects are observed with PCAF binding sites at 100 base pairs upstream or downstream of the 
provirus, Rad21 up or downstream and ZNF263 up or downstream, the effects of Rad21 and ZNF263 
most prominent at 100bp downstream of the proviral integration site. 
PCAF (P300/CBP-associated factor) is a transcriptional co-activator known to play a significant role in 
HTLV-1 infection.  Tax mediated viral transcriptional activation occurs via complex interactions 
between Tax and CREB at the Tax-responsive element-1 (TRE-1) of the 5’LTR.  The formation of Tax-
CREB promoter complex serves as a high-affinity binding site for the recruitment of the 
multifunctional cellular co-activators such as CBP, p300 and PCAF (Kashanchi and Brady, 2005).  
Rad21 is a component of the cohesin quaternary complex whose classical function is to prevent 
premature chromatin segregation during mitosis by tethering newly synthesised sister chromatids 
together.  Aberrant cohesion expression has been identified as a significant pathogenic factor in the 
development of various tumour types associated with chromosomal instability including lymphoid 
malignancies (Sajesh et al., 2013) and it is known that tumours which display aneuploidy, such as 
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ATL, are associated with poor prognosis and the rapid acquisition of multi-drug resistance (Duesberg 
et al., 2001).     The role of cohesin in HTLV-1 or other retroviruses, on higher order function is yet to 
be elucidated. 
Intermediate sized clones occurred in 48 cases ATL, with a total of 90 integration sites (median 1 site 
per case, range 1-11 sites).  Only a minority of integration sites were found in proximity to any 
particular TFBS and relate to 8 specific cases of ATL (17% of cases with intermediate sized clones).  
Therefore the existence of these TFBS in proximity to an integration site was not necessary for 
expansion of the intermediate abundance clones, but may have conferred a proliferative advantage 
on these clones, although the mechanism is not clear.  Whilst silencing of Tax expression may confer 
a selection advantage in early infection, we hypothesise that following transformation, in the 
presence of an inefficient CTL response, the viral –host dynamics change and allow these abundant 
intermediate sized clones to express Tax and proliferate.  To test this hypothesis would require cell-
sorting of Tax positive and Tax-negative ATL PBMCs, followed by high-throughput sequencing and 
correlation with clonal abundance. 
 Importantly, I have shown that the intermediate sized population remains relatively large, by 
comparison with AC/HAMs (absolute abundance of ATL intermediate clones 254/10,000 PBMC 
versus 1.52/10,000 PBMC in AC/HAM intermediate clones) suggesting that these clones have arisen 
as a consequence of ATL, rather than causative.    The presence of these intermediate sized clones 
also supports the hypothesis that malignant transformation occurs from a clone within the typical 
polyclonal background, since if it had arisen from the abnormal intermediate sized clones, we would 
expect the large ATL clones to have the same genomic characteristics as the intermediate sized 
clones.   
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5.4.4. ATL is not caused by integration in proximity to cancer-associated genes 
  
Although it has been known for 30 years that ATL is not caused by a recurrent genomic lesion (Seiki 
et al., 1984), it remained important to systematically investigate whether there were targeted 
regions (clusters/hotspots) of the host genome that may contribute to a small percentage of ATL 
cases.  These may only be detected by analysing large cohorts of patients.   Here we observe, that all 
in vivo sites in the ACs, small and large ATL clones show a preference for integration in proximity to 
‘cancer associated genes’ when compared with random (again not seen in the intermediate sized 
clones), but crucially there is no significant difference between the controls (AC, small ATLs ) and the 
large presumed malignant ATL clones.  Detailed cluster analysis using sensitive bioinformatic and 
statistical methods (Presson et al., 2011) does not convincingly suggest that any particular region of 
the genome is over-represented within the malignant ATL population. 
Gene ontology using the IPA® platform suggests that in a small percentage of ATL cases (5.8%), 
recurrent functional categories were over-represented in the nearest TSS downstream within the 
large ATL clones.  This was not seen in the other categories (random, AC, small ATL or intermediate 
ATL clones) and was not seen when looking at the nearest gene upstream in the large ATL clones.  
Furthermore, when these 11 cases of ATL were individually investigated, the implicated gene was 
close to the provirus (13,733 nucleotides) - significantly closer than the median distance of other 
larger clones to their respective nearest downstream TSS.  This strengthens the case that a provirus 
upstream may interact transcriptionally with a downstream host gene, contributing to clonal 
proliferation (Melamed et al., 2013).  All of these 11 genes are normally expressed in CD4+ T-
lymphocytes and 10 of the 11 genes have been implicated in tumorigenesis, particularly of 
leukaemias (Chao et al., 2011; Berndt et al., 2013; Fabbri et al., 2013; Hsieh et al., 2013; Kentsis et 
al., 2012; Lauc et al., 2013; Minato, 2013; Munoz et al., 2012).  These 11 cases were of mixed clinical 
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subtype, mixed proviral tax gene subtype and of mixed relative transcriptional orientation to the 
nearest downstream TSS, precluding inferences about mechanisms of transcriptional interference 
and the contribution of a nearby upstream HTLV-1 provirus. 
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Chapter 6. General discussion and summary of thesis work 
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6.1. Chapter Aim 
 
The aim of this chapter is to summarise the key points of the thesis, which have been discussed in 
detail at the end of each chapter, and then to place these findings in context with current 
understanding of ATL pathogenesis and to suggest the implications of these findings in terms of 
future research work and treatment strategies. 
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6.2. Summary of major findings  
 
The mechanism by which HTLV-1 transforms infected CD4+ T-cells is largely unknown and despite a 
wide variation in clinical presentation, few molecular determinants of different clinical presentations 
are known.   Whilst a higher PVL may predispose to clinical disease, we are still unable to predict 
which patients will develop disease on a per-patient basis and there is no robust prognostic 
stratification. 
Since ATL only arises in HTLV-1 infected individuals and is typically diagnosed 5 or 6 decades 
following infection, it may be considered that HTLV-1 per se is the ‘first hit’ to the host genome.  On 
the basis that Tax is only expressed in 40% cases of ATL, the currently accepted model for ATL 
development is that Tax expression is required in the early stages of leukaemogenesis and allows 
immortalisation of a particular clone which gives that clone a survival advantage and the opportunity 
to acquire further genetic or epigenetic aberrations.  Later in the disease the ATL clone then acquires 
a mechanism to down-regulate Tax and escape the immunodominant CTL response.  Since it has 
been shown that HBZ sequence is remarkably conserved and mRNA is always detected in ATL, it is 
considered that HBZ is important in the maintenance of transformed clones (Matsuoka, 2005).  
However, there are some problems with this model:  Firstly it has been shown that tax gene 
mutations and defective proviruses (Miyazaki et al., 2007) arise pre-integration suggesting that these 
clones would have never expressed Tax (Furukawa et al., 2001) and more recently, HBZ transgenic 
mice are capable of causing T-cell lymphoma (Satou et al., 2011), supporting the notion that HBZ 
may be the more dominant proviral gene in disease transformation. 
The aim of this work was test the hypothesis that the site of retroviral integration contributes to 
malignant transformation. That is to say, the integration site, in cis, constitutes a ‘viral factor’ in 
disease pathogenesis. 
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The approach taken here was to firstly confirm the widely-held assumption that in non-malignant 
infection, each T-cell clone carried a single provirus, which allows a robust and simple interpretation 
of HTS data (i.e. that each detected integration site represented a distinct clone).  As discussed in 
Chapter 3, this finding supports the hypothesis that there is an unknown mechanism of 
superinfection resistance and, additionally, validates the clinical utility of proviral load 
measurements.  That is to say that the proviral load will accurately reflect the proportion of infected 
PBMCs.  
We aimed to continue this approach with presumed malignant clones from ATL samples, but by 
comparison of isolated clones with HTS data from mixed PBMC recognised we found that we were 
not able to maintain these large clones in culture ex-vivo.  A line of future work would be to develop 
methods to isolate and successfully expand these clones, since they would be a useful research tool 
– for example, to investigate the effect of an integrated provirus in cis, on higher-order chromatin 
structure and for potential whole genome sequencing projects. 
The ATL integration site method described here allows the systematic evaluation of a large number 
of patients which was not previously possible using classical LMPCR/IPCR and Sanger sequencing.  
Previous studies of integration sites reported between 20-50 patients (Doi et al., 2005; Hanai et al., 
2004; Ozawa et al., 2004). Furthermore, rapid advances in the annotation of the human genome 
such as the ENCODE project (Bernstein et al., 2012) and publicly available ChIP-seq datasets allows 
for a new approach to identifying characteristics of proviral integration in ATL.  These new data also 
allows testing of dynamic changes in clonality over time, which can be applied not only in research, 
but also clinically in order to monitor the effects of therapy at clonal level (Hodson et al, in 
submission), to identify ‘abnormal’ clonal expansion in HTLV-1 infected siblings prior to allogeneic 
stem cell donation, and, in time, as part of clinical trials. 
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In chapters 4 and 5 regarding the analysis of the host genomic integration site, I present the main 
following findings:- 
1. There is a preference for clonal survival in acrocentric chromosomes, indicating that 
integration into these chromosomes provides an advantage, perhaps to evade the CTL 
response. 
2. The number of ATL cases with multiple proviruses has been quantified at 9.1% of the cohort 
– the majority in acute cases.  Whilst multiple proviruses had been previously observed, the 
proportion of cases had not been previously determined.   
3. By comparison of the presumed malignant ATL clones with smaller ATL clones and those 
from ACs, there were no discriminating genomic features that distinguished the transformed 
malignant clones from the polyclonal background.  This conclusion supports the hypothesis 
that trans-acting factors, which are likely to include Tax and HBZ, are critical in ATL 
oncogenesis. 
4. The presumed malignant clones do not show any recurrent hotspots or clusters of 
integration in the host genome, although gene ontogeny analysis supports the hypothesis 
that in a small number of cases (~5%), the nearest downstream gene may play a 
contributory role. 
5. An ‘intermediate’ population of clones has been identified within the ATL patients that are 
not present in the Kumamoto control ACs or in other AC or HAM/TSP cohorts.  These clones 
are substantially larger (in terms of absolute abundance) than the largest clones observed in 
ACs/HAM and show characteristics of the flanking host genome that are systematically 
different from those of other HTLV-1-infected clones, both the malignant clones in ATL and 
the clones from subjects with non-malignant infection. 
The work in this chapter adds significantly to the previous ATL integration site work  (Doi et al., 2005; 
Hanai et al., 2004), (Ozawa et al., 2004) and additionally to the HTS HTLV-1 integration site work of 
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(Gillet et al., 2011; Melamed et al., 2013) and Niederer et al (unpublished) to provide a growing 
picture of the factors associated with malignant transformation and how alterations in host 
dynamics shape clonal selection forces. 
Since the abundance of an HTLV-1-infected clone in vivo is determined by the net effect of mitotic 
proliferation and its susceptibility to CTL killing, I tested here the hypothesis that the integration site 
itself contributed to one of the proviral proliferative factors.  However, I conclude that malignant 
transformation may occur in any malignant clone, independently of the proviral integration site.  
This conclusion is consistent with the clinical example highlighted in Figure 5.1 (clonal evolution) in 
which longitudinal analysis of a single patient identified the future malignant clone in the minor 
population of clones prior to disease development.    It would be important to determine the effect 
of the proviral integration site on transcriptional regulation of host genes nearby and more distantly 
(both in cis and in trans) to elucidate whether the provirus causes transcriptional interference and 
dysregulates nearby host gene expression.  Although the ATL cohort reported here consisted of 
nearly 200 patients, this was still not sufficiently powered to analyse the effects of upstream or 
downstream integration and relative orientation effects on transcription of the provirus or nearby 
host genes.  The T-cell clones isolated by limiting dilution as described in chapter 3 would be good 
model systems for these experiments. 
The expanded intermediate clones observed in the ATL cases have not been previously seen.  We 
suggest that these clones arise as a consequence of ATL development due to an inefficient CTL 
response:  Whilst suppressing Tax might allow a clonal advantage early in ATL development (in 
contrast to the current model), once the malignant environment is established and the CTLs are 
inefficient then Tax-expressing clones may acquire a proliferative advantage i.e. the normal host 
dynamics are completely altered.   The evidence that these clones emerge after ATL has developed, 
and do not cause the disease, is that the host genomic properties of these clones have no 
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resemblance to the large presumed malignant clones, which would be expected if the malignant 
population were derived from these intermediate-abundance clones. 
It has been reported that approximately 5% CD8+ T-cells are infected with HTLV-1 and whilst CD8+-
ATL has been described, these arise in αβ-T cells (and not from γδ T-cells). Furthermore, Melamed et 
al (in submission) have observed that in infection with HTLV-2 which naturally infects CD8+ T-cells, 
infected T-cell clones become abnormally abundant, although they do not undergo malignant 
transformation.  Perhaps these intermediate-abundance clones observed in the ATL cases reflect 
abnormally expanded CD8+ infected T-cells in the face of abnormal host dynamics: This hypothesis 
needs to be tested.  It is also possible that these clones support the growth or persistence of the 
malignant clone.   
 
6.3. Absolute number of clones, rather than oligoclonal expansion, 
contributes to leukaemogenesis 
 
It has been known for many years that a high proviral load is the main predictor of  clinical disease, 
and it had be assumed that oligoclonal expansion was the cause of higher proviral loads seen in 
these individuals and that the monoclonal tumour population of ATL was an extension of this 
proliferation (polyclonal → oligoclonal → monoclonal).  However, (Gillet et al., 2011) recently 
showed that at any given proviral load,  individuals with HAM/TSP had a greater number of infected 
T-cell clones than ACs, and that the increased proviral load was due to the presence of an increased 
number of clones and not due to oligoclonal proliferation as previously assumed.   
Here, I show that the presumed malignant clones in ATL have host genomic characteristics with 
similar properties to both the AC clones and the small ATL clones.  This suggests that a small 
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proportion of individuals have a genetic predisposition towards widespread viral dissemination and 
an increased absolute numbers of clones.  A strong candidate for this genetic factor is the presence 
of a detrimental HLA haplotype or, conversely, the absence of a protective haplotype which results 
in less efficient presentation of viral peptides to the immune system.   The evidence for this genetic 
predisposition is based chiefly upon 3 main observations:  Firstly, AC individuals with a proviral load 
>10% are at higher risk of ATL (>4% in Japan) and an individual’s PVL set-point is determined early in 
the course of their infection.  Secondly,   specific HLA and KIR types are known to protect from 
HAM/TSP (as yet this has not been investigated in ATL).  These protective HLA types are predicted to 
present HBZ peptides efficiently to CTLs (Macnamara et al., 2010).  Thirdly, the observation that 
patients diagnosed with ATL often report 1st degree relatives that have died from 
leukaemia/lymphoma.  In addition, there are a few families anecdotally reported where significant 
numbers of family members develop ATL suggesting a more critical host germline genetic 
susceptibility e.g. loss of heterozygosity of a tumour suppressor gene, although as yet none of these 
families have undergone whole genome sequencing to identify these potential lesions  (Pombo-de-
Oliveira et al., 2001; Kondo et al., 1985). 
On a background of increased absolute numbers of clones, a series of step-wise ‘bad luck’ genetic or 
epigenetic events (reviewed recently by  Vogelstein et al., 2013) may occur over decades, each 
individually contributing a small survival advantage (it is estimated that each driver mutation confers 
a 0.4% increase in difference between cell birth and cell death).  Our Ingenuity Pathway Analysis® 
data suggests that in some of those cases (~6%) the ontogeny of the nearest downstream gene may 
play a contributory role.    The net effect of these individually small advantages is to allow a clone to 
become immortalised and, with further genetic or epigenetic changes, to transform to the malignant 
phenotype.  The number of genetic or epigenetic hits to the host genome is unknown – most whole 
genome/exome sequencing data suggest that leukaemias are associated with relatively few genetic 
hits (8-12 per case).   
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To test these hypotheses would ideally require longitudinal stored PBMC samples on reasonable 
numbers of individuals prior to and at the time of ATL development.  This would allow for robust 
calculations of absolute clonal abundance whilst still in the asymptomatic phase and additionally to 
track the malignant clone at a ‘pre-malignant’ phase, isolate and compare with the same clone at 
disease transformation by whole genome/exome sequencing. 
An interesting observation within this cohort, and in previously reported work, is that the proviral 
load of leukemic ATL patients is frequently not 100%, even when the blood film suggests large 
numbers of highly abnormal lymphocytes.  This suggests that there is a large population of 
uninfected T-lymphocytes with a flow-cytometry phenotype resembling ATL cells.  It is possible that 
these cells contributes to the profound immune suppression that is typical of ATL, particularly in 
cases where the cells share characteristics with the immune-suppressive regulatory T-cell such as 
expression of CCR4, FoxP3 and GITR.  It would therefore be interesting to subgroup ATL cases by 
presenting proviral load, compare their response to treatment, and quantify the immune response 
at presentation and again when in remission. 
 
6.4. Directions for future ATL research and direction of clinical 
management 
 
By comparison with progress that has been made with other acute or chronic leukaemias there is 
urgent need for basic, translational and clinical research on ATL.   The difficulties facing research in 
the ATL field include a high prevalence in parts of the world with limited resources and in wealthier 
nations limited access to high quality tumour material.  Furthermore, in the acute phase, treatment 
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needs to be started urgently and even in countries such as Japan there is little time to collect 
untreated biopsy material for research prior to commencing treatment.  
From a basic and clinical research perspective, there remain many important unanswered questions 
including:  
 What precisely are the leukaemia initiating cells (LIC) and could they be therapeutically 
targeted? 
 What, if any, are the molecular features that distinguish the clinical subtypes? 
 Why do only a small proportion of individuals develop ATL?  
 Who will develop ATL? 
 Why does it inevitably take 5 or 6 decades to develop disease? 
 Why does disease inevitably relapse? 
Having investigated the role of the integration site in cis the natural next step would be to consider 
the role of the integrated provirus in trans.    The integrated provirus may interact distally with 
important genes (e.g. oncogenes) on the same or other chromosomes.  This could be initially 
investigated by a combined approach of genome-wide mRNA sequencing with whole exome 
sequencing to identify target genes, validated with methods such as whole genome sequencing to 
identify copy number aberrations, deep sequencing and methylation analysis of candidate genes.  
Following identification of target regions, the transcriptional relationship with the host provirus can 
then be hypothesised and experimentally tested.  Experiments such as these are however costly, 
require large numbers of individuals to identify candidate regions (typical cancer exome sequencing 
projects investigate at least 100 samples) and require control DNA from the same individuals and 
purification of tumour material to exclude background noise in sequencing and to distinguish 
polymorphisms and de novo mutations. 
165 
 
The ‘first hit’ for ATL leukaemogenesis is thought be HTLV-1 proviral integration and most individuals 
are infected during infancy, but it remains unexplained as to why it takes several decades to develop 
disease.  By comparison, paediatric precursor B-cell acute lymphoblastic leukaemia is associated 
with ETV6-AML1 fusion oncoprotein as an early initiating genetic lesion (identified on the heel-prick 
Guthrie card test in the first week of life) followed by a modest number of ‘driver’ alterations, and 
results in clinical disease in susceptible children within just a few years.  Perhaps genetic lesions 
alone are not sufficient to drive ATL since one could assume that children and young adults would be 
observed to develop ATL more frequently.  The impact of an integrated provirus (or transgene) upon 
the methylation of a host genome remains unknown but changes to methylation of the genome are 
known to occur over decades as part of the normal ageing process. Perhaps HTLV-1 either 
accelerates or interacts with this process resulting in tumours after several decades.  This could be 
investigated by means of unbiased whole genome bisulfite sequencing of asymptomatic HTLV-1 
carriers and matched uninfected controls in younger and older age groups, followed by comparison 
with ATL cases. 
From a clinical perspective it has become clear that leukemic subtypes (acute or chronic) can 
respond to combination therapy with zidovudine and interferon whilst the lymphoma or ‘bulky 
acute’ subtypes still require induction with chemotherapy (Bazarbachi et al., 2010).  One of the 
difficulties of utilising trial data, particularly the chemotherapy trial data from Japan, is that these 
trials often combine all of the clinical subgroups together and exclude patients with a poor 
performance status, hypercalcaemia or renal failure which makes extrapolation to ‘real life’ clinical 
scenarios difficult.  
Despite the successes of ATL treatment in leukaemic cases with zidovudine and interferon, the 
mechanism of its action remains largely unknown, and only a proportion of individuals will tolerate 
long term treatment with almost inevitable disease progression on withdrawing treatment.  A future 
aim of ATL treatment trials has to be twofold: Firstly better induction regimens that result in more 
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complete remissions and secondly, the eradication of ‘leukemic clones’ whilst in an apparent state of 
complete remission.  There are emerging attempts to do both of these.  Ramos et al have trialled a 
histone de-acetylase inhibitor (valproate) in patients in remission from chronic ATL (Ramos J.C., 
2011) with the aim of inducing viral protein expression allowing autologous killing by the specific 
cytotoxic T-lymphocytes.  Kchour (Kchour et al., 2013; Kchour et al., 2009) and Suarez (Suarez F, 
2011) have both reported the successful clinical use of arsenic trioxide in combination with 
zidovudine and interferon to induce cell cycle arrest and apoptosis of HTLV-1 and ATL cells via a 
proposed mechanism of rapid shutdown of NFkB.   Novel monoclonal antibodies are rapidly being 
developed, trialled and marketed for many cancers. Mogamulizumab, which targets CCR4 expression 
on ATL tumour cells has shown improved overall response rates, complete remissions and overall 
survival in Japan when used as monotherapy in relapsed disease (Ishida et al., 2012) and more 
recently improved response rates when combined with chemotherapy in first line treatment 
although it is too early to extrapolate to overall survival (interim analysis, verbal communication Dr 
Tsukasaki, Japan Lymphoma Study Group).  Mogamulizumab is currently under clinical trial in Europe 
and the USA in patients that largely originate from Africa and the Caribbean.  However, lessons from 
other malignant diseases would suggest that this (or any) targeted therapies are unlikely to be 
curative alone, but may be suitable for a specific subtype of disease or subgroup of patients or in 
combination with other agents; the purpose of these trials should be to identify where the successes 
will lie.   
  
167 
 
References 
Aboud, M., Golde, D.W., Bersch, N., Rosenblatt, J.D., and Chen, I.S. (1987). A colony assay for in vitro 
transformation by human T cell leukemia viruses type I and type II. Blood 70, 432-436. 
Akagi, K., Suzuki, T., Stephens, R.M., Jenkins, N.A., and Copeland, N.G. (2004). RTCGD: retroviral 
tagged cancer gene database. Nucleic Acids Res 32, D523-527. 
Akagi, T., Ono, H., and Shimotohno, K. (1995). Characterization of T cells immortalized by Tax1 of 
human T-cell leukemia virus type 1. Blood 86, 4243-4249. 
Akizuki, S., Nakazato, O., Higuchi, Y., Tanabe, K., Setoguchi, M., Yoshida, S., Miyazaki, Y., Yamamoto, 
S., Sudou, S., Sannomiya, K., and et al. (1987). Necropsy findings in HTLV-I associated myelopathy. 
Lancet 1, 156-157. 
Allen, T.M., and Altfeld, M. (2003). HIV-1 superinfection. J Allergy Clin Immunol 112, 829-835. 
Amano, M., Kurokawa, M., Ogata, K., Itoh, H., Kataoka, H., and Setoyama, M. (2008). New entity, 
definition and diagnostic criteria of cutaneous adult T-cell leukemia/lymphoma: human T-
lymphotropic virus type 1 proviral DNA load can distinguish between cutaneous and smoldering 
types. J Dermatol 35, 270-275. 
Aparicio, S., and Caldas, C. (2013). The implications of clonal genome evolution for cancer medicine. 
N Engl J Med 368, 842-851. 
Arisawa, K., Soda, M., Endo, S., Kurokawa, K., Katamine, S., Shimokawa, I., Koba, T., Takahashi, T., 
Saito, H., Doi, H., and Shirahama, S. (2000). Evaluation of adult T-cell leukemia/lymphoma incidence 
and its impact on non-Hodgkin lymphoma incidence in southwestern Japan. Int J Cancer 85, 319-324. 
Ariumi, Y., Kaida, A., Lin, J.Y., Hirota, M., Masui, O., Yamaoka, S., Taya, Y., and Shimotohno, K. (2000). 
HTLV-1 tax oncoprotein represses the p53-mediated trans-activation function through coactivator 
CBP sequestration. Oncogene 19, 1491-1499. 
Arnold, J., Yamamoto, B., Li, M., Phipps, A.J., Younis, I., Lairmore, M.D., and Green, P.L. (2006). 
Enhancement of infectivity and persistence in vivo by HBZ, a natural antisense coded protein of 
HTLV-1. Blood 107, 3976-3982. 
Arnulf, B., Thorel, M., Poirot, Y., Tamouza, R., Boulanger, E., Jaccard, A., Oksenhendler, E., Hermine, 
O., and Pique, C. (2004). Loss of the ex vivo but not the reinducible CD8+ T-cell response to Tax in 
human T-cell leukemia virus type 1-infected patients with adult T-cell leukemia/lymphoma. 
Leukemia 18, 126-132. 
Bajenoff, M., Egen, J.G., Koo, L.Y., Laugier, J.P., Brau, F., Glaichenhaus, N., and Germain, R.N. (2006). 
Stromal cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes. 
Immunity 25, 989-1001. 
Banerjee, P., Tripp, A., Lairmore, M.D., Crawford, L., Sieburg, M., Ramos, J.C., Harrington, W., Jr., 
Beilke, M.A., and Feuer, G. (2010). Adult T-cell leukemia/lymphoma development in HTLV-1-infected 
humanized SCID mice. Blood 115, 2640-2648. 
168 
 
Bangham C.R.M, C.L.B., Melamed A. (2013). HTLV-1 clonality in adult T-cell leukaemia and non-
malignant HTLV-1 infection. Seminars in Cancer Biology in press. 
Bangham, C.R. (2009). CTL quality and the control of human retroviral infections. Eur J Immunol 39, 
1700-1712. 
Barski, A., Cuddapah, S., Cui, K., Roh, T.Y., Schones, D.E., Wang, Z., Wei, G., Chepelev, I., and Zhao, K. 
(2007). High-resolution profiling of histone methylations in the human genome. Cell 129, 823-837. 
Basbous, J., Bazarbachi, A., Granier, C., Devaux, C., and Mesnard, J.M. (2003). The central region of 
human T-cell leukemia virus type 1 Tax protein contains distinct domains involved in subunit 
dimerization. J Virol 77, 13028-13035. 
Bazarbachi, A., Plumelle, Y., Carlos Ramos, J., Tortevoye, P., Otrock, Z., Taylor, G., Gessain, A., 
Harrington, W., Panelatti, G., and Hermine, O. (2010). Meta-analysis on the use of zidovudine and 
interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic 
subtypes. J Clin Oncol 28, 4177-4183. 
Bentley, D.R., Balasubramanian, S., Swerdlow, H.P., Smith, G.P., Milton, J., Brown, C.G., Hall, K.P., 
Evers, D.J., Barnes, C.L., Bignell, H.R., et al. (2008). Accurate whole human genome sequencing using 
reversible terminator chemistry. Nature 456, 53-59. 
Berndt, S.I., Gustafsson, S., Magi, R., Ganna, A., Wheeler, E., Feitosa, M.F., Justice, A.E., Monda, K.L., 
Croteau-Chonka, D.C., Day, F.R., et al. (2013). Genome-wide meta-analysis identifies 11 new loci for 
anthropometric traits and provides insights into genetic architecture. Nat Genet 45, 501-512. 
Bernstein, B.E., Birney, E., Dunham, I., Green, E.D., Gunter, C., and Snyder, M. (2012). An integrated 
encyclopedia of DNA elements in the human genome. Nature 489, 57-74. 
Berry, C.C., Gillet, N.A., Melamed, A., Gormley, N., Bangham, C.R., and Bushman, F.D. (2012). 
Estimating abundances of retroviral insertion sites from DNA fragment length data. Bioinformatics 
28, 755-762. 
Birzele, F., Fauti, T., Stahl, H., Lenter, M.C., Simon, E., Knebel, D., Weith, A., Hildebrandt, T., and 
Mennerich, D. (2011). Next-generation insights into regulatory T cells: expression profiling and FoxP3 
occupancy in Human. Nucleic Acids Res 39, 7946-7960. 
Boisvert, F.M., van Koningsbruggen, S., Navascues, J., and Lamond, A.I. (2007). The multifunctional 
nucleolus. Nat Rev Mol Cell Biol 8, 574-585. 
Botcheva, K., McCorkle, S.R., McCombie, W.R., Dunn, J.J., and Anderson, C.W. (2011). Distinct p53 
genomic binding patterns in normal and cancer-derived human cells. Cell Cycle 10, 4237-4249. 
Brady, T., Agosto, L.M., Malani, N., Berry, C.C., O'Doherty, U., and Bushman, F. (2009). HIV 
integration site distributions in resting and activated CD4+ T cells infected in culture. AIDS 23, 1461-
1471. 
Burke, D.S. (1997). Recombination in HIV: an important viral evolutionary strategy. Emerg Infect Dis 
3, 253-259. 
Bushman, F.D., Hoffmann, C., Ronen, K., Malani, N., Minkah, N., Rose, H.M., Tebas, P., and Wang, 
G.P. (2008). Massively parallel pyrosequencing in HIV research. AIDS 22, 1411-1415. 
169 
 
Cartier, L.M., Cea, J.G., Vergara, C., Araya, F., and Born, P. (1997). Clinical and neuropathological 
study of six patients with spastic paraparesis associated with HTLV-I: an axomyelinic degeneration of 
the central nervous system. J Neuropathol Exp Neurol 56, 403-413. 
Cattoglio, C., Facchini, G., Sartori, D., Antonelli, A., Miccio, A., Cassani, B., Schmidt, M., von Kalle, C., 
Howe, S., Thrasher, A.J., et al. (2007). Hot spots of retroviral integration in human CD34+ 
hematopoietic cells. Blood 110, 1770-1778. 
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, 
T., Westerman, K., et al. (2010). Transfusion independence and HMGA2 activation after gene 
therapy of human beta-thalassaemia. Nature 467, 318-322. 
Cavrois, M., Gessain, A., Wain-Hobson, S., and Wattel, E. (1996). Proliferation of HTLV-1 infected 
circulating cells in vivo in all asymptomatic carriers and patients with TSP/HAM. Oncogene 12, 2419-
2423. 
Cavrois, M., Wain-Hobson, S., and Wattel, E. (1995). Stochastic events in the amplification of HTLV-I 
integration sites by linker-mediated PCR. Res Virol 146, 179-184. 
Chang, Y.B., Kaidarova, Z., Hindes, D., Bravo, M., Kiely, N., Kamel, H., Dubay, D., Hoose, B., and 
Murphy, E.L. (2013). Seroprevalence and Demographic Determinants of Human T-Lymphotropic 
Virus Type-1 and -2 Infections among First-time Blood Donors, U.S. 2000-2009. J Infect Dis.  2013 Oct 
31 [epub ahead of print] 
Chao, M.P., Alizadeh, A.A., Tang, C., Jan, M., Weissman-Tsukamoto, R., Zhao, F., Park, C.Y., 
Weissman, I.L., and Majeti, R. (2011). Therapeutic antibody targeting of CD47 eliminates human 
acute lymphoblastic leukemia. Cancer Res 71, 1374-1384. 
Chen, S., Ishii, N., Ine, S., Ikeda, S., Fujimura, T., Ndhlovu, L.C., Soroosh, P., Tada, K., Harigae, H., 
Kameoka, J., et al. (2006). Regulatory T cell-like activity of Foxp3+ adult T cell leukemia cells. Int 
Immunol 18, 269-277. 
Chou, K.S., Okayama, A., Su, I.J., Lee, T.H., and Essex, M. (1996). Preferred nucleotide sequence at 
the integration target site of human T-cell leukemia virus type I from patients with adult T-cell 
leukemia. Int J Cancer 65, 20-24. 
Ciminale, V., Zotti, L., D'Agostino, D.M., Ferro, T., Casareto, L., Franchini, G., Bernardi, P., and Chieco-
Bianchi, L. (1999). Mitochondrial targeting of the p13II protein coded by the x-II ORF of human T-cell 
leukemia/lymphotropic virus type I (HTLV-I). Oncogene 18, 4505-4514. 
Cole, C.G., McCann, O.T., Collins, J.E., Oliver, K., Willey, D., Gribble, S.M., Yang, F., McLaren, K., 
Rogers, J., Ning, Z., et al. (2008). Finishing the finished human chromosome 22 sequence. Genome 
Biol 9, R78. 
Craigie, R., and Bushman, F.D. (2012). HIV DNA integration. Cold Spring Harb Perspect Med 2, 
a006890. 
D'Agostino, D.M., Silic-Benussi, M., Hiraragi, H., Lairmore, M.D., and Ciminale, V. (2005). The human 
T-cell leukemia virus type 1 p13II protein: effects on mitochondrial function and cell growth. Cell 
Death Differ 12 Suppl 1, 905-915. 
170 
 
De Castro-Costa, C.M., Araujo, A.Q., Barreto, M.M., Takayanagui, O.M., Sohler, M.P., da Silva, E.L., de 
Paula, S.M., Ishak, R., Ribas, J.G., Rovirosa, L.C., et al. (2006). Proposal for diagnostic criteria of 
tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM). AIDS Res Hum Retroviruses 
22, 931-935. 
de The, G., and Bomford, R. (1993). An HTLV-I vaccine: why, how, for whom? AIDS Res Hum 
Retroviruses 9, 381-386. 
Delamarre, L., Rosenberg, A.R., Pique, C., Pham, D., Callebaut, I., and Dokhelar, M.C. (1996). The 
HTLV-I envelope glycoproteins: structure and functions. J Acquir Immune Defic Syndr Hum Retrovirol 
13 Suppl 1, S85-91. 
Demontis, M.A., Hilburn, S., and Taylor, G.P. (2013). Human T cell lymphotropic virus type 1 viral 
load variability and long-term trends in asymptomatic carriers and in patients with human T cell 
lymphotropic virus type 1-related diseases. AIDS Res Hum Retroviruses 29, 359-364. 
Derse, D., Crise, B., Li, Y., Princler, G., Lum, N., Stewart, C., McGrath, C.F., Hughes, S.H., Munroe, D.J., 
and Wu, X. (2007). Human T-cell leukemia virus type 1 integration target sites in the human genome: 
comparison with those of other retroviruses. J Virol 81, 6731-6741. 
Devereux, S. (2011). Two-faced T cells in CLL. Blood 117, 5273-5274. 
Djilali, S., and Parodi, A.L. (1989). The BLV-induced leukemia--lymphosarcoma complex in sheep. Vet 
Immunol Immunopathol 22, 233-244. 
Doi, K., Wu, X., Taniguchi, Y., Yasunaga, J., Satou, Y., Okayama, A., Nosaka, K., and Matsuoka, M. 
(2005). Preferential selection of human T-cell leukemia virus type I provirus integration sites in 
leukemic versus carrier states. Blood 106, 1048-1053. 
Dow, B.C., Munro, H., Ferguson, K., Buchanan, I., Jarvis, L., Jordan, T., Franklin, I.M., and McClelland, 
M. (2001). HTLV antibody screening using mini-pools. Transfus Med 11, 419-422. 
Duesberg, P., Stindl, R., and Hehlmann, R. (2001). Origin of multidrug resistance in cells with and 
without multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy. Proc Natl 
Acad Sci U S A 98, 11283-11288. 
Einsiedel, L., Fernandes, L., Spelman, T., Steinfort, D., and Gotuzzo, E. (2012). Bronchiectasis is 
associated with human T-lymphotropic virus 1 infection in an Indigenous Australian population. Clin 
Infect Dis 54, 43-50. 
Endo, K., Hirata, A., Iwai, K., Sakurai, M., Fukushi, M., Oie, M., Higuchi, M., Hall, W.W., Gejyo, F., and 
Fujii, M. (2002). Human T-cell leukemia virus type 2 (HTLV-2) Tax protein transforms a rat fibroblast 
cell line but less efficiently than HTLV-1 Tax. J Virol 76, 2648-2653. 
Enose-Akahata, Y., Abrams, A., Massoud, R., Bialuk, I., Johnson, K.R., Green, P.L., Maloney, E.M., and 
Jacobson, S. (2013). Humoral immune response to HTLV-1 basic leucine zipper factor (HBZ) in HTLV-
1-infected individuals. Retrovirology 10, 19. 
Euskirchen, G.M., Auerbach, R.K., Davidov, E., Gianoulis, T.A., Zhong, G., Rozowsky, J., Bhardwaj, N., 
Gerstein, M.B., and Snyder, M. (2011). Diverse roles and interactions of the SWI/SNF chromatin 
remodeling complex revealed using global approaches. PLoS Genet 7, e1002008. 
171 
 
Fabbri, G., Khiabanian, H., Holmes, A.B., Wang, J., Messina, M., Mullighan, C.G., Pasqualucci, L., 
Rabadan, R., and Dalla-Favera, R. (2013). Genetic lesions associated with chronic lymphocytic 
leukemia transformation to Richter syndrome. J Exp Med 210, 2273-2288. 
Fan, J., Ma, G., Nosaka, K., Tanabe, J., Satou, Y., Koito, A., Wain-Hobson, S., Vartanian, J.P., and 
Matsuoka, M. (2010). APOBEC3G generates nonsense mutations in human T-cell leukemia virus type 
1 proviral genomes in vivo. J Virol 84, 7278-7287. 
Felipe, L., Goncalves, D.U., Santos, M.A., Proietti, F.A., Ribas, J.G., Carneiro-Proietti, A.B., and 
Lambertucci, J.R. (2008). Vestibular-evoked myogenic potential (VEMP) to evaluate cervical 
myelopathy in human T-cell lymphotropic virus type I infection. Spine (Phila Pa 1976) 33, 1180-1184. 
Franchini, G. (1995). Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I 
infection. Blood 86, 3619-3639. 
Frietze, S., Lan, X., Jin, V.X., and Farnham, P.J. (2010). Genomic targets of the KRAB and SCAN 
domain-containing zinc finger protein 263. J Biol Chem 285, 1393-1403. 
Fujita, P.A., Rhead, B., Zweig, A.S., Hinrichs, A.S., Karolchik, D., Cline, M.S., Goldman, M., Barber, 
G.P., Clawson, H., Coelho, A., et al. (2011). The UCSC Genome Browser database: update 2011. 
Nucleic Acids Res 39, D876-882. 
Fujiwara, T., O'Geen, H., Keles, S., Blahnik, K., Linnemann, A.K., Kang, Y.A., Choi, K., Farnham, P.J., 
and Bresnick, E.H. (2009). Discovering hematopoietic mechanisms through genome-wide analysis of 
GATA factor chromatin occupancy. Mol Cell 36, 667-681. 
Furukawa, Y., Fujisawa, J., Osame, M., Toita, M., Sonoda, S., Kubota, R., Ijichi, S., and Yoshida, M. 
(1992). Frequent clonal proliferation of human T-cell leukemia virus type 1 (HTLV-1)-infected T cells 
in HTLV-1-associated myelopathy (HAM-TSP). Blood 80, 1012-1016. 
Furukawa, Y., Kubota, R., Tara, M., Izumo, S., and Osame, M. (2001). Existence of escape mutant in 
HTLV-I tax during the development of adult T-cell leukemia. Blood 97, 987-993. 
Furukawa, Y., Yamashita, M., Usuku, K., Izumo, S., Nakagawa, M., and Osame, M. (2000). 
Phylogenetic subgroups of human T cell lymphotropic virus (HTLV) type I in the tax gene and their 
association with different risks for HTLV-I-associated myelopathy/tropical spastic paraparesis. J 
Infect Dis 182, 1343-1349. 
Futreal, P.A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., and Stratton, 
M.R. (2004). A census of human cancer genes. Nat Rev Cancer 4, 177-183. 
Gabet, A.S., Gessain, A., and Wattel, E. (2003). High simian T-cell leukemia virus type 1 proviral loads 
combined with genetic stability as a result of cell-associated provirus replication in naturally 
infected, asymptomatic monkeys. Int J Cancer 107, 74-83. 
Gaudray, G., Gachon, F., Basbous, J., Biard-Piechaczyk, M., Devaux, C., and Mesnard, J.M. (2002). The 
complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP 
transcription factor that down-regulates viral transcription. J Virol 76, 12813-12822. 
Genovese, G., Handsaker, R.E., Li, H., Kenny, E.E., and McCarroll, S.A. (2013). Mapping the human 
reference genome's missing sequence by three-way admixture in Latino genomes. Am J Hum Genet 
93, 411-421. 
172 
 
Gessain, A., and Cassar, O. (2012). Epidemiological Aspects and World Distribution of HTLV-1 
Infection. Front Microbiol 3, 388. 
Ghez, D., Lepelletier, Y., Jones, K.S., Pique, C., and Hermine, O. (2010). Current concepts regarding 
the HTLV-1 receptor complex. Retrovirology 7, 99. 
Ghez, D., Lepelletier, Y., Lambert, S., Fourneau, J.M., Blot, V., Janvier, S., Arnulf, B., van Endert, P.M., 
Heveker, N., Pique, C., and Hermine, O. (2006). Neuropilin-1 is involved in human T-cell lymphotropic 
virus type 1 entry. J Virol 80, 6844-6854. 
Gillet, N.A., Gutierrez, G., Rodriguez, S.M., de Brogniez, A., Renotte, N., Alvarez, I., Trono, K., and 
Willems, L. (2013). Massive Depletion of Bovine Leukemia Virus Proviral Clones Located in Genomic 
Transcriptionally Active Sites during Primary Infection. PLoS Pathog 9, e1003687. 
Gillet, N.A., Malani, N., Melamed, A., Gormley, N., Carter, R., Bentley, D., Berry, C., Bushman, F.D., 
Taylor, G.P., and Bangham, C.R. (2011). The host genomic environment of the provirus determines 
the abundance of HTLV-1-infected T-cell clones. Blood 117, 3113-3122. 
Gini, C., Cuppini, C. (1912). Italian. Variabilita e Mutabilità, (Variability and Mutability), 156 pages. 
Glowacka, I., Korn, K., Potthoff, S.A., Lehmann, U., Kreipe, H.H., Ivens, K., Barg-Hock, H., Schulz, T.F., 
and Heim, A. (2013). Delayed seroconversion and rapid onset of lymphoproliferative disease after 
transmission of human T-cell lymphotropic virus type 1 from a multiorgan donor. Clin Infect Dis 57, 
1417-1424. 
Grassmann, R., Aboud, M., and Jeang, K.T. (2005). Molecular mechanisms of cellular transformation 
by HTLV-1 Tax. Oncogene 24, 5976-5985. 
Gratton, S., Cheynier, R., Dumaurier, M.J., Oksenhendler, E., and Wain-Hobson, S. (2000). Highly 
restricted spread of HIV-1 and multiply infected cells within splenic germinal centers. Proc Natl Acad 
Sci U S A 97, 14566-14571. 
Greten, T.F., Slansky, J.E., Kubota, R., Soldan, S.S., Jaffee, E.M., Leist, T.P., Pardoll, D.M., Jacobson, S., 
and Schneck, J.P. (1998). Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific 
CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP 
patients. Proc Natl Acad Sci U S A 95, 7568-7573. 
Hacein-Bey-Abina, S., Garrigue, A., Wang, G.P., Soulier, J., Lim, A., Morillon, E., Clappier, E., 
Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008). Insertional oncogenesis in 4 patients after 
retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118, 3132-3142. 
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M.P., Wulffraat, N., Leboulch, P., Lim, 
A., Osborne, C.S., Pawliuk, R., Morillon, E., et al. (2003). LMO2-associated clonal T cell proliferation in 
two patients after gene therapy for SCID-X1. Science 302, 415-419. 
Hahn, W.C., Counter, C.M., Lundberg, A.S., Beijersbergen, R.L., Brooks, M.W., and Weinberg, R.A. 
(1999). Creation of human tumour cells with defined genetic elements. Nature 400, 464-468. 
Hajj, H.E., Nasr, R., Kfoury, Y., Dassouki, Z., Nasser, R., Kchour, G., Hermine, O., de The, H., and 
Bazarbachi, A. (2012). Animal models on HTLV-1 and related viruses: what did we learn? Front 
Microbiol 3, 333. 
173 
 
Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57-70. 
Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674. 
Hanai, S., Nitta, T., Shoda, M., Tanaka, M., Iso, N., Mizoguchi, I., Yashiki, S., Sonoda, S., Hasegawa, Y., 
Nagasawa, T., and Miwa, M. (2004). Integration of human T-cell leukemia virus type 1 in genes of 
leukemia cells of patients with adult T-cell leukemia. Cancer Sci 95, 306-310. 
Hanon, E., Hall, S., Taylor, G.P., Saito, M., Davis, R., Tanaka, Y., Usuku, K., Osame, M., Weber, J.N., 
and Bangham, C.R. (2000). Abundant tax protein expression in CD4+ T cells infected with human T-
cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. Blood 95, 1386-1392. 
Hare, S., Gupta, S.S., Valkov, E., Engelman, A., and Cherepanov, P. (2010). Retroviral intasome 
assembly and inhibition of DNA strand transfer. Nature 464, 232-236. 
Hasegawa, H., Sawa, H., Lewis, M.J., Orba, Y., Sheehy, N., Yamamoto, Y., Ichinohe, T., Tsunetsugu-
Yokota, Y., Katano, H., Takahashi, H., et al. (2006). Thymus-derived leukemia-lymphoma in mice 
transgenic for the Tax gene of human T-lymphotropic virus type I. Nat Med 12, 466-472. 
Hewitt, P.E., Davison, K., Howell, D.R., and Taylor, G.P. (2013). Human T-lymphotropic virus lookback 
in NHS Blood and Transplant (England) reveals the efficacy of leukoreduction. Transfusion 53, 2168-
2175. 
Hilburn, S., Rowan, A., Demontis, M.A., MacNamara, A., Asquith, B., Bangham, C.R., and Taylor, G.P. 
(2011). In vivo expression of human T-lymphotropic virus type 1 basic leucine-zipper protein 
generates specific CD8+ and CD4+ T-lymphocyte responses that correlate with clinical outcome. J 
Infect Dis 203, 529-536. 
Hiramatsu, K., and Yoshikura, H. (1986). Frequent partial deletion of human adult T-cell leukemia 
virus type I proviruses in experimental transmission: pattern and possible implication. J Virol 58, 508-
512. 
Hiraragi, H., Michael, B., Nair, A., Silic-Benussi, M., Ciminale, V., and Lairmore, M. (2005). Human T-
lymphotropic virus type 1 mitochondrion-localizing protein p13II sensitizes Jurkat T cells to Ras-
mediated apoptosis. J Virol 79, 9449-9457. 
Hodson, A., Laydon, D.J., Bain, B.J., Fields, P.A., and Taylor, G.P. (2013). Pre-morbid human T-
lymphotropic virus type I proviral load, rather than percentage of abnormal lymphocytes, is 
associated with an increased risk of aggressive adult T-cell leukemia/lymphoma. Haematologica 98, 
385-388. 
Hoshida, Y., Li, T., Dong, Z., Tomita, Y., Yamauchi, A., Hanai, J., and Aozasa, K. (2001). 
Lymphoproliferative disorders in renal transplant patients in Japan. Int J Cancer 91, 869-875. 
Hsieh, Y.T., Gang, E.J., Geng, H., Park, E., Huantes, S., Chudziak, D., Dauber, K., Schaefer, P., 
Scharman, C., Shimada, H., et al. (2013). Integrin alpha4 blockade sensitizes drug resistant pre-B 
acute lymphoblastic leukemia to chemotherapy. Blood 121, 1814-1818. 
Huret, J.L., Minor, S.L., Dorkeld, F., Dessen, P., and Bernheim, A. (2000). Atlas of genetics and 
cytogenetics in oncology and haematology, an interactive database. Nucleic Acids Res 28, 349-351. 
174 
 
Igakura, T., Stinchcombe, J.C., Goon, P.K., Taylor, G.P., Weber, J.N., Griffiths, G.M., Tanaka, Y., 
Osame, M., and Bangham, C.R. (2003). Spread of HTLV-I between lymphocytes by virus-induced 
polarization of the cytoskeleton. Science 299, 1713-1716. 
Ijichi, S., Izumo, S., Eiraku, N., Machigashira, K., Kubota, R., Nagai, M., Ikegami, N., Kashio, N., 
Umehara, F., Maruyama, I., and et al. (1993). An autoaggressive process against bystander tissues in 
HTLV-I-infected individuals: a possible pathomechanism of HAM/TSP. Med Hypotheses 41, 542-547. 
Imura, A., Hori, T., Imada, K., Kawamata, S., Tanaka, Y., Imamura, S., and Uchiyama, T. (1997). OX40 
expressed on fresh leukemic cells from adult T-cell leukemia patients mediates cell adhesion to 
vascular endothelial cells: implication for the possible involvement of OX40 in leukemic cell 
infiltration. Blood 89, 2951-2958. 
Ishida, T., Joh, T., Uike, N., Yamamoto, K., Utsunomiya, A., Yoshida, S., Saburi, Y., Miyamoto, T., 
Takemoto, S., Suzushima, H., et al. (2012). Defucosylated anti-CCR4 monoclonal antibody (KW-0761) 
for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 30, 837-842. 
Iwanaga, M., Watanabe, T., Utsunomiya, A., Okayama, A., Uchimaru, K., Koh, K.R., Ogata, M., 
Kikuchi, H., Sagara, Y., Uozumi, K., et al. (2010). Human T-cell leukemia virus type I (HTLV-1) proviral 
load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in 
Japan. Blood 116, 1211-1219. 
Iwasaki, Y., Ohara, Y., Kobayashi, I., and Akizuki, S. (1992). Infiltration of helper/inducer T 
lymphocytes heralds central nervous system damage in human T-cell leukemia virus infection. Am J 
Pathol 140, 1003-1008. 
Jason, J.M., McDougal, J.S., Cabradilla, C., Kalyanaraman, V.S., and Evatt, B.L. (1985). Human T-cell 
leukemia virus (HTLV-I) p24 antibody in New York City blood product recipients. Am J Hematol 20, 
129-137. 
Jeang, K.T., Boros, I., Brady, J., Radonovich, M., and Khoury, G. (1988). Characterization of cellular 
factors that interact with the human T-cell leukemia virus type I p40x-responsive 21-base-pair 
sequence. J Virol 62, 4499-4509. 
Jeffery, K.J., Siddiqui, A.A., Bunce, M., Lloyd, A.L., Vine, A.M., Witkover, A.D., Izumo, S., Usuku, K., 
Welsh, K.I., Osame, M., and Bangham, C.R. (2000). The influence of HLA class I alleles and 
heterozygosity on the outcome of human T cell lymphotropic virus type I infection. J Immunol 165, 
7278-7284. 
Jeffery, K.J., Usuku, K., Hall, S.E., Matsumoto, W., Taylor, G.P., Procter, J., Bunce, M., Ogg, G.S., 
Welsh, K.I., Weber, J.N., et al. (1999). HLA alleles determine human T-lymphotropic virus-I (HTLV-I) 
proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci U S A 96, 3848-3853. 
Jin, D.Y., and Jeang, K.T. (1997). HTLV-I Tax self-association in optimal trans-activation function. 
Nucleic Acids Res 25, 379-387. 
Jin, D.Y., Spencer, F., and Jeang, K.T. (1998). Human T cell leukemia virus type 1 oncoprotein Tax 
targets the human mitotic checkpoint protein MAD1. Cell 93, 81-91. 
Johnson, D.S., Mortazavi, A., Myers, R.M., and Wold, B. (2007). Genome-wide mapping of in vivo 
protein-DNA interactions. Science 316, 1497-1502. 
175 
 
Johnson, J.M., Nicot, C., Fullen, J., Ciminale, V., Casareto, L., Mulloy, J.C., Jacobson, S., and Franchini, 
G. (2001). Free major histocompatibility complex class I heavy chain is preferentially targeted for 
degradation by human T-cell leukemia/lymphotropic virus type 1 p12(I) protein. J Virol 75, 6086-
6094. 
Jones, K.S., Petrow-Sadowski, C., Bertolette, D.C., Huang, Y., and Ruscetti, F.W. (2005). Heparan 
sulfate proteoglycans mediate attachment and entry of human T-cell leukemia virus type 1 virions 
into CD4+ T cells. J Virol 79, 12692-12702. 
Jones, K.S., Petrow-Sadowski, C., Huang, Y.K., Bertolette, D.C., and Ruscetti, F.W. (2008). Cell-free 
HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells. Nat Med 
14, 429-436. 
Josefsson, L., King, M.S., Makitalo, B., Brannstrom, J., Shao, W., Maldarelli, F., Kearney, M.F., Hu, 
W.S., Chen, J., Gaines, H., et al. (2011). Majority of CD4+ T cells from peripheral blood of HIV-1-
infected individuals contain only one HIV DNA molecule. Proc Natl Acad Sci U S A 108, 11199-11204. 
Jothi, R., Cuddapah, S., Barski, A., Cui, K., and Zhao, K. (2008). Genome-wide identification of in vivo 
protein-DNA binding sites from ChIP-Seq data. Nucleic Acids Res 36, 5221-5231. 
Jung, A., Maier, R., Vartanian, J.P., Bocharov, G., Jung, V., Fischer, U., Meese, E., Wain-Hobson, S., 
and Meyerhans, A. (2002). Recombination: Multiply infected spleen cells in HIV patients. Nature 418, 
144. 
Kamihira, S., Sohda, H., Atogami, S., Toriya, K., Yamada, Y., Tsukazaki, K., Momita, S., Ikeda, S., 
Kusano, M., Amagasaki, T., and et al. (1992). Phenotypic diversity and prognosis of adult T-cell 
leukemia. Leuk Res 16, 435-441. 
Kamihira, S., Sugahara, K., Tsuruda, K., Minami, S., Uemura, A., Akamatsu, N., Nagai, H., Murata, K., 
Hasegawa, H., Hirakata, Y., et al. (2005). Proviral status of HTLV-1 integrated into the host genomic 
DNA of adult T-cell leukemia cells. Clin Lab Haematol 27, 235-241. 
Kannagi, M., Sugamura, K., Kinoshita, K., Uchino, H., and Hinuma, Y. (1984). Specific cytolysis of fresh 
tumor cells by an autologous killer T cell line derived from an adult T cell leukemia/lymphoma 
patient. J Immunol 133, 1037-1041. 
Kaplan, J.E., Osame, M., Kubota, H., Igata, A., Nishitani, H., Maeda, Y., Khabbaz, R.F., and Janssen, 
R.S. (1990). The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis 
among persons infected with HTLV-I. J Acquir Immune Defic Syndr 3, 1096-1101. 
Kashanchi, F., and Brady, J.N. (2005). Transcriptional and post-transcriptional gene regulation of 
HTLV-1. Oncogene 24, 5938-5951. 
Kasowski, M., Grubert, F., Heffelfinger, C., Hariharan, M., Asabere, A., Waszak, S.M., Habegger, L., 
Rozowsky, J., Shi, M., Urban, A.E., et al. (2010). Variation in transcription factor binding among 
humans. Science 328, 232-235. 
Kattan, T., MacNamara, A., Rowan, A.G., Nose, H., Mosley, A.J., Tanaka, Y., Taylor, G.P., Asquith, B., 
and Bangham, C.R. (2009). The avidity and lytic efficiency of the CTL response to HTLV-1. J Immunol 
182, 5723-5729. 
176 
 
Kchour, G., Rezaee, R., Farid, R., Ghantous, A., Rafatpanah, H., Tarhini, M., Kooshyar, M.M., El Hajj, 
H., Berry, F., Mortada, M., et al. (2013). The combination of arsenic, interferon-alpha, and 
zidovudine restores an "immunocompetent-like" cytokine expression profile in patients with adult T-
cell leukemia lymphoma. Retrovirology 10, 91. 
Kchour, G., Tarhini, M., Kooshyar, M.M., El Hajj, H., Wattel, E., Mahmoudi, M., Hatoum, H., Rahimi, 
H., Maleki, M., Rafatpanah, H., et al. (2009). Phase 2 study of the efficacy and safety of the 
combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-
cell leukemia/lymphoma (ATL). Blood 113, 6528-6532. 
Kentsis, A., Reed, C., Rice, K.L., Sanda, T., Rodig, S.J., Tholouli, E., Christie, A., Valk, P.J., Delwel, R., 
Ngo, V., et al. (2012). Autocrine activation of the MET receptor tyrosine kinase in acute myeloid 
leukemia. Nat Med 18, 1118-1122. 
Kidd, J.M., Sampas, N., Antonacci, F., Graves, T., Fulton, R., Hayden, H.S., Alkan, C., Malig, M., 
Ventura, M., Giannuzzi, G., et al. (2010). Characterization of missing human genome sequences and 
copy-number polymorphic insertions. Nat Methods 7, 365-371. 
Kondo, T., Nonaka, H., Miyamoto, N., Yoshida, R., Matsue, Y., Ohguchi, Y., Inouye, H., Komoda, H., 
Hinuma, Y., and Hanaoka, M. (1985). Incidence of adult T-cell leukemia-lymphoma and its familial 
clustering. Int J Cancer 35, 749-751. 
Koralnik, I.J., Gessain, A., Klotman, M.E., Lo Monico, A., Berneman, Z.N., and Franchini, G. (1992). 
Protein isoforms encoded by the pX region of human T-cell leukemia/lymphotropic virus type I. Proc 
Natl Acad Sci U S A 89, 8813-8817. 
Korber, B., Okayama, A., Donnelly, R., Tachibana, N., and Essex, M. (1991). Polymerase chain 
reaction analysis of defective human T-cell leukemia virus type I proviral genomes in leukemic cells 
of patients with adult T-cell leukemia. J Virol 65, 5471-5476. 
Koyanagi, Y., Itoyama, Y., Nakamura, N., Takamatsu, K., Kira, J., Iwamasa, T., Goto, I., and Yamamoto, 
N. (1993). In vivo infection of human T-cell leukemia virus type I in non-T cells. Virology 196, 25-33. 
Kozako, T., Arima, N., Toji, S., Masamoto, I., Akimoto, M., Hamada, H., Che, X.F., Fujiwara, H., 
Matsushita, K., Tokunaga, M., et al. (2006). Reduced frequency, diversity, and function of human T 
cell leukemia virus type 1-specific CD8+ T cell in adult T cell leukemia patients. J Immunol 177, 5718-
5726. 
Kozako, T., Yoshimitsu, M., Fujiwara, H., Masamoto, I., Horai, S., White, Y., Akimoto, M., Suzuki, S., 
Matsushita, K., Uozumi, K., et al. (2009). PD-1/PD-L1 expression in human T-cell leukemia virus type 
1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia 23, 375-382. 
Kwok, S., Ehrlich, G., Poiesz, B., Kalish, R., and Sninsky, J.J. (1988). Enzymatic amplification of HTLV-I 
viral sequences from peripheral blood mononuclear cells and infected tissues. Blood 72, 1117-1123. 
Langerak, A.W., Groenen, P.J., Bruggemann, M., Beldjord, K., Bellan, C., Bonello, L., Boone, E., Carter, 
G.I., Catherwood, M., Davi, F., et al. (2012). EuroClonality/BIOMED-2 guidelines for interpretation 
and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia 26, 2159-2171. 
Langerak, A.W., van Dongen J.J.M (2012). Multiple clonal Ig/TCR products: implications for 
interpretation of clonality findings. J Hematolpathol 5, 35-43. 
177 
 
Lauc, G., Huffman, J.E., Pucic, M., Zgaga, L., Adamczyk, B., Muzinic, A., Novokmet, M., Polasek, O., 
Gornik, O., Kristic, J., et al. (2013). Loci associated with N-glycosylation of human immunoglobulin G 
show pleiotropy with autoimmune diseases and haematological cancers. PLoS Genet 9, e1003225. 
Lee, B.K., Bhinge, A.A., and Iyer, V.R. (2011). Wide-ranging functions of E2F4 in transcriptional 
activation and repression revealed by genome-wide analysis. Nucleic Acids Res 39, 3558-3573. 
Levin, A., Hayouka, Z., Friedler, A., Brack-Werner, R., Volsky, D.J., and Loyter, A. (2010). A novel role 
for the viral Rev protein in promoting resistance to superinfection by human immunodeficiency virus 
type 1. J Gen Virol 91, 1503-1513. 
Li, H., Malani, N., Hamilton, S.R., Schlachterman, A., Bussadori, G., Edmonson, S.E., Shah, R., Arruda, 
V.R., Mingozzi, F., Wright, J.F., et al. (2011). Assessing the potential for AAV vector genotoxicity in a 
murine model. Blood 117, 3311-3319. 
Liao, W., Lin, J.X., Wang, L., Li, P., and Leonard, W.J. (2011). Modulation of cytokine receptors by IL-2 
broadly regulates differentiation into helper T cell lineages. Nat Immunol 12, 551-559. 
Liu, L., Li, Y., Li, S., Hu, N., He, Y., Pong, R., Lin, D., Lu, L., and Law, M. (2012). Comparison of next-
generation sequencing systems. J Biomed Biotechnol 2012, 251364. 
Lunardi-Iskandar, Y., Gessain, A., Lam, V.H., and Gallo, R.C. (1993). Abnormal in vitro proliferation 
and differentiation of T cell colony-forming cells in patients with tropical spastic paraparesis/human 
T lymphocyte virus type I (HTLV-I)-associated myeloencephalopathy and healthy HTLV-I carriers. The 
Journal of experimental medicine 177, 741-750. 
Macnamara, A., Rowan, A., Hilburn, S., Kadolsky, U., Fujiwara, H., Suemori, K., Yasukawa, M., Taylor, 
G., Bangham, C.R., and Asquith, B. (2010). HLA class I binding of HBZ determines outcome in HTLV-1 
infection. PLoS Pathog 6 (9): e1001117. doi:10.1371/journal.ppat.1001117 
Maertens, G.N., Hare, S., and Cherepanov, P. (2010). The mechanism of retroviral integration from X-
ray structures of its key intermediates. Nature 468, 326-329. 
Mahieux, R., and Gessain, A. (2007). Adult T-cell leukemia/lymphoma and HTLV-1. Curr Hematol 
Malig Rep 2, 257-264. 
Majorovits, E., Nejmeddine, M., Tanaka, Y., Taylor, G.P., Fuller, S.D., and Bangham, C.R. (2008). 
Human T-lymphotropic virus-1 visualized at the virological synapse by electron tomography. PLoS 
One 3, e2251. 
Manel, N., Kim, F.J., Kinet, S., Taylor, N., Sitbon, M., and Battini, J.L. (2003). The ubiquitous glucose 
transporter GLUT-1 is a receptor for HTLV. Cell 115, 449-459. 
Marcos, L.A., Terashima, A., Dupont, H.L., and Gotuzzo, E. (2008). Strongyloides hyperinfection 
syndrome: an emerging global infectious disease. Trans R Soc Trop Med Hyg 102, 314-318. 
Marshall, N.A., Christie, L.E., Munro, L.R., Culligan, D.J., Johnston, P.W., Barker, R.N., and Vickers, 
M.A. (2004). Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of 
Hodgkin lymphoma. Blood 103, 1755-1762. 
Matsuoka, M. (2005). Human T-cell leukemia virus type I (HTLV-I) infection and the onset of adult T-
cell leukemia (ATL). Retrovirology 2, 27. 
178 
 
Matsuoka, M., and Jeang, K.T. (2007). Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and 
cellular transformation. Nat Rev Cancer 7, 270-280. 
Matsuoka, M., and Jeang, K.T. (2011). Human T-cell leukemia virus type 1 (HTLV-1) and leukemic 
transformation: viral infectivity, Tax, HBZ and therapy. Oncogene 30, 1379-1389. 
McCarthy, T.J., Kennedy, J.L., Blakeslee, J.R., and Bennett, B.T. (1990). Spontaneous malignant 
lymphoma and leukemia in a simian T-lymphotropic virus type I (STLV-I) antibody positive olive 
baboon. Lab Anim Sci 40, 79-81. 
Meekings, K.N., Leipzig, J., Bushman, F.D., Taylor, G.P., and Bangham, C.R. (2008). HTLV-1 integration 
into transcriptionally active genomic regions is associated with proviral expression and with 
HAM/TSP. PLoS Pathog 4, e1000027. 
Melamed, A., Laydon, D.J., Gillet, N.A., Tanaka, Y., Taylor, G.P., and Bangham, C.R. (2013). Genome-
wide determinants of proviral targeting, clonal abundance and expression in natural HTLV-1 
infection. PLoS Pathog 9, e1003271. 
Minato, N. (2013). Rap G protein signal in normal and disordered lymphohematopoiesis. Exp Cell Res 
319, 2323-2328. 
Miura, M., Yasunaga, J.I., Tanabe, J., Sugata, K., Zhao, T., Ma, G., Miyazato, P., Ohshima, K., Kaneko, 
A., Watanabe, A., et al. (2013). Characterization of simian T-cell leukemia virus type 1 in naturally 
infected Japanese macaques as a model of HTLV-1 infection. Retrovirology 10, 118. 
Miyazaki, M., Yasunaga, J., Taniguchi, Y., Tamiya, S., Nakahata, T., and Matsuoka, M. (2007). 
Preferential selection of human T-cell leukemia virus type 1 provirus lacking the 5' long terminal 
repeat during oncogenesis. J Virol 81, 5714-5723. 
Mochizuki, M., Watanabe, T., Yamaguchi, K., Yoshimura, K., Nakashima, S., Shirao, M., Araki, S., 
Takatsuki, K., Mori, S., and Miyata, N. (1992). Uveitis associated with human T-cell lymphotropic 
virus type I. Am J Ophthalmol 114, 123-129. 
Morgan, O.S., Rodgers-Johnson, P., Mora, C., and Char, G. (1989). HTLV-1 and polymyositis in 
Jamaica. Lancet 2, 1184-1187. 
Munoz, M., Gonzalez-Ortega, A., and Covenas, R. (2012). The NK-1 receptor is expressed in human 
leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists 
on acute lymphoblastic leukemia cell lines. Invest New Drugs 30, 529-540. 
Murphy, E.L., Figueroa, J.P., Gibbs, W.N., Brathwaite, A., Holding-Cobham, M., Waters, D., Cranston, 
B., Hanchard, B., and Blattner, W.A. (1989). Sexual transmission of human T-lymphotropic virus type 
I (HTLV-I). Ann Intern Med 111, 555-560. 
Murphy, E.L., Lee, T.H., Chafets, D., Nass, C.C., Wang, B., Loughlin, K., and Smith, D. (2004). Higher 
human T lymphotropic virus (HTLV) provirus load is associated with HTLV-I versus HTLV-II, with 
HTLV-II subtype A versus B, and with male sex and a history of blood transfusion. J Infect Dis 190, 
504-510. 
Nagai, K., Jinnai, I., Hata, T., Usui, T., Sasaki, D., Tsukasaki, K., Sugahara, K., Hishikawa, Y., Yamada, Y., 
Tanaka, Y., et al. (2008). Adhesion-dependent growth of primary adult T cell leukemia cells with 
179 
 
down-regulation of HTLV-I p40Tax protein: a novel in vitro model of the growth of acute ATL cells. 
Int J Hematol 88, 551-564. 
Nagai, M., Brennan, M.B., Sakai, J.A., Mora, C.A., and Jacobson, S. (2001). CD8(+) T cells are an in vivo 
reservoir for human T-cell lymphotropic virus type I. Blood 98, 1858-1861. 
Nagai, M., and Jacobson, S. (2001). Immunopathogenesis of human T cell lymphotropic virus type I-
associated myelopathy. Curr Opin Neurol 14, 381-386. 
Nagai, M., and Osame, M. (2003). Human T-cell lymphotropic virus type I and neurological diseases. J 
Neurovirol 9, 228-235. 
Nagasato, K., Nakamura, T., Ohishi, K., Shibayama, K., Motomura, M., Ichinose, K., Tsujihata, M., and 
Nagataki, S. (1991). Active production of anti-human T-lymphotropic virus type I (HTLV-I) IgM 
antibody in HTLV-I-associated myelopathy. J Neuroimmunol 32, 105-109. 
Nam, S.H., Copeland, T.D., Hatanaka, M., and Oroszlan, S. (1993). Characterization of ribosomal 
frameshifting for expression of pol gene products of human T-cell leukemia virus type I. J Virol 67, 
196-203. 
Neel, B.G., Hayward, W.S., Robinson, H.L., Fang, J., and Astrin, S.M. (1981). Avian leukosis virus-
induced tumors have common proviral integration sites and synthesize discrete new RNAs: 
oncogenesis by promoter insertion. Cell 23, 323-334. 
Nejmeddine, M., and Bangham, C.R. (2010). The HTLV-1 Virological Synapse. Viruses 2, 1427-1447. 
Nejmeddine, M., Negi, V.S., Mukherjee, S., Tanaka, Y., Orth, K., Taylor, G.P., and Bangham, C.R. 
(2009). HTLV-1-Tax and ICAM-1 act on T-cell signal pathways to polarize the microtubule-organizing 
center at the virological synapse. Blood 114, 1016-1025. 
Nicot, C., Dundr, M., Johnson, J.M., Fullen, J.R., Alonzo, N., Fukumoto, R., Princler, G.L., Derse, D., 
Misteli, T., and Franchini, G. (2004). HTLV-1-encoded p30II is a post-transcriptional negative 
regulator of viral replication. Nat Med 10, 197-201. 
Niewiesk, S., Daenke, S., Parker, C.E., Taylor, G., Weber, J., Nightingale, S., and Bangham, C.R. (1995). 
Naturally occurring variants of human T-cell leukemia virus type I Tax protein impair its recognition 
by cytotoxic T lymphocytes and the transactivation function of Tax. J Virol 69, 2649-2653. 
Oh, U., and Jacobson, S. (2008). Treatment of HTLV-I-associated myelopathy/tropical spastic 
paraparesis: toward rational targeted therapy. Neurol Clin 26, 781-797, ix-x. 
Ohshima, K., Hashimoto, K., Izumo, S., Suzumiya, J., and Kikuchi, M. (1996). Detection of human T 
lymphotrophic virus type I (HTLV-I) DNA and mRNA in individual cells by polymerase chain reaction 
(PCR) in situ hybridization (ISH) and reverse transcription (RT)-PCR ISH. Hematol Oncol 14, 91-100. 
Ohshima, K., Kikuchi, M., Masuda, Y., Kobari, S., Sumiyoshi, Y., Eguchi, F., Mohtai, H., Yoshida, T., 
Takeshita, M., and Kimura, N. (1991). Defective provirus form of human T-cell leukemia virus type I 
in adult T-cell leukemia/lymphoma: clinicopathological features. Cancer Res 51, 4639-4642. 
Osame, M., Usuku, K., Izumo, S., Ijichi, N., Amitani, H., Igata, A., Matsumoto, M., and Tara, M. (1986). 
HTLV-I associated myelopathy, a new clinical entity. Lancet 1, 1031-1032. 
180 
 
Overbaugh, J., and Bangham, C.R. (2001). Selection forces and constraints on retroviral sequence 
variation. Science 292, 1106-1109. 
Ozawa, T., Itoyama, T., Sadamori, N., Yamada, Y., Hata, T., Tomonaga, M., and Isobe, M. (2004). 
Rapid isolation of viral integration site reveals frequent integration of HTLV-1 into expressed loci. J 
Hum Genet 49, 154-165. 
Pais-Correia, A.M., Sachse, M., Guadagnini, S., Robbiati, V., Lasserre, R., Gessain, A., Gout, O., 
Alcover, A., and Thoulouze, M.I. (2010). Biofilm-like extracellular viral assemblies mediate HTLV-1 
cell-to-cell transmission at virological synapses. Nat Med 16, 83-89. 
Parsons, B.L. (2008). Many different tumor types have polyclonal tumor origin: evidence and 
implications. Mutat Res 659, 232-247. 
Patten, P.E., Buggins, A.G., Richards, J., Wotherspoon, A., Salisbury, J., Mufti, G.J., Hamblin, T.J., and 
Devereux, S. (2008). CD38 expression in chronic lymphocytic leukemia is regulated by the tumor 
microenvironment. Blood 111, 5173-5181. 
Payne, G.S., Bishop, J.M., and Varmus, H.E. (1982). Multiple arrangements of viral DNA and an 
activated host oncogene in bursal lymphomas. Nature 295, 209-214. 
Pederson, T., and Tsai, R.Y. (2009). In search of nonribosomal nucleolar protein function and 
regulation. J Cell Biol 184, 771-776. 
Pedral-Sampaio, D.B., Martins Netto, E., Pedrosa, C., Brites, C., Duarte, M., and Harrington, W., Jr. 
(1997). Co-Infection of Tuberculosis and HIV/HTLV Retroviruses: Frequency and Prognosis Among 
Patients Admitted in a Brazilian Hospital. Braz J Infect Dis 1, 31-35. 
Poiesz, B.J., Ruscetti, F.W., Gazdar, A.F., Bunn, P.A., Minna, J.D., and Gallo, R.C. (1980). Detection and 
isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with 
cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 77, 7415-7419. 
Pombo-de-Oliveira, M.S., Carvalho, S.M., Borducchi, D., Dobbin, J., Salvador, J., Correa, R.B., 
Moellman, A., Loureiro, P., Chiattone, C., and Rios, M. (2001). Adult T-cell leukemia/lymphoma and 
cluster of HTLV-I associated diseases in Brazilian settings. Leuk Lymphoma 42, 135-144. 
Pozzatti, R., Vogel, J., and Jay, G. (1990). The human T-lymphotropic virus type I tax gene can 
cooperate with the ras oncogene to induce neoplastic transformation of cells. Mol Cell Biol 10, 413-
417. 
Presson, A.P., Kim, N., Xiaofei, Y., Chen, I.S., and Kim, S. (2011). Methodology and software to detect 
viral integration site hot-spots. BMC Bioinformatics 12, 367. 
Raha, D., Wang, Z., Moqtaderi, Z., Wu, L., Zhong, G., Gerstein, M., Struhl, K., and Snyder, M. (2010). 
Close association of RNA polymerase II and many transcription factors with Pol III genes. Proc Natl 
Acad Sci U S A 107, 3639-3644. 
Ram, O., Goren, A., Amit, I., Shoresh, N., Yosef, N., Ernst, J., Kellis, M., Gymrek, M., Issner, R., Coyne, 
M., et al. (2011). Combinatorial patterning of chromatin regulators uncovered by genome-wide 
location analysis in human cells. Cell 147, 1628-1639. 
181 
 
Ramirez, E., Fernandez, J., Cartier, L., Villota, C., and Rios, M. (2003). Defective human T-cell 
lymphotropic virus type I (HTLV-I) provirus in seronegative tropical spastic paraparesis/HTLV-I-
associated myelopathy (TSP/HAM) patients. Virus Res 91, 231-239. 
Ramos J.C., T., N., Diaz L, Ruiz P., Barber G, and  Harrington W (2011). Targeting HTLV-I latency in 
Adult T-cell Leukemia/Lymphoma. Retrovirology 8, A48. 
Rende, F., Cavallari, I., Corradin, A., Silic-Benussi, M., Toulza, F., Toffolo, G.M., Tanaka, Y., Jacobson, 
S., Taylor, G.P., D'Agostino, D.M., et al. (2011). Kinetics and intracellular compartmentalization of 
HTLV-1 gene expression: nuclear retention of HBZ mRNAs. Blood 117, 4855-4859. 
Richardson, J.H., Edwards, A.J., Cruickshank, J.K., Rudge, P., and Dalgleish, A.G. (1990). In vivo cellular 
tropism of human T-cell leukemia virus type 1. J Virol 64, 5682-5687. 
Ronen, K., Negre, O., Roth, S., Colomb, C., Malani, N., Denaro, M., Brady, T., Fusil, F., Gillet-Legrand, 
B., Hehir, K., et al. (2011). Distribution of lentiviral vector integration sites in mice following 
therapeutic gene transfer to treat beta-thalassemia. Mol Ther 19, 1273-1286. 
Rosenberg, N., and Jolicoeur, P. (1997). Retroviral Pathogenesis, in:  Coffin, J., Hughes, S., Varmus, 
H., editors. Retroviruses, Cold Spring Harbor Lab Press, 1997. 
Rowan, A.G., and Bangham, C.R. (2012). Is There a Role for HTLV-1-Specific CTL in Adult T-Cell 
Leukemia/Lymphoma? Leuk Res Treatment 2012, 391953. 
Rozowsky, J., Abyzov, A., Wang, J., Alves, P., Raha, D., Harmanci, A., Leng, J., Bjornson, R., Kong, Y., 
Kitabayashi, N., et al. (2011). AlleleSeq: analysis of allele-specific expression and binding in a network 
framework. Mol Syst Biol 7, 522. 
Sabouri, A.H., Saito, M., Lloyd, A.L., Vine, A.M., Witkover, A.W., Furukawa, Y., Izumo, S., Arimura, K., 
Marshall, S.E., Usuku, K., et al. (2004). Polymorphism in the interleukin-10 promoter affects both 
provirus load and the risk of human T lymphotropic virus type I-associated myelopathy/tropical 
spastic paraparesis. J Infect Dis 190, 1279-1285. 
Sadelain, M., Papapetrou, E.P., and Bushman, F.D. (2012). Safe harbours for the integration of new 
DNA in the human genome. Nat Rev Cancer 12, 51-58. 
Sajesh, B.V., Lichtensztejn, Z., and McManus, K.J. (2013). Sister chromatid cohesion defects are 
associated with chromosome instability in Hodgkin lymphoma cells. BMC Cancer 13, 391. 
Sasaki, D., Doi, Y., Hasegawa, H., Yanagihara, K., Tsukasaki, K., Iwanaga, M., Yamada, Y., Watanabe, 
T., and Kamihira, S. (2010). High human T cell leukemia virus type-1(HTLV-1) provirus load in patients 
with HTLV-1 carriers complicated with HTLV-1-unrelated disorders. Virol J 7, 81. 
Sasaki, H., Nishikata, I., Shiraga, T., Akamatsu, E., Fukami, T., Hidaka, T., Kubuki, Y., Okayama, A., 
Hamada, K., Okabe, H., et al. (2005). Overexpression of a cell adhesion molecule, TSLC1, as a possible 
molecular marker for acute-type adult T-cell leukemia. Blood 105, 1204-1213. 
Satou, Y., and Matsuoka, M. (2007). Implication of the HTLV-I bZIP factor gene in the leukemogenesis 
of adult T-cell leukemia. Int J Hematol 86, 107-112. 
Satou, Y., Yasunaga, J., Yoshida, M., and Matsuoka, M. (2006). HTLV-I basic leucine zipper factor gene 
mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci U S A 103, 720-725. 
182 
 
Satou, Y., Yasunaga, J., Zhao, T., Yoshida, M., Miyazato, P., Takai, K., Shimizu, K., Ohshima, K., Green, 
P.L., Ohkura, N., et al. (2011). HTLV-1 bZIP factor induces T-cell lymphoma and systemic 
inflammation in vivo. PLoS Pathog 7, e1001274. 
Schneider, U., Schwenk, H.U., and Bornkamm, G. (1977). Characterization of EBV-genome negative 
"null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic 
transformed non-Hodgkin lymphoma. Int J Cancer 19, 621-626. 
Schroder, A.R., Shinn, P., Chen, H., Berry, C., Ecker, J.R., and Bushman, F. (2002). HIV-1 integration in 
the human genome favors active genes and local hotspots. Cell 110, 521-529. 
Seich Al Basatena, N.K., Macnamara, A., Vine, A.M., Thio, C.L., Astemborski, J., Usuku, K., Osame, M., 
Kirk, G.D., Donfield, S.M., Goedert, J.J., et al. (2011). KIR2DL2 enhances protective and detrimental 
HLA class I-mediated immunity in chronic viral infection. PLoS Pathog 7, e1002270. 
Seiki, M., Eddy, R., Shows, T.B., and Yoshida, M. (1984). Nonspecific integration of the HTLV provirus 
genome into adult T-cell leukaemia cells. Nature 309, 640-642. 
Seiki, M., Hattori, S., Hirayama, Y., and Yoshida, M. (1983). Human adult T-cell leukemia virus: 
complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. Proc Natl 
Acad Sci U S A 80, 3618-3622. 
Seiki, M., Inoue, J., Hidaka, M., and Yoshida, M. (1988). Two cis-acting elements responsible for 
posttranscriptional trans-regulation of gene expression of human T-cell leukemia virus type I. Proc 
Natl Acad Sci U S A 85, 7124-7128. 
Seiki, M., Inoue, J., Takeda, T., and Yoshida, M. (1986). Direct evidence that p40x of human T-cell 
leukemia virus type I is a trans-acting transcriptional activator. EMBO J 5, 561-565. 
Shan, L., Yang, H.C., Rabi, S.A., Bravo, H.C., Shroff, N.S., Irizarry, R.A., Zhang, H., Margolick, J.B., 
Siliciano, J.D., and Siliciano, R.F. (2011). Influence of host gene transcription level and orientation on 
HIV-1 latency in a primary-cell model. J Virol 85, 5384-5393. 
Shembade, N., and Harhaj, E.W. (2010). Role of post-translational modifications of HTLV-1 Tax in NF-
kappaB activation. World J Biol Chem 1, 13-20. 
Shimizu, Y., Takamori, A., Utsunomiya, A., Kurimura, M., Yamano, Y., Hishizawa, M., Hasegawa, A., 
Kondo, F., Kurihara, K., Harashima, N., et al. (2009). Impaired Tax-specific T-cell responses with 
insufficient control of HTLV-1 in a subgroup of individuals at asymptomatic and smoldering stages. 
Cancer Sci 100, 481-489. 
Shimoyama, M. (1991). Diagnostic criteria and classification of clinical subtypes of adult T-cell 
leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 79, 428-
437. 
Siliciano, R.F., and Greene, W.C. (2011). HIV latency. Cold Spring Harb Perspect Med 1, a007096. 
Sjoblom, T., Jones, S., Wood, L.D., Parsons, D.W., Lin, J., Barber, T.D., Mandelker, D., Leary, R.J., Ptak, 
J., Silliman, N., et al. (2006). The consensus coding sequences of human breast and colorectal 
cancers. Science 314, 268-274. 
183 
 
Slattery, J.P., Franchini, G., and Gessain, A. (1999). Genomic evolution, patterns of global 
dissemination, and interspecies transmission of human and simian T-cell leukemia/lymphotropic 
viruses. Genome Res 9, 525-540. 
Souza, H.C., Carvalho, B.N., Morais, M.G., Monteiro, G.Z., Emori, F.T., and Latorre, L.C. (2011). 
Tropical pyomyositis in a patient with systemic lupus erythematosus and HTLV 1/2 infection. Rev 
Bras Reumatol 51, 97-103. 
Suarez F, M.A., Ghez D,  Delarue R, Deau-Fischer B,  Flore Sicre de Fontbrune C.A, Ysebaert L,  Asnafi 
V,  Canioni D, deThe H, Bazarbachi A and  Hermine O (2011). Arsenic trioxyde in the treatment of 
HTLV1 associated ATLL. Retrovirology 8, A59   
Suemori, K., Fujiwara, H., Ochi, T., Ogawa, T., Matsuoka, M., Matsumoto, T., Mesnard, J.M., and 
Yasukawa, M. (2009). HBZ is an immunogenic protein, but not a target antigen for human T-cell 
leukemia virus type 1-specific cytotoxic T lymphocytes. J Gen Virol 90, 1806-1811. 
Suzuki, S., Uozumi, K., Maeda, M., Yamasuji, Y., Hashimoto, S., Komorizono, Y., Owatari, S., 
Tokunaga, M., Haraguchi, K., and Arima, N. (2006). Adult T-cell leukemia in a liver transplant 
recipient that did not progress after onset of graft rejection. Int J Hematol 83, 429-432. 
Suzuki, T., Shen, H., Akagi, K., Morse, H.C., Malley, J.D., Naiman, D.Q., Jenkins, N.A., and Copeland, 
N.G. (2002). New genes involved in cancer identified by retroviral tagging. Nat Genet 32, 166-174. 
Suzuki, T., Uchida-Toita, M., and Yoshida, M. (1999). Tax protein of HTLV-1 inhibits CBP/p300-
mediated transcription by interfering with recruitment of CBP/p300 onto DNA element of E-box or 
p53 binding site. Oncogene 18, 4137-4143. 
Takasaki, Y., Iwanaga, M., Imaizumi, Y., Tawara, M., Joh, T., Kohno, T., Yamada, Y., Kamihira, S., 
Ikeda, S., Miyazaki, Y., et al. (2010). Long-term study of indolent adult T-cell leukemia-lymphoma. 
Blood 115, 4337-4343. 
Takeda, S., Maeda, M., Morikawa, S., Taniguchi, Y., Yasunaga, J., Nosaka, K., Tanaka, Y., and 
Matsuoka, M. (2004). Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. 
Int J Cancer 109, 559-567. 
Takemoto, S., Matsuoka, M., Yamaguchi, K., and Takatsuki, K. (1994). A novel diagnostic method of 
adult T-cell leukemia: monoclonal integration of human T-cell lymphotropic virus type I provirus DNA 
detected by inverse polymerase chain reaction. Blood 84, 3080-3085. 
Takenouchi, N., Yamano, Y., Usuku, K., Osame, M., and Izumo, S. (2003). Usefulness of proviral load 
measurement for monitoring of disease activity in individual patients with human T-lymphotropic 
virus type I-associated myelopathy/tropical spastic paraparesis. J Neurovirol 9, 29-35. 
Tamiya, S., Matsuoka, M., Etoh, K., Watanabe, T., Kamihira, S., Yamaguchi, K., and Takatsuki, K. 
(1996). Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia. 
Blood 88, 3065-3073. 
Taniguchi, Y., Nosaka, K., Yasunaga, J., Maeda, M., Mueller, N., Okayama, A., and Matsuoka, M. 
(2005). Silencing of human T-cell leukemia virus type I gene transcription by epigenetic mechanisms. 
Retrovirology 2, 64. 
184 
 
Tateno, M., Kondo, N., Itoh, T., Chubachi, T., Togashi, T., and Yoshiki, T. (1984). Rat lymphoid cell 
lines with human T cell leukemia virus production. I. Biological and serological characterization. The 
Journal of experimental medicine 159, 1105-1116. 
Taylor, G.P., Bodeus, M., Courtois, F., Pauli, G., Del Mistro, A., Machuca, A., Padua, E., Andersson, S., 
Goubau, P., Chieco-Bianchi, L., et al. (2005). The seroepidemiology of human T-lymphotropic viruses: 
types I and II in Europe: a prospective study of pregnant women. J Acquir Immune Defic Syndr 38, 
104-109. 
Taylor, G.P., Goon, P., Furukawa, Y., Green, H., Barfield, A., Mosley, A., Nose, H., Babiker, A., Rudge, 
P., Usuku, K., et al. (2006). Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-
associated myelopathy: a randomised trial. Retrovirology 3, 63. 
Tie, F., Adya, N., Greene, W.C., and Giam, C.Z. (1996). Interaction of the human T-lymphotropic virus 
type 1 Tax dimer with CREB and the viral 21-base-pair repeat. J Virol 70, 8368-8374. 
Tosswill, J.H., Taylor, G.P., Tedder, R.S., and Mortimer, P.P. (2000). HTLV-I/II associated disease in 
England and Wales, 1993-7: retrospective review of serology requests. BMJ 320, 611-612. 
Toulza, F., Heaps, A., Tanaka, Y., Taylor, G.P., and Bangham, C.R. (2008). High frequency of 
CD4+FoxP3+ cells in HTLV-1 infection: inverse correlation with HTLV-1-specific CTL response. Blood 
111, 5047-5053. 
Toulza, F., Nosaka, K., Takiguchi, M., Pagliuca, T., Mitsuya, H., Tanaka, Y., Taylor, G.P., and Bangham, 
C.R. (2009). FoxP3+ regulatory T cells are distinct from leukemia cells in HTLV-1-associated adult T-
cell leukemia. Int J Cancer 125, 2375-2382. 
Toulza, F., Nosaka, K., Tanaka, Y., Schioppa, T., Balkwill, F., Taylor, G.P., and Bangham, C.R. (2010). 
Human T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of 
functional FoxP3+ regulatory T cells. J Immunol 185, 183-189. 
Trojer, P., Cao, A.R., Gao, Z., Li, Y., Zhang, J., Xu, X., Li, G., Losson, R., Erdjument-Bromage, H., 
Tempst, P., et al. (2011). L3MBTL2 protein acts in concert with PcG protein-mediated 
monoubiquitination of H2A to establish a repressive chromatin structure. Mol Cell 42, 438-450. 
Tsujimoto, H., Noda, Y., Ishikawa, K., Nakamura, H., Fukasawa, M., Sakakibara, I., Sasagawa, A., 
Honjo, S., and Hayami, M. (1987). Development of adult T-cell leukemia-like disease in African green 
monkey associated with clonal integration of simian T-cell leukemia virus type I. Cancer Res 47, 269-
274. 
Tsukasaki, K., Hermine, O., Bazarbachi, A., Ratner, L., Ramos, J.C., Harrington, W., Jr., O'Mahony, D., 
Janik, J.E., Bittencourt, A.L., Taylor, G.P., et al. (2009). Definition, prognostic factors, treatment, and 
response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus 
meeting. J Clin Oncol 27, 453-459. 
Tsukasaki, K., Tsushima, H., Yamamura, M., Hata, T., Murata, K., Maeda, T., Atogami, S., Sohda, H., 
Momita, S., Ideda, S., et al. (1997). Integration patterns of HTLV-I provirus in relation to the clinical 
course of ATL: frequent clonal change at crisis from indolent disease. Blood 89, 948-956. 
Tsukasaki, K., Utsunomiya, A., Fukuda, H., Shibata, T., Fukushima, T., Takatsuka, Y., Ikeda, S., 
Masuda, M., Nagoshi, H., Ueda, R., et al. (2007). VCAP-AMP-VECP compared with biweekly CHOP for 
185 
 
adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 25, 
5458-5464. 
Uchiyama, T. (1997). Human T cell leukemia virus type I (HTLV-I) and human diseases. Annu Rev 
Immunol 15, 15-37. 
Uchiyama, T., Hori, T., Tsudo, M., Wano, Y., Umadome, H., Tamori, S., Yodoi, J., Maeda, M., Sawami, 
H., and Uchino, H. (1985). Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia 
cells. J Clin Invest 76, 446-453. 
Umino, A., and Seto, M. (2013). Array CGH reveals clonal evolution of adult T-cell 
leukemia/lymphoma. Methods Mol Biol 973, 189-196. 
Uren, A.G., Kool, J., Berns, A., and van Lohuizen, M. (2005). Retroviral insertional mutagenesis: past, 
present and future. Oncogene 24, 7656-7672. 
Ureta-Vidal, A., Angelin-Duclos, C., Tortevoye, P., Murphy, E., Lepere, J.F., Buigues, R.P., Jolly, N., 
Joubert, M., Carles, G., Pouliquen, J.F., et al. (1999). Mother-to-child transmission of human T-cell-
leukemia/lymphoma virus type I: implication of high antiviral antibody titer and high proviral load in 
carrier mothers. Int J Cancer 82, 832-836. 
Usui, T., Yanagihara, K., Tsukasaki, K., Murata, K., Hasegawa, H., Yamada, Y., and Kamihira, S. (2008). 
Characteristic expression of HTLV-1 basic zipper factor (HBZ) transcripts in HTLV-1 provirus-positive 
cells. Retrovirology 5, 34. 
Van Beveren, C., Rands, E., Chattopadhyay, S.K., Lowy, D.R., and Verma, I.M. (1982). Long terminal 
repeat of murine retroviral DNAs: sequence analysis, host-proviral junctions, and preintegration site. 
J Virol 41, 542-556. 
van Dongen, J.J., Langerak, A.W., Bruggemann, M., Evans, P.A., Hummel, M., Lavender, F.L., 
Delabesse, E., Davi, F., Schuuring, E., Garcia-Sanz, R., et al. (2003). Design and standardization of PCR 
primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene 
recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-
CT98-3936. Leukemia 17, 2257-2317. 
van Koningsbruggen, S., Gierlinski, M., Schofield, P., Martin, D., Barton, G.J., Ariyurek, Y., den 
Dunnen, J.T., and Lamond, A.I. (2010). High-resolution whole-genome sequencing reveals that 
specific chromatin domains from most human chromosomes associate with nucleoli. Mol Biol Cell 
21, 3735-3748. 
Van Prooyen, N., Gold, H., Andresen, V., Schwartz, O., Jones, K., Ruscetti, F., Lockett, S., Gudla, P., 
Venzon, D., and Franchini, G. (2010). Human T-cell leukemia virus type 1 p8 protein increases cellular 
conduits and virus transmission. Proc Natl Acad Sci U S A 107, 20738-20743. 
Verdonck, K., Gonzalez, E., Van Dooren, S., Vandamme, A.M., Vanham, G., and Gotuzzo, E. (2007). 
Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 7, 
266-281. 
Vernant, J.C., Buisson, G.G., Sobesky, G., Arfi, S., Gervaise, G., and Roman, G.C. (1987). Can HTLV-1 
lead to immunological disease? Lancet 2, 404. 
186 
 
Villaudy, J., Wencker, M., Gadot, N., Gillet, N.A., Scoazec, J.Y., Gazzolo, L., Manz, M.G., Bangham, 
C.R., and Dodon, M.D. (2011). HTLV-1 propels thymic human T cell development in "human immune 
system" Rag2(-)/(-) gamma c(-)/(-) mice. PLoS Pathog 7, e1002231. 
Vincent, K.A., York-Higgins, D., Quiroga, M., and Brown, P.O. (1990). Host sequences flanking the HIV 
provirus. Nucleic Acids Res 18, 6045-6047. 
Vine, A.M., Witkover, A.D., Lloyd, A.L., Jeffery, K.J., Siddiqui, A., Marshall, S.E., Bunce, M., Eiraku, N., 
Izumo, S., Usuku, K., et al. (2002). Polygenic control of human T lymphotropic virus type I (HTLV-I) 
provirus load and the risk of HTLV-I-associated myelopathy/tropical spastic paraparesis. J Infect Dis 
186, 932-939. 
Voevodin, A., Samilchuk, E., Schatzl, H., Boeri, E., and Franchini, G. (1996). Interspecies transmission 
of macaque simian T-cell leukemia/lymphoma virus type 1 in baboons resulted in an outbreak of 
malignant lymphoma. J Virol 70, 1633-1639. 
Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A., Jr., and Kinzler, K.W. (2013). 
Cancer genome landscapes. Science 339, 1546-1558. 
Volsky, D.J., Simm, M., Shahabuddin, M., Li, G., Chao, W., and Potash, M.J. (1996). Interference to 
human immunodeficiency virus type 1 infection in the absence of downmodulation of the principal 
virus receptor, CD4. J Virol 70, 3823-3833. 
Wang, G.P., Garrigue, A., Ciuffi, A., Ronen, K., Leipzig, J., Berry, C., Lagresle-Peyrou, C., Benjelloun, F., 
Hacein-Bey-Abina, S., Fischer, A., et al. (2008). DNA bar coding and pyrosequencing to analyze 
adverse events in therapeutic gene transfer. Nucleic Acids Res 36, e49. 
Wang, Z., Zang, C., Cui, K., Schones, D.E., Barski, A., Peng, W., and Zhao, K. (2009). Genome-wide 
mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 138, 1019-
1031. 
Watanabe, T., Seiki, M., Tsujimoto, H., Miyoshi, I., Hayami, M., and Yoshida, M. (1985). Sequence 
homology of the simian retrovirus genome with human T-cell leukemia virus type I. Virology 144, 59-
65. 
Wattel, E., Vartanian, J.P., Pannetier, C., and Wain-Hobson, S. (1995). Clonal expansion of human T-
cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without 
malignancy. J Virol 69, 2863-2868. 
Williams-Carrier, R., Stiffler, N., Belcher, S., Kroeger, T., Stern, D.B., Monde, R.A., Coalter, R., and 
Barkan, A. (2010). Use of Illumina sequencing to identify transposon insertions underlying mutant 
phenotypes in high-copy Mutator lines of maize. Plant J 63, 167-177. 
Wolfe, N.D., Heneine, W., Carr, J.K., Garcia, A.D., Shanmugam, V., Tamoufe, U., Torimiro, J.N., 
Prosser, A.T., Lebreton, M., Mpoudi-Ngole, E., et al. (2005). Emergence of unique primate T-
lymphotropic viruses among central African bushmeat hunters. Proc Natl Acad Sci U S A 102, 7994-
7999. 
Wu, X., Li, Y., Crise, B., and Burgess, S.M. (2003). Transcription start regions in the human genome 
are favored targets for MLV integration. Science 300, 1749-1751. 
187 
 
Wu, X., Li, Y., Crise, B., Burgess, S.M., and Munroe, D.J. (2005). Weak palindromic consensus 
sequences are a common feature found at the integration target sites of many retroviruses. J Virol 
79, 5211-5214. 
Wu, X., Luke, B.T., and Burgess, S.M. (2006). Redefining the common insertion site. Virology 344, 
292-295. 
Yamada, Y., Tomonaga, M., Fukuda, H., Hanada, S., Utsunomiya, A., Tara, M., Sano, M., Ikeda, S., 
Takatsuki, K., Kozuru, M., et al. (2001). A new G-CSF-supported combination chemotherapy, LSG15, 
for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 113, 
375-382. 
Yamaguchi, K., and Watanabe, T. (2002). Human T lymphotropic virus type-I and adult T-cell 
leukemia in Japan. Int J Hematol 76 Suppl 2, 240-245. 
Yamamoto, N., Okada, M., Koyanagi, Y., Kannagi, M., and Hinuma, Y. (1982). Transformation of 
human leukocytes by cocultivation with an adult T cell leukemia virus producer cell line. Science 217, 
737-739. 
Yoshida, M. (2001). Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu 
Rev Immunol 19, 475-496. 
Yoshida, M., Miyoshi, I., and Hinuma, Y. (1982). Isolation and characterization of retrovirus from cell 
lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci U S A 79, 
2031-2035. 
Yoshida, M., Seiki, M., Yamaguchi, K., and Takatsuki, K. (1984). Monoclonal integration of human T-
cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human 
T-cell leukemia virus in the disease. Proc Natl Acad Sci U S A 81, 2534-2537. 
Zhang, W., Nisbet, J.W., Bartoe, J.T., Ding, W., and Lairmore, M.D. (2000). Human T-lymphotropic 
virus type 1 p30(II) functions as a transcription factor and differentially modulates CREB-responsive 
promoters. J Virol 74, 11270-11277. 
 
 
  
188 
 
Appendices 
  
189 
 
Appendix 1: Datasets used in this work  
 
 
Annotation Reference 
RefSeq genes (Fujita et al., 2011) 
CpG islands (Fujita et al., 2011) 
 
‘AllOnco’ Cancer gene database (Available from The Bushman Lab cancer gene list website),(Sadelain 
et al., 2012) 
Gene set Total number of 
Genes 
7 Reference databases drawn 
together to compile AllOnco by 
Bushman lab 
AllOnco 2070  (Huret et al., 2000) 
  (Rosenberg and Jolicoeur, 1997) 
  (Sjoblom et al., 2006) 
  (Akagi et al., 2004) 
  (Futreal et al., 2004) 
  Cavazzana-Calvo and colleagues, 
Hopital Necker, Paris, France 
  Waldman cancer gene database 
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Annotation Mark Cell type  Reference 
Activatory epigenetic 
marks 
H2BK120ac Primary CD4+ T-cells (Barski et al., 2007) 
 H2BK5ac Primary CD4+ T-cells (Barski et al., 2007) 
 H2BK20ac Primary CD4+ T-cells (Barski et al., 2007) 
 H3K18ac Primary CD4+ T-cells (Barski et al., 2007) 
 H3K27ac Primary CD4+ T-cells (Barski et al., 2007) 
 H3K4ac Primary CD4+ T-cells (Barski et al., 2007) 
 H4K5ac Primary CD4+ T-cells (Barski et al., 2007) 
 H4K8ac Primary CD4+ T-cells (Barski et al., 2007) 
 H4K91ac Primary CD4+ T-cells (Barski et al., 2007) 
Inhibitory epigenetic 
marks 
H3K9me2 Primary CD4+ T-cells (Barski et al., 2007) 
 H3K9me3 Primary CD4+ T-cells (Barski et al., 2007) 
 H4K20me3 Primary CD4+ T-cells (Barski et al., 2007) 
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Annotation Cell type Reference 
BAF155 HeLa (Euskirchen et al., 2011) 
BAF170 HeLa (Euskirchen et al., 2011) 
BRG1 HeLa (Euskirchen et al., 2011) 
CBP CD4 (Wang et al., 2009) 
cFos GM12878 (Rozowsky et al., 2011) 
cJun GM12878 (Raha et al., 2010) 
cMyc GM12878 (Rozowsky et al., 2011) 
CTCF Primary CD4+ T-cells  (Barski et al., 2007; Jothi et al., 2008) 
E2F4 GM06990 (Lee et al., 2011) 
E2F6 K562 (Trojer et al., 2011) 
EZH2 K562 Bernstein lab for the ENCODE project 
FOXP3  Activated CD4 (Birzele et al., 2011) 
FOXP3 Treg (Birzele et al., 2011) 
GATA1 K562 (Fujiwara et al., 2009) 
GATA2 K562 (Fujiwara et al., 2009) 
HDAC1 Primary CD4+ T-cells (Wang et al., 2009) 
HDAC2 Primary CD4+ T-cells (Wang et al., 2009) 
HDAC3 Primary CD4+ T-cells (Wang et al., 2009) 
HDAC6 Primary CD4+ T-cells (Wang et al., 2009) 
Ini1 HeLa (Euskirchen et al., 2011) 
IRF1 K562 Struhl lab for the ENCODE project 
JunD GM12878 (Rozowsky et al., 2011) 
MEF2C  GM12878 Myers lab for the ENCODE project 
MOF Primary CD4+ T-cells (Wang et al., 2009) 
Myb HepG2 Myers lab for the ENCODE project 
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Jurkat:  T-lymphoblastic cell line; GM06990: B-lymphoblastoid cell line; GM12878:  Lymphoblastoid 
cell line; K562: erythroleukaemia cell line; HeLa: Cervical cancer cell line; IMR90:  fetal lung fibroblast 
cell line; HepG2:  Hepatocellular carcinoma cell line 
 
 
 
 
NFkB GM12878 (Kasowski et al., 2010) 
NRSF Jurkat (Johnson et al., 2007; Jothi et al., 2008) 
P300 Primary CD4+ T-cells (Wang et al., 2009) 
p53 IMR90 (Botcheva et al., 2011) 
PCAF Primary CD4+ T-cells (Wang et al., 2009) 
PML K562 Myers lab for the ENCODE project 
Rad21 GM12878 Myers lab for the ENCODE project 
STAT1 Primary CD4+ T-cells (Liao et al., 2011) 
STAT1 IFN Interferon stimulated CD4+ T-cells (Liao et al., 2011) 
STAT5a K562 Myers lab for the ENCODE project 
SUZ12 K562 (Ram et al., 2011) 
TAL1 K562 Struhl lab for the ENCODE project 
TCF7 HeLa Struhl lab for the ENCODE project 
Tip60 Primary CD4+ T-cells (Wang et al., 2009) 
Yy1 K562 Myers lab for the ENCODE project 
ZNF263 K562 (Frietze et al., 2010) 
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Appendix 2:  Summary results for each patient sample 
ATL Subtype Age* Sex* 
PVL 
% Proviral tax status 
Number of 
proviruses in 
presumed 
malignant 
clone 
ATL1 acute 
 
F 82 Type 1 defective 1 
ATL3 acute 
 
M 60 Complete 1 
ATL4 acute 
 
F 66 Complete 1 
ATL5 chronic 
 
M 101 Hypermethylated 5'LTR 1 
ATL7 acute 
 
M 112 Complete 1 
ATL8 acute 
 
F 287 Complete 2 
ATL9 acute 
 
F 71 Type 2 defective 1 
ATL10 chronic 
 
M 153 Complete 1 
ATL11 chronic 
 
F 173 Hypermethylated 5'LTR 1 
ATL13 lymphoma 
 
F 52 Type 2 defective 1 
ATL14 acute 
 
M 247 Complete 2 
ATL15 chronic 
 
M 40 nonsense tax exon 3 1 
ATL16 acute 
 
M 33 Complete 1 
ATL17 acute 52 F 75 Type 2 defective 1 
ATL18 acute 
 
M 35 Complete 1 
ATL20 lymphoma 67 M 144 Complete 1 
ATL21 lymphoma 
 
F 77 Complete 1 
ATL22 lymphoma 
 
M 27 Complete 1 
ATL25 acute 66 F 163 Complete 1 
ATL26 chronic 
 
F 116 Indeterminate defective 1 
ATL27 lymphoma 
 
F 20 Type 1 defective 1 
ATL28 chronic 71 F 54 Complete 1 
ATL29 acute 77 M 151 Complete 1 
ATL30 chronic 
 
F 90 Type 1 defective 1 
ATL31 acute 54 F 56 nonsense tax exon 3 1 
ATL32 lymphoma 61 F 72 Type 2 defective 1 
ATL33 acute 73 M 77 Type 2 defective 1 
ATL34 chronic 
 
F 97 Complete 1 
ATL35 acute 55 M 68 Hypermethylated 5'LTR 1 
ATL36 acute 64 M 73 Complete 2 
ATL37 chronic 
 
F 69 Complete 1 
ATL38 acute 77 M 84 Hypermethylated 5'LTR 1 
ATL39 chronic 46 M 54 Type 1 defective 1 
ATL40 lymphoma 65 M 25 Type 1 defective 1 
ATL41 lymphoma 44 F 50 Indeterminate defective 1 
ATL42 acute 45 M 52 Type 2 defective 1 
ATL43 acute 43 F 39 Complete 1 
ATL45 lymphoma 
 
M 55 Type 1 defective 1 
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ATL Subtype Age Sex 
PVL 
% Proviral tax status 
Number of 
proviruses in 
presumed 
malignant 
clone 
ATL46 acute 
 
M 63 Type 1 defective 1 
ATL47 acute 
 
M 65 Complete 1 
ATL49 acute 
 
F 38 Complete 1 
 
ATL50 acute 
 
M 110 Type 1 defective 1 
ATL51 acute 
 
F 24 Type 2 defective 1 
ATL52 acute 77 F 54 Hypermethylated 5'LTR 1 
ATL53 lymphoma 
 
F 55 Complete 1 
ATL54 acute 
 
M 92 Type 1 defective 1 
ATL55 acute 49 F 55 Complete 1 
ATL56 acute 56 M 71 Type 2 defective 1 
ATL57 chronic 47 F 83 Complete 1 
ATL58 acute 54 F 87 nonsense tax exon 3 1 
ATL60 chronic 
 
M 19 Type 2 defective 1 
ATL62 chronic 
 
M 36 Type 2 defective 1 
ATL64 acute 37 M 13 Type 1 defective 1 
ATL65 acute 
 
F 55 Complete 1 
ATL66 chronic 
 
F 54 Complete 1 
ATL69 acute 
 
M 49 Complete 1 
ATL70 lymphoma 
 
M 143 Complete 1 
ATL71 acute 63 M 162 Complete 1 
ATL73 acute 64 F 9 Complete 2 
ATL74 acute 64 M 11 Complete 1 
ATL75 acute 70 F 21 Complete 1 
ATL78 acute 
 
F 103 Type 1 defective 2 
ATL79 lymphoma 
 
M 41 Type 1 defective 1 
ATL81 acute 49 F 17 Complete 1 
ATL82 acute 62 F 79 Type 2 defective 1 
ATL83 lymphoma 
 
M 0 Tax exon 3 deletion 1 
ATL84 acute 47 M 120 Complete 1 
ATL85 chronic 
 
F 68 Type 1 defective 2 
ATL86 acute 75 F 109 nonsense tax exon 3 1 
ATL87 acute 
 
M 159 Complete 1 
ATL88 acute 
 
M 85 Complete 1 
ATL89 acute 53 M 105 missense tax exon 2 1 
ATL90 acute 
 
M 106 Hypermethylated 5'LTR 1 
ATL91 acute 
 
M 85 Type 1 defective 1 
ATL92 acute 
 
F 101 Type 2 defective 1 
ATL93 chronic 
 
M 107 Hypermethylated 5'LTR 1 
ATL94 acute 33 F 79 Complete 1 
ATL95 lymphoma 41 M 50 Complete 1 
195 
 
ATL Subtype Age Sex 
PVL 
% Proviral tax status 
Number of 
proviruses in 
presumed 
malignant 
clone 
ATL96 acute 74 F 180 Complete 1 
ATL97 acute 51 M 201 Complete 2 
ATL99 lymphoma 
 
M 78 Type 1 defective 1 
ATL100 acute 
 
F 62 Complete 1 
ATL102 acute 76 F 71 Type 2 defective 1 
ATL103 smoldering 78 M 13 Complete 1 
ATL104 acute 
 
M 40 Type 1 defective 1 
ATL105 acute 
  
116 Type 1 defective 1 
ATL107 acute 
  
96 Complete 1 
ATL110 lymphoma 
  
80 Type 2 defective 1 
ATL112 lymphoma 
  
10 Complete 1 
ATL114 acute 67 F 51 Complete 1 
ATL115 acute 
  
166 Complete 1 
ATL116 acute 
  
1 Indeterminate defective 1 
ATL117 chronic 
  
116 nonsense tax exon 3 1 
ATL118 lymphoma 
 
F 58 Type 2 defective 1 
ATL119 chronic 40 F 52 Type 1 defective 1 
ATL122 lymphoma 76 F 53 Type 2 defective 1 
ATL123 lymphoma 
 
M 359 Complete 2 
ATL125 acute 73 M 20 nonsense tax exon 3 1 
ATL128 acute 
  
309 Complete 1 
ATL129 chronic 
 
F 22 Type 2 defective 1 
ATL130 acute 
 
M 12 Type 2 defective 1 
ATL131 acute 
 
F 700 Type 1 defective 1 
ATL132 lymphoma 
 
F 40 Type 2 defective 1 
ATL133 acute 
  
12 Complete 2 
ATL135 acute 53 
 
103 Type 2 defective 1 
ATL136 acute 55 F 152 Complete 1 
ATL137 acute 
  
49 Complete 1 
ATL138 chronic 38 F 39 Type 1 defective 1 
ATL139 acute 56 F 146 Complete 1 
ATL141 acute 52 F 12 Type 1 defective 1 
ATL142 chronic 
 
F 88 Type 1 defective 1 
ATL143 acute 
 
M 195 Complete 1 
ATL144 chronic 64 F 156 Complete 2 
ATL145 acute 
  
98 Type 2 defective 1 
ATL146 acute 64 
 
147 Type 1 defective 2 
ATL147 acute 
 
M 118 Complete 1 
ATL148 lymphoma 
 
F 170 Type 2 defective 1 
ATL149 chronic 
 
M 96 Indeterminate defective 1 
ATL150 acute 50 F 116 Complete 1 
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ATL Subtype Age Sex 
PVL 
% Proviral tax status 
Number of 
proviruses in 
presumed 
malignant 
clone 
ATL151 chronic 61 F 63 Complete 1 
ATL152 acute 66 F 242 Complete 1 
ATL153 chronic 
 
M 73 Complete 1 
ATL154 acute 44 M 80 Type 1 defective 1 
ATL155 acute 
  
158 Complete 1 
ATL156 acute 
  
86 Complete 1 
ATL157 acute 57 
 
126 Complete 1 
ATL158 acute 68 F 97 Hypermethylated 5'LTR 1 
ATL159 acute 71 
 
7 Indeterminate defective 1 
ATL161 acute 54 M 38 Complete 1 
ATL162 acute 65 M 266 Type 1 defective 1 
ATL163 acute 35 F 34 Type 2 defective 1 
ATL164 acute 58 M 100 Hypermethylated 5'LTR 1 
ATL165 acute 
 
F 99 Indeterminate defective 1 
ATL166 chronic 52 
 
70 Hypermethylated 5'LTR 1 
ATL167 acute 
  
74 Type 2 defective 1 
ATL168 acute 54 M 114 Type 2 defective 1 
ATL169 acute 71 M 154 Indeterminate defective 1 
ATL171 acute 52 F 94 Complete 1 
ATL172 lymphoma 
 
M 40 Indeterminate defective 1 
ATL173 acute 79 
 
75 Complete 1 
ATL174 acute 47 F 15 Type 1 defective 1 
ATL175 acute 
 
M 43 Complete 1 
ATL176 lymphoma 
  
163 Type 2 defective 1 
ATL177 lymphoma 55 M 21 Type 2 defective 1 
ATL180 acute 43 F 124 Complete 1 
ATL182 acute 
  
152 Complete 1 
ATL183 lymphoma 69 
 
2 Type 1 defective 1 
ATL185 acute 64 M 96 
Nonsense exon 3 and missense 
exon 2 1 
ATL186 chronic 
  
69 nonsense tax exon 3 1 
ATL187 acute 
  
152 Complete 1 
ATL189 acute 46 F 77 Complete 1 
ATL190 lymphoma 73 F 56 Complete 1 
ATL191 acute 
 
F 84 Hypermethylated 5'LTR 1 
ATL192 acute 49 M 65 Type 1 defective 1 
ATL193 acute 
 
F 71 Type 2 defective 1 
ATL195 lymphoma 
  
44 Complete 1 
ATL196 lymphoma 73 M 75 Complete 1 
ATL197 acute 
 
M 154 Complete 1 
ATL198 acute 39 M 178 Complete 2 
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ATL Subtype Age Sex 
PVL 
% Proviral tax status 
Number of 
proviruses in 
presumed 
malignant 
clone 
ATL199 smoldering 79 M 174 Complete 2 
ATL200 lymphoma 
  
67 Type 2 defective 1 
ATL201 acute 
  
174 nonsense tax exon 3 1 
ATL202 acute 
  
148 Hypermethylated 5'LTR 1 
ATL204 acute 
  
2 Complete 1 
ATL205 acute 
  
96 Complete 1 
ATL206 acute 
  
65 Hypermethylated 5'LTR 1 
ATL207 acute 
  
5 nonsense tax exon 3 1 
ATL208 acute 
  
137 Complete 2 
ATL209 acute 
  
19 Type 2 defective 1 
ATL210 acute 
  
0 Indeterminate defective 1 
ATL211 acute 
  
120 Complete 1 
ATL212 lymphoma 
  
3 Type 2 defective 1 
ATL215 smoldering 
  
38 Hypermethylated 5'LTR 1 
ATL217 acute 
  
122 Complete 1 
ATL218 acute 
  
7 Complete 2 
ATL220 smoldering 
  
3 Complete 1 
ATL221 acute 
  
56 Complete 1 
ATL222 acute 
  
243 Type 1 defective 1 
ATL223 acute 
  
133 Complete 2 
ATL224 acute 
  
52 Hypermethylated 5'LTR 1 
ATL225 acute 
  
56 Complete 1 
ATL226 acute 
  
71 Hypermethylated 5'LTR 1 
ATL227 acute  
  
21 Type 1 defective 1 
ATL229 acute 
  
3 Type 2 defective 1 
ATL230 smoldering 
  
37 Complete 2 
ATL231 chronic 
  
28 nonsense tax exon 3 1 
ATL232 smoldering 
  
48 nonsense tax exon 3 1 
ATL233 acute 
  
35 Complete 2 
ATL234 acute 
  
6 Indeterminate defective 1 
ATL235 acute 
  
66 Complete 1 
ATL236 chronic 
  
27 Type 2 defective 1 
ATL237 acute 
  
72 Type 1 defective 1 
ATL238 acute 
  
132 Complete 1 
ATL239 acute 
  
264 Complete 1 
ATL240 ATL 
  
111 Complete 1 
ATL241 ATL 
  
111 Type 2 defective 1 
ATL242 chronic 
  
68 Type 2 defective 1 
*Age and gender provided where known.   
198 
 
Appendix 3:  Shimoyama classification of ATL 
Table adapted from (Shimoyama, 1991) 
 Smoldering Chronic Lymphoma Acute 
Anti-HTLV-1 
antibody 
Present Present Present Present 
Lymphocyte (x109) <4 ≥4 <4 Usually ≥ 4 
Abnormal T-
lymphocytes 
≥5% ≥5% ≤1% Usually ≥ 5% 
Flower cells Occasionally Occasionally No Present 
LDH ≤ 1.5 normal ≤ 2 normal Often high, not 
essential 
Often high, not 
essential 
Corrected Ca 
(mmol/L) 
Normal Normal Often high, not 
essential 
Often high, not 
essential 
Histology proven 
lymphadenopathy 
No Yes, not essential Yes Yes, not essential 
Tumour lesion     
Skin Yes, not essential Yes, not essential Yes, not essential Yes, not essential 
Lung Yes, not essential Yes, not essential Yes, not essential Yes, not essential 
Lymph node No Yes, not essential Yes Yes, not essential 
Liver  No Yes, not essential Yes, not essential Yes, not essential 
Spleen No Yes, not essential Yes, not essential Yes, not essential 
CNS No No Yes, not essential Yes, not essential 
Bone No No Yes, not essential Yes, not essential 
Ascites No No Yes, not essential Yes, not essential 
Pleural effusion  No No Yes, not essential Yes, not essential 
GI tract No No Yes, not essential Yes, not essential 
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Appendix 4:  Samples not suitable for bioinformatic analysis 
ATL Samples provided 
by Kyoto University 
Number of cases =242 
No evidence of HTLV-1 
provirus 
4 
Not ATL 6 (3 AC, 3 B-cell lymphoma in HTLV-1 carriers) 
Post treatment 
remission samples 
9 
Duplicate samples 2 
LMPCR failed to 
amplify (no gel smear) 
6 
Flow cell sequencing 
primer binding site 
polymorphism 
1 
Poor sequencing 
(defined by sisters < 
100) 
7 
Not uniquely mapped 
to host genome at 
both read1 and read2 
10 
Total number samples 
suitable for analysis 
Number of cases=197 
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Appendix 5: Abstract of publication associated with this thesis 
HTLV-1-infected T cells contain a single integrated provirus in natural infection,  
Cook LB, Rowan AG, Melamed A, Taylor GP, Bangham CR 
Blood 2012, 120(17):3488-3490 
Human T lymphotropic virus type 1 (HTLV-1) appears to persist in the chronic phase of infection by 
driving oligoclonal proliferation of infected T cells. Our recent high-throughput sequencing study 
revealed a large number (often > 104) of distinct proviral integration sites of HTLV-1 in each host that 
is greatly in excess of previous estimates. Here we use the highly sensitive, quantitative high-
throughput sequencing protocol to show that circulating HTLV-1+ clones in natural infection each 
contain a single integrated proviral copy. We conclude that a typical host possesses a large number 
of distinct HTLV-1–infected T-cell clones. 
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